WO2008150486A2 - 2-acylaminopropoanol-type glucosylceramide synthase inhibitors - Google Patents

2-acylaminopropoanol-type glucosylceramide synthase inhibitors Download PDF

Info

Publication number
WO2008150486A2
WO2008150486A2 PCT/US2008/006906 US2008006906W WO2008150486A2 WO 2008150486 A2 WO2008150486 A2 WO 2008150486A2 US 2008006906 W US2008006906 W US 2008006906W WO 2008150486 A2 WO2008150486 A2 WO 2008150486A2
Authority
WO
WIPO (PCT)
Prior art keywords
group
substituted
unsubstituted
halogen
haloalkyl
Prior art date
Application number
PCT/US2008/006906
Other languages
French (fr)
Other versions
WO2008150486A3 (en
Inventor
Craig Siegel
Cecilia M. Bastos
David J. Harris
Angeles Dios
Edward Lee
Richard Silva
Lisa M. Cuff
Mikaela Levine
Cassandra Celatka
Frederic Vinick
Thomas Jozefiak
Yibin Xiang
John Kane
Junkai Liao
Original Assignee
Genzyme Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genzyme Corporation filed Critical Genzyme Corporation
Priority to EP08768008.8A priority Critical patent/EP2167485B1/en
Priority to US12/601,871 priority patent/US8304447B2/en
Priority to EP13154955.2A priority patent/EP2594563B1/en
Priority to EP13154970.1A priority patent/EP2594565B1/en
Publication of WO2008150486A2 publication Critical patent/WO2008150486A2/en
Publication of WO2008150486A3 publication Critical patent/WO2008150486A3/en
Priority to HK10105161.0A priority patent/HK1138282A1/en
Priority to US13/595,349 priority patent/US8940776B2/en
Priority to US14/571,922 priority patent/US9745294B2/en
Priority to US15/649,128 priority patent/US20180093981A1/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/12—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms
    • C07D295/125—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by singly or doubly bound nitrogen atoms with the ring nitrogen atoms and the substituent nitrogen atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/10—1,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/14—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/16—1,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D319/18—Ethylenedioxybenzenes, not substituted on the hetero ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D411/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Definitions

  • Gangliosides such as GMl, GM2 and GM3, are glycosphingolipids (GSLs) comprised of ceramide and at least one acidic sugar. Gangliosides are generally found in the outer leaflet of the plasma membrane (Nojri et al., Proc. Natl. Acad. ScL USA 83:782 (1986)). Gangliosides are involved in cell signaling and act as modulators of receptor activity (Yamashita et al., Proc. Natl. Acad. ScL USA
  • GSLs are derived from glucosylceramide, which is enzymatically formed from ceramide and UDP-glucose. The formation of glucosylceramide is catalyzed by glucosylceramide synthase.
  • GSLs controls a variety of cell functions, such as growth, differentiation, adhesion between cells or between cells and matrix proteins, binding of microorganisms and viruses to cells, and metastasis of tumor cells.
  • the glucosylceramide precursor, ceramide may cause differentiation or inhibition of cell growth and be involved in the functioning of vitamin D 3 , tumor necrosis factor- ⁇ , interleukins, and apoptosis.
  • Sphingols, precursors of ceramide, and products of ceramide catabolism have also been shown to influence many cell systems, possibly by inhibiting protein kinase C.
  • GSL metabolizing enzymes can cause serious disorders.
  • Tay-Sachs, Gaucher' s, and Fabry's diseases result from enzymatic defects in the GSL degradative pathway and the accumulation of GSL.
  • GMl accumulates in the nervous system leading to mental retardation and liver enlargement.
  • GM2 accumulates in brain tissue leading to mental retardation and blindness.
  • mutant mice lacking GM3 synthase, and thus lacking in GM3, are protected from insulin resistance caused by a high-fat diet (Yamashita et al, Proc. Natl. Acad. Sc. USA 100:3445-3449 (2003)).
  • inhibitors of glycosylceramide synthase can be effective in treating diabetes.
  • inhibitors of glucosylceramide synthase have been proposed for treating Type 2 diabetes (see WO 2006/053043).
  • agents which inhibit glucosylceramide synthesis, or reduce intracellular content of GSLs have the potential to treat conditions associated with altered GSL levels and/or GSL precursor levels.
  • agents which can act as glucosylceramide synthase inhibitors have the potential to treat conditions associated with altered GSL levels and/or GSL precursor levels.
  • the present invention is directed to compounds represented by Structural Formula (I):
  • R 1 is a substituted or unsubstituted aryl group
  • Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group.
  • R 2 and R 3 are each independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R and R taken together with the nitrogen atom OfN(R 2 R 3 ) form a substituted or unsubstituted non-aromatic heterocyclic ring;
  • X is -(CR 5 RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR 7 -, -NR 7 -, -NR 7 C(O)-, -NR 7 C(O)NR 7 -, -OC(O)-, -SO 3 -, -SO-, -S(O) 2 -, -SO 2 NR 7 -, or -NR 7 SO 2 -; and R 4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; Alternatively, X is -O-, -S- or -NR 7 -; and R 4 is a substituted or unsubstituted aliphatic group, or substituted or unsubstituted
  • X is -(CR 5 R 6 ) n -; and R 4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO 2 or a halogen;
  • X is a covalent bond
  • R 4 is a substituted or unsubstituted aryl group
  • R 5 and R 6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6;
  • Each R is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R 7 and R 4 taken together with the nitrogen atom OfNR 7 R 4 form a substituted or unsubstituted non-aromatic heterocyclic group.
  • the present invention is directed to a pharmaceutical composition
  • a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by Structural Formula (1) or a pharmaceutically acceptable salt thereof.
  • the present invention is directed to a method of treating a subject having type 2 diabetes, comprising administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of treating a subject having renal hypertrophy or hyperplasia associated with diabetic nephropathy is also included in the invention.
  • the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of decreasing plasma TNF- ⁇ in a subject in need thereof is also included in the present invention.
  • the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of lowering blood glucose levels in a subject in need thereof is also included in the present invention.
  • the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of decreasing glycated hemoglobin levels in a subject in need thereof is also included in the present invention.
  • the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof is also included in the present invention.
  • the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a method of treating a subject with Tay-Sachs, Gaucher's or Fabry's disease is also included in the present invention.
  • the method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • the medicament is for treating a subject having type 2 diabetes; for treating a subject having renal hypertrophy or hyperplasia associated with diabetic nephropathy; for decreasing plasma TNF- ⁇ in a subject in need thereof; for lowering blood glucose levels in a subject in need thereof; for decreasing glycated hemoglobin levels in a subject in need thereof; for inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof; or for treating a subject with Tay-Sachs, Gaucher's or Fabry's disease.
  • the compounds of the invention are inhibitors of glucosylceramide synthesis. As such, they can be used for treating various disorders associated with GSL metabolism, including diabetes and lysosomal storage diseases.
  • the compounds of the invention can effectively inhibit glucosylceramide synthesis and at the same time have high metabolic stability at the liver.
  • the compounds of the invention can have a clearance value of less than 50%, and commonly less than 30%, at the liver relative to hepatic blood flow.
  • the invention is directed to a compound represented by
  • Structural Formula (I) or a pharmaceutically acceptable salt thereof.
  • a first set of values and preferred values for the variables in Structural Formula (I) is provided in the following paragraphs:
  • R 1 is a substituted or unsubstituted aryl group, such as a substituted or unsubstituted phenyl group.
  • R 1 is an aryl group optionally substituted with one or more substituents selected from halogen, alkyl, haloalkyl, Ar 1 , -OR 30 , -O(haloalkyl), -SR 30 , -NO 2, -CN, -NCS, -N(R 31 ) 2 , -NR 31 C(O)R 30 , -NR 31 C(O)OR 32 , -N(R 31 )C(O)N(R 31 ) 2 , -C(O)R 30 , -C(S)R 30 , -C(O)OR 30 , -OC(O)R 30 , -C(O)N(R 31 ) 2 , -S(O) 2 R 30 , -SO 2 N(R 31 ) 2 , -S(
  • R 1 is an aryl group, such as a phenyl group, optionally substituted with one or more halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V 0 -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V,-N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V,-N(R 31 ) 2 , -N(R 31 )-V 0 -Ar', -N(R 3 I )-V,-N(R 31 ) 2 , -0-
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O-, and -[CH 2 ] q -.
  • R 1 is a phenyl group optionally substituted with -OH, -OCH 3 , -OC 2 H 5 or -O-[CH 2 ] P -O-.
  • R 1 is
  • Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group.
  • hydrolyzable groups include -C(O)R, -C(O)OR, -C(O)NRR', C(S)R, -C(S)OR, -C(O)SR or -C(S)NRR 1 .
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR 1 ; more preferably, -H.
  • R and R are each independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a substituted or unsubstituted non-aromatic heterocyclic ring.
  • R 2 and R 3 taken together with the nitrogen atom of N(R 2 R 3 ) form a 5- or 6-membered, optionally-substituted non-aromatic heterocyclic ring .
  • -N(R 2 R 3 ) is an optionally substituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group. Even more preferably, -N(R 2 R 3 ) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, preferably an unsubstituted pyrrolidinyl group.
  • Suitable substituents for the aliphatic and aryl groups represented by R 2 and R 3 , and suitable substituents for the non-aromatic heterocyclic ring represented by N(R 2 R 3 ) each independently include halogen, alkyl, haloalkyl, -OR 40 , -O(haloalkyl), -SR 40 , -NO 2, -CN, -N(R 41 ) 2 , -NR 41 C(O)R 40 , -NR 41 C(O)OR 42 , -N(R 41 )C(O)N(R 41 ) 2 , -C(O)R 40 , -C(S)R 40 , -C(O)OR 40 , -OC(O)R 40 , -C(O)N(R 41 ) 2 , -S(O) 2 R 40 , -SO 2 N(R 41 ) 2 , -S(O)R 42 , -SO 3 R 40 , Ar
  • suitable substituents for the aliphatic and aryl groups represented by R 2 and R 3 each independently include halogen, alkyl, haloalkyl, -OR 40 , -O(haloalkyl), -SR 40 , -NO 2 , -CN, -N(R 41 ) 2 , -C(O)R 40 , -C(S)R 40 , -C(O)OR 40 , -OC(O)R 40 , -C(O)N(R 41 ) 2 , Ar 2 , V 2 -Ar 2 , -V 2 -OR 40 , -V 2 -O(haloalkyl), -V 2 -SR 40 , -V 2 -NO 2 , -V 2 -CN, -V 2 -N(R 41 ) 2 , -V 2
  • suitable substituents for the aliphatic and aryl groups represented by R 2 and R 3 each independently include halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, -0(Cl-ClO alkyl), -O(phenyl), -0(Cl -C 10 haloalkyl), -S(Cl -C 10 alkyl), -S(phenyl), -S(Cl-ClO haloalkyl), -NO 2, -CN, -NH(Cl-ClO alkyl), -N(Cl-ClO alkyl) 2 , -NH(Cl-ClO haloalkyl), -N(Cl-ClO haloalkyl) 2 , -NH(phenyl), -N(phenyl) 2
  • suitable substituents for the aliphatic and aryl groups represented by R 2 and R 3 each independently include halogen, Cl- C5 alkyl, C 1 -C5 haloalkyl, hydroxy, C 1 -C5 alkoxy, nitro, cyano, C 1 -C5 alkoxycarbonyl, C1-C5 alkylcarbonyl, C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
  • X is -(CR 5 RVQ-;
  • Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR 7 -, -NR 7 -, -NR 7 C(O)-, -NR 7 C(O)NR 7 -, -OC(O)-, -SO 3 -, -SO-, -S(O) 2 -, -SO 2 NR 7 -, or -NR 7 SO 2 -; and R 4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group.
  • Q is -0-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR 7 -, -NR 7 C(O)NR 7 -, -OC(O)-, -SO 3 -, -SO-, -S(O) 2 -, -SO 2 NR 7 - or -NR 7 SO 2 -.
  • Q is -0-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR 7 - or -OC(O)-. Even more preferably, Q is -0-, -S-, -C(O)- or -C(S)-.
  • X is -0-, -S- or -NR 7 -; and R 4 is a substituted or unsubstituted aliphatic group, or substituted or unsubstituted aryl group.
  • X is -(CR 5 R 6 ) n -; and R 4 is a substituted or unsubstituted cyclic alkyl (e.g., C3-C8) group, or a substituted or unsubstituted cyclic alkenyl (C3-C8) group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO 2 or a halogen.
  • R 4 is a substituted or unsubstituted cyclic alkyl (e.g., C3-C8) group, or a substituted or unsubstituted cyclic alkenyl (C3-C8) group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO 2 or a halogen.
  • X is a covalent bond; and R 4 is a substituted or unsubstituted aryl group.
  • R 4 is an optionally substituted aliphatic, such as a lower alkyl, or aryl group. More preferably, R 4 is an optionally substituted aryl or lower arylalkyl group. Even more preferably, R 4 is selected from the group consisting of:
  • each of rings A-Z5 is optionally and independently substituted; and each x is independently 0 or 1 , specifically x is 0. Even more preferably, R 4 is an
  • rings A-Z5 can be attached to variable "X" of Structural Formula (I) through -(CH 2 ) X - at any ring carbon of rings A-Z5 which is not at a position bridging two aryl groups.
  • R 4 represented by means that R is attached to variable "X" through either ring J or ring K.
  • Preferred substituents for each of the aliphatic group and the aryl group represented by R 4 include halogen, alkyl, haloalkyl, Ar 3 , Ar 3 -Ar 3 , -OR 50 , -O(haloalkyl), -SR 50 , -NO 2 , -CN, -NCS, -N(R 51 ) 2 , -NR 51 C(O)R 50 , -NR 51 C(O)OR 52 , -N(R 51 )C(O)N(R 51 ) 2 , -C(O)R 50 , -C(S)R 50 , -C(O)OR 50 , -OC(O)R 50 , -C(O)N(R 51 ) 2 , -S(O) 2 R 50 , -SO 2 N(R 51 ) 2 , -S(O)R 52 ,
  • substituents for each of the aliphatic group and the aryl group represented by R 4 include halogen, Cl-ClO alkyl, Cl- ClO haloalkyl, Ar 3 , Ar 3 -Ar 3 , -OR 50 , -O(haloalkyl), -SR 50 , -NO 2, -CN, -N(R 51 ) 2 , -NR 51 C(O)R 50 , -C(O)R 50 , -C(O)OR 50 , -OC(O)R 50 , -C(O)N(R 51 ) 2 , -V 4 -Ar 3 , -V-OR 50 , -V 4 -O(haloalkyl), -V 4 -SR 50 , -V 4 -NO 2 , -V 4 -CN, -V 4 -N(R 51 )
  • substituents for each of the aliphatic group and the aryl group represented by R 4 include halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-IO alkoxy, -0-[CH 2 ] p -0- or -[CH 2 ] q -.
  • substituents for each of the aliphatic group and the aryl group represented by R 4 include halogen, cyano, amino, nitro, Ar 3 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy.
  • substituents for each of the aliphatic and aryl groups represented by R 4 include -OH, -OCH 3 , -OC 2 H 5 and -O-[CH 2 ] P -O-.
  • phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, -OR 50 , -Ar 3 , -V 4 -Ar 3 , -V-OR 50 , -0(Cl-ClO haloalkyl), -V 4 -O(Cl-ClO haloalkyl), -0-V 4 -Ar 3 , -0-[CH 2 ] p -0- and-[CH 2 ] q -.
  • substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkyla
  • phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-IO alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -. Even more preferably, phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH 3 and -OC 2 H 5.
  • R 5 and R 6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group.
  • R 5 and R 6 are each independently -H; -OH; a halogen; or a lower alkoxy or lower alkyl group. More preferably, R 5 and R 6 are each independently -H, -OH or a halogen. Even more preferably, R 5 and R 6 are each independently -H.
  • Each R 7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R 7 and R 4 taken together with the nitrogen atom of NR 7 R 4 form a substituted or unsubstituted non-aromatic heterocyclic group.
  • each R 7 is independently -H, an aliphatic group or phenyl. Even more preferably, each R 7 is independently -H or C1-C6 alkyl.
  • Each n is independently 1, 2, 3, 4, 5 or 6.
  • each n is independently 1, 2, 3 or 4.
  • each n is independently 2, 3, 4 or 5.
  • Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
  • Each q is independently 3, 4, 5 or 6, preferably 3 or 4.
  • Each p 1 is independently 1, 2, 3 or 4, preferably 1 or 2.
  • Each q 1 is independently 3, 4, 5 or 6, preferably 3 or 4.
  • Each V 0 is independently a Cl-ClO alkylene group, preferably C1-C4 alkylene group.
  • Each Vi is independently a C2-C10 alkylene group, specifically C2-C4 alkylene group.
  • Each V 2 is independently a C1-C4 alkylene group.
  • Each V 4 is independently a Cl-ClO alkylene group, preferably a C1-C4 alkylene group.
  • Each V 5 is independently a C2-C10 alkylene group, preferably a C2-C4 alkylene group.
  • Each Ar 1 is an aryl group optionally and independently substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy and haloalkyl.
  • Ar 1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl .
  • substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl .
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Each Ar 2 is an aryl group optionally and independently substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, Cl- C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, Cl- C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino.
  • Each Ar 3 is independently an aryl group, such as phenyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy and haloalkyl.
  • Ar 3 is independently an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, Cl-ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino.
  • substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, Cl-ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino.
  • Ar 3 is independently an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
  • Each R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl and alkylcarbonyl.
  • each R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C 1 -C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl and Cl -C6 alkylcarbonyl.
  • each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl and C1-C6 alkylcarbonyl.
  • Each R 31 is independently R 30 , -CO 2 R 30 , -SO 2 R 30 or -C(O)R 30 ; or -N(R 31 ) 2 taken together is an optionally substituted non-aromatic heterocyclic group.
  • each R 31 is independently R 30 , or -N(R 31 ) 2 is an optionally substituted non-aromatic heterocyclic group.
  • Each R 32 is independently an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl and alkylcarbonyl.
  • each R 32 is independently an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl and Cl -C6 alkylcarbonyl.
  • substituents selected from the group consist
  • each R 32 is independently a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy and C1-C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, Cl- C6 haloalkoxy, C1-C6 alkoxycarbonyl and C1-C6 alkylcarbonyl.
  • Each R 40 is independently hydrogen; an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, Cl- C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alky
  • Each R 41 is independently R 40 , -CO 2 R 40 , -SO 2 R 40 or -C(O)R 40 ; or -N(R 41 ) 2 taken together is an optionally substituted non-aromatic heterocyclic group.
  • Each R 42 is independently an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, Cl- C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamin
  • Each R 50 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl.
  • each R 50 is independently hydrogen; an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, Cl- C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C 1 -C6 haloalkoxy, amino, C 1
  • Each R 51 is independently R 50 , -CO 2 R 50 , -SO 2 R 50 or -C(O)R 50 , or -N(R 51 ) 2 taken together is an optionally substituted non-aromatic heterocyclic group.
  • each R 51 is independently R 50 , or -N(R 31 ) 2 is an optionally substituted non-aromatic heterocyclic group.
  • Each R 52 is independently an aryl group optionally substituted with one or two substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl.
  • each R 52 is independently an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, Cl- C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkyl,
  • R and R 1 are each independently -H; a lower aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO 2 , -NH 2 , lower alkoxy, lower haloalkoxy and aryl; or an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO 2 , -NH 2 , lower alkoxy, lower haloalkoxy, lower aliphatic group and lower haloaliphatic group; or R and R' taken together with the nitrogen atom of NRR' form a non-aromatic heterocyclic ring optionally substituted with one or more substituents selected from the group consisting of: halogen; -OH; -CN; -NCS; -NO 2 ; -NH 2 ; lower alkoxy; lower haloalkoxy
  • R and R' are each independently -H; a lower aliphatic group; a lower aliphatic group substituted with phenyl; or an aryl group. More preferably, R and R' are each independently -H, Cl- C4 alkyl, phenyl or benzyl.
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR 1 , preferably -H.
  • R 1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar 1 , -OR 30 , -O(haloalkyl), -SR 30 , -NO 2, -CN, -NCS, -N(R 31 ) 2 , -NR 31 C(O)R 30 , -NR 31 C(O)OR 32 , -N(R 31 )C(O)N(R 31 ) 2 , -C(O)R 30 , -C(S)R 30 , -C(O)OR 30 , -OC(O)R 30 , -C(O)N(R 31 ) 2 , -S(O) 2 R 30 , -SO 2 N(R 31 )
  • Formula (I) are each independently as described above for the first set of values.
  • a third set of values for the variables in Structural Formula (I) is provided in the following four paragraphs.
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR 1 , preferably -H.
  • R 1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar 1 , -OR 30 , -O(haloalkyl), -SR 30 , -NO 2, -CN, -NCS, -N(R 31 ) 2 , -NR 31 C(O)R 30 , -NR 31 C(O)OR 32 , -N(R 31 )C(O)N(R 31 ) 2 , -C(O)R 30 , -C(S)R 30 , -C(O)OR 30 , -OC(O)R 30 , -C(O)N(R 31 ) 2 , -S(O) 2 R 30 , -SO 2 N(R 31 )
  • R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
  • suitable substituents for the non-aromatic heterocyclic ring represented by -NR 2 R 3 are as described in the first set of values for Structural Formula (I). Values and preferred values for the remainder of the variables of Structural
  • Formula (I) are as described above for the first set of values.
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR 1 , preferably -H.
  • R 1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar 1 , -OR 30 , -O(haloalkyl), -SR 30 , -NO 2 , -CN, -NCS, -N(R 31 ) 2 , -NR 31 C(O)R 30 , -NR 31 C(O)OR 32 , -N(R 31 )C(O)N(R 31 ) 2 , -C(O)R 30 , -C(S)R 30 , -C(O)OR 30 , -OC(O)R 30 , -C(O)N(R 31 ) 2 , -S(O) 2 R 30 , -SO 2 N(R 31
  • R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
  • R 5 and R 6 are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR', preferably -H.
  • R 1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar 1 , -OR 30 ,
  • -O(haloalkyl), -SR 30 -NO 2 , -CN, -NCS, -N(R 31 ) 2 , -NR 31 C(O)R 30 , -NR 31 C(O)OR 32 , -N(R 31 )C(O)N(R 31 ) 2 , -C(O)R 30 , -C(S)R 30 , -C(O)OR 30 , -OC(O)R 30 , -C(O)N(R 31 ) 2 , -S(O) 2 R 30 , -SO 2 N(R 31 ) 2 , -S(O)R 32 , -SO 3 R 30 , -NR 31 SO 2 N(R 3 ⁇ 2 , -NR 31 SO 2 R 32 , -V 0 -Ar 1 , -V 0 -OR 30 , -Vo-O(haloalkyl), -V 0 -SR 30 ,
  • R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
  • R 4 is an aliphatic or aryl group each optionally substituted with one or more substituents. Examples of suitable substituents are as described above for the first set of values.
  • R 5 and R 6 are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR 1 , preferably -H.
  • R is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar 1 , -OR 30 , -O(haloalkyl), -SR 30 , -NO 2 , -CN, -NCS, -N(R 31 ) 2 , -NR 31 C(O)R 30 , -NR 31 C(O)OR 32 , -N(R 31 )C(O)N(R 31 ) 2 , -C(O)R 30 , -C(S)R 30 , -C(O)OR 30 , -OC(O)R 30 , -C(O)N(R 31 ) 2 , -S(O) 2 R 30 , -SO 2 N(R 31
  • R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
  • R 4 is an optionally substituted cyclic alkyl group, or an optionally substituted cyclic alkenyl group, an optionally substituted aryl group, -CN, -NCS, -NO 2 or a halogen. Examples of suitable substituents are as described above for the first set.
  • R 5 and R 6 are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group. Values and preferred values of the remainder of the variables of Structural
  • Formula (I) are each independently as described above for the first set of values.
  • R 1 , Y, R 2 , R 3 , R 5 and R 6 are each independently as described above for the sixth set.
  • R 4 is an optionally substituted cyclic alkyl group, or an optionally substituted cyclic alkenyl group, or an optionally substituted aryl group, specifically optionally substituted aryl group. Examples of suitable substituents are as described above for the first set.
  • the compound of the invention is represented by Structural Formula (II), (III), (IV), (V), (VI), (VII) or (VIII):
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -0-V 1 -N(R 31 ),, -S-V 0 -Ar 1 , -S-V 1 -N(R 31 ) 2 , -N(R 3 v 1 0 )--Ar 1 , -N(R 31 )-V
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • Ar 1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6
  • R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C
  • Each R 31 is independently R 30 , or -N(R 31 ) 2 is an optionally substituted non- aromatic heterocyclic group.
  • suitable substituents are as described above in the first set of values for Structural Formula (I).
  • R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
  • suitable substituents for the non-aromatic heterocyclic ring represented by -NR 2 R 3 are as described above in the first set of values for Structural Formula (I).
  • R 4 is an aliphatic or aryl group each optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I).
  • R 5 and R 6 for Structural Fomrulas (II), (III) and (V) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • R 7 is -H or C1-C6 alkyl, preferably -H. Values and preferred values of the remainder of the variables of Structural
  • Formulas (II)-(VIII) are each independently as described above in the first set of values for Structural Formula (I).
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-Vi-N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V 1 -N(R 31 ) 2 , -N(R 3 ⁇ -V 0 -Ar 1 , -N(R 31 )-V,-N(R 31 ) 2 , -N(R 3 ⁇ -V 0 -Ar 1 , -N(R 31 )-V
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • Ar 1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloal
  • R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C
  • -N(R 2 R 3 ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
  • R 4 is an aliphatic or aryl group each optionally substituted with one or more substituents. Examples of suitable substituents are described above in the first set of values for Structural Formula (I).
  • R 5 and R 6 for Structural Fomrulas (II), (III) and (V) are each independently
  • R 7 is -H or C1-C6 alkyl, preferably -H.
  • Values and preferred values of the remainder of the variables of Structural Formulas (II)-(VIII) are each independently as described above in the first set of values for Structural Formula (I).
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V 1 -N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V 1 -N(R 3 ] ) 2 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V,-N(R 31 ) 2 , -O-[CH 2 ] P -O-, -S-[CH 2 Jp-S
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • Ar 1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, C 1 -C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxy carbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, C 1 -C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxy carbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 - C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6
  • R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C
  • Each R 31 is independently R 30 , or -N(R 31 ) 2 is an optionally substituted non- aromatic heterocyclic group.
  • -N(R 2 R 3 ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
  • R 4 is an optionally substituted aryl or an optionally substituted lower arylalkyl group.
  • Example of suitable substituents are as described in the first set of values for Structural Formula (I).
  • R 5 and R 6 for Structural Fomrulas (II), (III) and (V) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • R 7 is -H .
  • Q in Structural Formula (II) is -O- , -S-, -C(O)-, -C(S)-, -NR 7 (CO)- or -C(O)NR 7 -
  • Values and preferred values of the remainder of the variables of Structural Formulas (H)-(VIII) are each independently as described above in the first set of values for Structural Formula (I).
  • Q is -O-, -S-, -C(O)-, -C(S)-, -NR 7 (C0)- or -C(O)NR 7 -.
  • a fourth set of values for the variables in Structural Formulas (H)-(VIII) is provided in the following paragraphs:
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V,-N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V 1 -N(R 31 ) 2 , -N(R 31 VV 0 -Ar 1 , -N(R 31 )-V,-N(R 31 ) 2 , -N(R 31 VV 0 -Ar 1 , -N(R 31 )-V,-N(
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • Ar is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C 1 -C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-
  • -N(R 2 R 3 ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl
  • R 4 is an optionally substituted aryl or an optionally substituted lower arylalkyl group.
  • suitable substitutents for R 4 are as provided above in the first set of values for Structural Formula (I).
  • R 4 is selected from the group consisting of:
  • R 7 is -H.
  • a fifth set of values for the variables in Structural Formulas (II)-(VIII) independently is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set of values for the variables for Structural Formula (I).
  • the compound of the invention is represented by Structural Formula (IX) or (X):
  • R 1 is a phenyl group optionally substituted with one or more substituents.
  • substituents include halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V,-N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V 1 -N(R 31 ),, -N(R 31 )- V 0 - Ar 1 , -N(R 31 )-V,-N(R 31 ) 2 , -O-[CH 2 ] P -O-, -S-[CH 2 ] p -S-, and -[CH 2 ] q -;preferably, R 1 is a phenyl,
  • -N(R 2 R 3 ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino; preferably, -N(R 2 R 3 ) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
  • Phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, -OR 50 , -Ar 3 , -V 4 -Ar 3 , -V-OR 50 , -0(Cl-ClO haloalkyl), -V 4 -O(Cl-ClO haloalkyl), -0-V 4 -Ar 3 , -O-[CH 2 ] P -O- and -[CH 2 ] q .-.
  • Ar 3 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Each R 5 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 hal
  • n is 1, 2, 3 or 4.
  • n is 3, 4 or 5.
  • a second set of values and preferred values for the variables in Structural Formulas (IX) and (X) is as defined in the following paragraphs:
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH 3 , -OC 2 H 5 and -O-[CH 2 ] P -O-.
  • -N(R 2 R 3 ) is pyrrolidinyl.
  • Phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-ClO alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH 3 or -OC 2 H 5 .
  • n is 1, 2, 3 or 4.
  • n is 3, 4 or 5.
  • a third set of values for the variables in Structural Formulas (IX) and (X) independently is as defined in the first set, second set, third set, fourth set or fifth set, of values for Structural Formulas (H)-(VIII).
  • the compound of the invention is represented by Structural Formula (XI), (XII) or (XIII):
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V 1 -N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V 1 -N(R 31 ),, -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 1 -N(R 31 ) 2 , -O-[CH 2 ] P -O-, -S-[CH 2 ] P -S-
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O- and -[CH 2 ] q -.
  • Ar 1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloal
  • R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C 1 -C6 alkylamino, C 1 -C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl;
  • Each R 31 is independently R 30 , or -N(R 3 ! ) 2 is an optionally substituted non- aromatic heterocyclic group.
  • suitable substituents are as described above in the first set of values for Structural Formula (I).
  • R 2 and R 3 taken together with the nitrogen atom OfN(R 2 R 3 ) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
  • suitable substituents for the non-aromatic heterocyclic group represented by -NR R are as described above in the first set of values for Structural Formula (I).
  • R 4 is an optionally substituted aryl group.
  • suitable substituents for R 4 are as provided above in the first set of values for Structural Formula (I).
  • R 5 and R 6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V 1 -N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V,-N(R 31 ) 2 , -N(R 31 )- V 0 - Ar 1 , -N(R 31 )-V,-N(R 31 ) 2 , -N(R 31 )- V 0 - Ar 1 , -N(R 31 )-V,-
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O-, and -[CH 2 ] q -.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 hal
  • Each R 31 is independently R 30 , or -N(R 31 ) 2 is an optionally substituted non- aromatic heterocyclic group.
  • -N(R 2 R 3 ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl
  • R 4 is an optionally substituted aryl group. Suitable substituents and preferred substitutents are as provided above in the first set of values for Structural Formula (I). Preferably, R 4 is selected from the group consisting of:
  • each of rings A-Z5 is optionally and independently substituted.
  • each of rings A-Z5 is optionally and independently substituted with one or more substituents selected from Ar 3 and Ar 3 -Ar 3 wherein values and preferred values of Ar 3 are as described above for the first set of values for Structural Formula (I).
  • Ar 3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, C 1 - ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino.
  • substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, C 1 - ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino.
  • Ar 3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C 1 -C4 haloalkoxy, amino, C 1 -C4 alkylamino and C 1 -C4 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C 1 -C4 haloalkoxy, amino, C 1 -C4 alkylamino and C 1 -C4 dialkylamino.
  • R 5 and R 6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -0-V 1 -N(R 31 ),, -S-V 0 -Ar 1 , -S-V,-N(R 31 ) 2 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 1 -N(
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C 1 -C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkylamino, C 1 -C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O-, and -[CH 2 ] q -.
  • substituents selected from the group consisting of halogen, cyano, nitro, C 1 -C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkylamino, C 1 -C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O-, and -[CH 2 ] q
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6
  • Each R 31 is independently R 30 , or -N(R 31 ) 2 is an optionally substituted non- aromatic heterocyclic group.
  • -N(R 2 R 3 ) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
  • R 4 is a biaryl group, such as a biphenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar 3 , C 1 -C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkoxy, hydroxy and C 1 -C6 haloalkoxy.
  • R 5 and R 6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group, preferably -H.
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH 3 , -OC 2 H 5 and -O-[CH 2 ] P -O-,
  • R 1 is w here r is 1, 2, 3 or 4, preferably 1 or 2.
  • -N(R R 3 ) is an unsubstituted pyrrolidinyl group.
  • R 4 is a biaryl group, such as a biphenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar 3 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy.
  • R 5 and R 6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group, preferably -H.
  • n is an integer from 1 to 4.
  • a fifth set of values preferred values for the variables of Structural Formulas (XI)-(XIII) is defined in the following paragraphs:
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH 3 , -OC 2 H 5 and -O-[CH 2 ] P -O-.
  • R 1 is where r is 1, 2, 3 or 4, preferably 1 or 2.
  • -N(R 2 R 3 ) is pyrrolidinyl.
  • R 4 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar 3 , C1-C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkoxy, hydroxy and C 1 -C6 haloalkoxy.
  • n is 1.
  • R 5 and R 6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group, preferably -H.
  • a sixth set of values values for the variables in Structural Formulas (XI)- (XIII) independently is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set of values for Structural Formula (I).
  • the compound of the invention is represented by Structural Formula (XIV) or (XV):
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V 0 -OR 30 , -V O -N(R 31 ) 2 , -V 0 -Ar 1 , -0-V 0 -Ar 1 , -O-V,-N(R 31 ) 2 , -S-V 0 -Ar 1 , -S-V, -N(R 31 ) 2 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 0 -Ar 1 , -N(R 31 )-V 0
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH 2 ] P -O-, and -[CH 2 ] q -.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy and C1-C6 haloalkyl.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6
  • Each R 31 is independently R 30 , or -N(R 31 ) 2 is an optionally substituted non- aromatic heterocyclic group.
  • -N(R 2 R 3 ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
  • k is O, 1, 2, 3, 4, 5 or 6.
  • R 8 is -H, or an optionally substituted aryl or an optionally substituted lower alkyl group. Examples of suitable substituents are as described for the first set of values for Structural Formula (I). Preferably, R 8 is selected from the group consisting of:
  • Each of rings A-Z5 is optionally and independently substituted.
  • suitable substituents for R 8 are as provided above in the first set of values for R 4 in
  • R is group.
  • R 8 is an aryl group substituted with Ar 3 , such as a phenyl group substituted with Ar 3 , where values and preferred values of Ar 3 are as described above in Structural
  • Formulas (XIV) and (XV) are each independently as described above in the first set of values for Structural Formula (I).
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR 30 , -SR 30 , -N(R 31 ) 2 , Ar 1 , -V-OR 30 , -V-N(R 31 ) 2 , -V-Ar 1 , -O-V-Ar 1 , -O-V,-N(R 31 ) 2 , -S-V-Ar 1 , -S-V 1 -N(R 31 ) 2 , -N(R 31 )-V-Ar ⁇ -N(R 31 )-V 1 -N(R 31 ) 2 , -O-[CH 2 ]p-O-, -S-[CH 2 ]p-S- and -[CH 2 ] q -.
  • Ar 1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl , C 1 -C6 alkylcarbonyl and C 1 - C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6
  • -N(R 2 R 3 ) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, preferably an unsubstituted pyrrolidinyl group.
  • R 1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH 3 , -OC 2 H 5 and -O-[CH 2 ] P -O-.
  • R is where r is 1, 2, 3 or 4, preferably 1 or 2.
  • -N(R 2 R 3 ) is pyrrolidinyl.
  • Values and preferred values for k and R 8 are each independently as provided above in the first set of values for Structural Formulas (XIV) and (XV).
  • a fourth set of values for the variables in Structural Formulas (XIV)-(XV) is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set for Structural Formula (I).
  • a first set of values and preferred values for the variables in Structural Formula (XXI) is as defined in the following paragraphs:
  • Each of A and B independently is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.
  • k 1 is 0, 1 or 2.
  • k" is 0, 1 or 2.
  • k" is 0 or 1.
  • More preferably k" is 1.
  • m' is 0, 1 or 2.
  • m' is 1.
  • Y is -H, -C(O)R, -C(O)OR or -C(O)NRR 1 , preferably -H.
  • Values and preferred values for A, B, k', k" and m' are each independently as described above in the first set of values for Structural Formula (XXI).
  • R 30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloal
  • R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C
  • R 30 is independently hydrogen; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • R 30 is independently hydrogen, or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 haloalkoxy and hydroxy.
  • Y is -H.
  • the compound of the invention is represented by Structural Formula (XXII), (XXIII), (XXIV), (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), (XXX) or (XXXI):
  • Each of A and B independently is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6
  • R 30 is independently hydrogen; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
  • R 30 is independently hydrogen, or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 haloalkoxy and hydroxy.
  • Each k' is independently 0, 1 or 2.
  • Each k" is independently 0, 1 or 2.
  • Each m 1 is independently 0, 1 or 2.
  • each m' is 1.
  • each n is independently 1, 2, 3, 4, 5 or 6.
  • each n in Structual Formulas (XXV) and (XXVI) is independently 1 , 2, 3 or 4, and each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5.
  • Each R 4 in Structural Formulas (XXII) -(XXVIII) is independently an aliphatic or aryl group each optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I).
  • each R 4 in Structural Formulas (XXII) -(XXVIII) is independently an optionally substituted aryl or an optionally substituted lower arylalkyl group. Examples of suitable substituents are as described in the first set of values for Structural Formula
  • Each R 4 in Structural Formulas (XXIX) -(XXXI) is independently an aryl group optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I).
  • R 5 and R 6 in Structural Fomrulas (XXII), (XXIII), (XV) and (XXIX) are each independently -H, -OH, a halogen, a C1-C6 alkoxy group or a C1-C6 alkyl group.
  • R 7 is -H or C1-C6 alkyl, preferably -H.
  • Values and preferred values for A, B, R 30 , k', k", m' and n are each independently as described above in the first set of values for the variables in Structural Formulas (XXII) - (XXXI).
  • each n in Structual Formulas (XXV) and (XXVI) is independently 1, 2, 3 or 4
  • each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5. Values and preferred values for the remainder of the variables of Structural
  • Formulas (XXII) - (XXXI) are each independently as described above in the first set of values for Structural Formula (I).
  • a third set of values for the variables in Structural Formulas (XXII) — (XXXI) is provided in the following paragraphs:
  • Each R 4 in Structural Formulas (XXII) -(XXVIII) is independently an optionally substituted aryl or an optionally substituted lower arylalkyl group.
  • Example of suitable substituents are as described in the first set of values for Structural Formula (I).
  • Each R 4 in Structural Formulas (XXIX) -(XXXI) is independently an aryl group optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I).
  • R 5 and R 6 for Structural Fomrulas are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
  • R 7 is -H .
  • Q in Structural Formula (XXII) is -O- , -S-, -C(O)-, -C(S)-, -NR 7 (CO)- or
  • each n in Structual Formulas (XXV) and (XXVI) is independently 1, 2, 3 or 4, and each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5.
  • Values and preferred values for the remainder of the variables of Structural Formulas (XXII)-(XXXI) are each independently as described above in the first set of values for Structural Formula (I).
  • R 4 in Structural Formulas (XXII) -(XXVIII) is independently selected from the group consisting of:
  • each x is independently 0 or 1
  • each of rings A-Z5 is optionally and independently substituted.
  • R 4 in Structural Formulas (XXIX) -(XXXI) is independently selected from the group consisting of:
  • each of rings A-Z5 is optionally and independently substituted.
  • each R 4 in Structural Formulas (XXII) - (XXXI) is independently monocyclic.
  • each of rings A-Z5 is optionally and independently substituted with one or more substituents selected from Ar 3 and Ar 3 -Ar 3 wherein values and preferred values of Ar are as described above for the first set of values for Structural Formula (I).
  • Ar 3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, Cl-ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino.
  • substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, Cl-ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino.
  • Ar 3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
  • R 5 , R 6 , R 7 , R 30 , Q, k', k", m' and n are each independently as described above in the third set of values for the variables in Structural Formulas (XXII) - (XXXII).
  • each n in Structual Formulas (XXV) and (XXVI) is independently 1, 2, 3 or 4
  • each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5.
  • Each ring A is optionally substituted.
  • Example of suitable substituents for rings A are as described in the first set of values for Structural Formula (I).
  • ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar 3 , C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy.
  • Ar 3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
  • substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
  • a sixth set of values for the variables other than A, B, k', k" and m' in Structural Formulas (XXII) - (XXXI) is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set of values for the varibales for Structural Formula (I), and values and preferred values for A, B, k', k" and m' are each independently as described above in the first set of values for the variables in Structural Formulas (XXII) - (XXXI).
  • the compound of the invention is represented by Structural Formula (XXXII) or (XXXIII ):
  • Each of A and B independently is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C 1 -C6 alkoxy or C 1 -C6 haloalkoxy.
  • Each R 30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6
  • R 30 is independently hydrogen; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C 1 -C6 haloalkyl.
  • substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C 1 -C6 haloalkyl.
  • R 30 is independently hydrogen, or a C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 haloalkoxy and hydroxy.
  • Each k 1 is independently 0, 1 or 2.
  • Each k" is independently 0, 1 or 2.
  • Each m' is independently 0, 1 or 2.
  • Each q is independently 0, 1, 2, 3, 4, 5 or 6.
  • Each R 8 independently is -H, or an optionally substituted aryl or an optionally substituted lower alkyl group. Examples of suitable substituents are as described for the first set of values for Structural Formula (I).
  • each R independently is selected from the group consisting of:
  • Each of rings A-Z5 is optionally and independently substituted.
  • suitable substituents for R 8 are as provided above in the first set of values for R 4 in
  • each R 8 is independently a group.
  • each R 8 is independently an aryl group substituted with Ar 3 , such as a phenyl group substituted with Ar 3 , where values and preferred values of Ar 3 are as described above in Structural Formula (I).
  • each k' in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1.
  • each A independently is positioned at a meta position of the phenyl ring.
  • each k" in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1 , more preferably 1.
  • each m' in Structural Formulas (XXI) - (XXXIII) is independently 1.
  • each k' in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1; and each k" in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1 , more preferably 1.
  • Each R 30 is independently hydrogen or a C1-C6 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C3 alkylamino, C1-C3 dialkylamino, C1-C3 alkoxy, nitro, cyano, hydroxy, C1-C3 haloalkoxy, C1-C3 alkoxycarbonyl and C1-C3 alkylcarbonyl; each k' in Structural Formulas (XXI) - (XXXIV) is independently 0 or 1.
  • each A independently is positioned at a meta position of the phenyl ring; and each k" in Structural Formulas (XXI) - (XXXIV) is independently 0 or 1, preferably 1.
  • each -OR 30 is independently -OH or -O-Cl -C6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C3 C1-C3 alkoxy, hydroxy and C1-C3 haloalkoxy; each k 1 in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1.
  • each A is independently positioned at a meta position of the phenyl ring; and each k" in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1, preferably 1.
  • the compound of the invention is represented by Structural Formula (XVIA) or (XVIB):
  • Q is -O- , -C(O)- or -NH, specifically, -O- or -C(O)-; r and s are each independently 1, 2, 3 or 4; each n independently is 1, 2, 3, 4, 5 or 6; and R 4 has values and preferred values provided above in the fist set of values for Structural Formula (I).
  • the compound of the invention is represented by Structural Formula (XVIC) or (XVID):
  • Q is -O- , -C(O)- or -NH, specifically, -O- or -C(O)-; r and s are each independently 1, 2, 3 or 4; each n independently is 1, 2, 3, 4, 5 or 6;
  • R 4 has values and preferred values provided above in the fist set of values for Structural Formula (I).
  • B is is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.
  • B is halogen, hydroxy, C1-C5 alkoxy or C1-C5 haloalkoxy.
  • the compound of the invention is represented by Structural Formula (XVII), (XVIII), (XIX) or (XIX):
  • phenyl ring A is optionally substituted; each n is 1, 2, 3, 4, 5, or 6; and k is 0, 1 or 2.
  • Values and preferred values of suitable substituents of phenyl ring A are as described above in the first set of values for Structural Formula (I).
  • the invention also includes compounds represented by Structural Formulas (XXI) - (XXXIII) and (XVIC) -
  • the non-aromatic heterocyclic ring represented by -NR 2 R 3 can be a bridged heterobicyclic ring comprising 5-12 ring carbon atoms and 1 or 2 nitrogen atoms.
  • bridged eterobicyclic ring comprising 5-12 ring carbon atoms
  • the bridged bicyclic ring carbon atoms can be optionally subsituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-CO alkyl), -O(C1-C6 haloalkyl), -S(Cl-Co haloalkyl), C1-C6 alkyl, C1-C6 haloalkyl, amino, C1-C6 alkylamino and C1-C6 dialkylamino.
  • substituents selected from the group consisting of halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-CO alkyl), -O(C1-C6 haloalkyl), -S(Cl-Co haloalkyl), C1-C6 alkyl, C1-
  • the bridged bicyclic ring carbon atoms can be optionally subsituted with one or more substituents selected from the group consisting of halogen, -OH, -0(Cl -C6 alkyl) and -O(C1 -C6 haloalkyl).
  • the bridged bicyclic ring nitrogen atoms can be optionally subsituted with one or more substituents selected from the group consisting of C1-C6 alkyl and phenyl, the alkyl being optionally substituted with halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-CO alkyl), -O(C1-C6 haloalkyl), -S(C1-C6 haloalkyl), phenyl, amino, C1-C6 alkylamino and C1-C6 dialkylamino, and the phenyl being optionally substituted with halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-Co alkyl), -O(C1-C6 haloalkyl), -S(C1-C6 haloalkyl), C1
  • the bridged bicyclic ring nitrogen atoms can be optionally subsituted with C1-C6 alkyl that is optionally substituted with halogen, -OH, -O(C 1 -C6 alkyl) and -0(C 1 -C6 haloalkyl).
  • the compound of the invention is represented by a structural formula selected from Structural Formulas (I) - (VIII) and (XI) - (XV), wherein values, including preferred values, of the variables in the structural formulas, other than R 30 , R 31 and R 32 for the substituents of R 1 , are independently as defined in each embodiment described above for Structural Formulas (I) - (VIII) and (XI) - (XV).
  • each R 30 is independently: i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or iii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl, alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl.
  • Each R 31 is independently R 30 , -CO 2 R 30 , -SO 2 R 30 or -C(O)R 30 ; or -N(R 31 ) 2 taken together is an optionally substituted non- aromatic heterocyclic group.
  • Each R is independently: i) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkylcarbonyl and haloalkoxy and haloalkyl; or ii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl, alkylamino, dialkylamino, alkoxy, al
  • Each of the phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl for the substituents of the alkyl group respresented by R 30 and R 32 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, C1-C5 alkyl, C1-C5 haloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C1-C5 alkylamino, C1-C5 dialkylamino, (C1-C5 alkoxy)carbonyl and (C1-C5 alkyl)carbonyl.
  • Each of the alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl for the substituents of the alkyl group respresented by R 30 and R 32 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, phenyl, C1-C5 alkoxy, C1-C5 haloalkoxy, phenylamino, C1-C5 alkylamino, C1-C5 dialkylamino, diphenylamino, (C1-C5 alkoxy)carbonyl, (C1-C5 alkyl)carbonyl, benzoyl and phenoxycarbonyl.
  • solvates, hydrates or polymorphs of the disclosed compounds herein are included.
  • solvates, hydrates and polymorphs thereof are included.
  • the compounds of the invention may contain one or more chiral centers and/or double bonds and, therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers.
  • stereoisomers such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers.
  • stereoisomers such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers.
  • stereoisomers such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers.
  • the compound represented by Structural Formula (I) below has chiral centers 1 and 2.
  • the compounds of the invention depicted by Structural Formula (I) include (IR, 2R), (IR, 2S), (IS, 2R) and (IS, 2S) stereoisomers and mixtures thereof.
  • a racemic mixture means about 50% of one enantiomer and about 50% of is corresponding enantiomer relative to all chiral centers in the molecule.
  • the invention encompasses all enantiomerically-pure, enantiomerically- enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures of the compounds of the invention.
  • the compounds of the invention are (IR, 2R) stereoisomers.
  • Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well known methods, such as chiral- phase gas chromatography, chiral -phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent.
  • Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods.
  • Included in the invention are pharmaceutically acceptable salts of the compounds disclosed herein.
  • the disclosed compounds have basic amine groups and therefore can form pharamceutically acceptable salts with pharmaceutically acceptable acid(s).
  • Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention include salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric, and sulfuric acids) and of organic acids (such as, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p- toluenesulfonic, and tartaric acids).
  • Compounds of the invention with acidic groups such as carboxylic acids can form pharamceutically acceptable salts with pharmaceutically acceptable base(s).
  • Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts).
  • Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like.
  • Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid.
  • the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to the other stereoisomers.
  • the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enatiomer over the weight of the enantiomer plus the weight of its optical isomer.
  • hydrolyzable group means an amide, ester, carbamate, carbonate, ureide, or phosphate analogue, respectively, that either: 1) does not destroy the biological activity of the compound and confers upon that compound advantageous properties in vivo, such as improved water solubility, improved circulating half-life in the blood (e.g., because of reduced metabolism of the prodrug), improved uptake, improved duration of action, or improved onset of action; or 2) is itself biologically inactive but is converted to a biologically active compound.
  • hydrolyzable amides include, but are not limited to, lower alkyl amides, ⁇ -amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides.
  • biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters.
  • biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines.
  • An "aliphatic group” is non-aromatic, consists solely of carbon and hydrogen and may optionally contain one or more units of unsaturation, e.g., double and/or triple bonds.
  • An aliphatic group may be straight chained, branched or cyclic. When straight chained or branched, an aliphatic group typically contains between about one and about twenty carbon atoms, typically between about one and about ten carbon atoms, more typically between about one and about six carbon atoms. When cyclic, an aliphatic group typically contains between about three and about ten carbon atoms, more typically between about three and about seven carbon atoms.
  • a “substituted aliphatic group” is substituted at any one or more "substitutable carbon atom".
  • a “substitutable carbon atom” in an aliphatic group is a carbon in an aliphatic group that is bonded to one or more hydrogen atoms.
  • One or more hydrogen atoms can be optionally replaced with a suitable substituent group.
  • a “haloaliphatic group” is an aliphatic group, as defined above, substituted with one or more halogen atoms. Suitable substituents on a substitutable carbon atom of an aliphatic group are the same as those for an alkyl group.
  • alkyl used alone or as part of a larger moiety, such as “alkoxy”, “haloalkyl”, “arylalkyl”, “alkylamine”, “cycloalkyl”, “dialkyamine”, “alkylamino”, “dialkyamino” “alkylcarbonyl”, “alkoxycarbonyl” and the like, includes as used herein means saturated straight-chain, cyclic or branched aliphatic group.
  • a C1-C6 alkyl group is referred to "lower alkyl.”
  • the terms “lower alkoxy”, “lower haloalkyl”, “lower arylalkyl”, “lower alkylamine”, “lower cycloalkylalkyl”, “lower dialkyamine”, “lower alkylamino”, “lower dialkyamino” “lower alkylcarbonyl”, “lower alkoxycarbonyl” include straight and branched saturated chains containing one to six carbon atoms.
  • alkoxy means -O-alkyl
  • hydroxyalkyl means alkyl substituted with hydroxy
  • aralkyl means alkyl substituted with an aryl group
  • alkoxyalkyl mean alkyl substituted with an alkoxy group
  • alkylamine means amine substituted with an alkyl group
  • cycloalkylalkyl means alkyl substituted with cycloalkyl
  • dialkylamine means amine substituted with two alkyl groups
  • alkylcarbonyl means -C(O)-R*, wherein R* is alkyl
  • alkoxycarbonyl means -C(O)-OR*, wherein R* is alkyl; and where alkyl is as defined above.
  • amine and “amino” are used interchangeably throughout herein and mean -NH 2 , -NHR or -NR 2 , wherein R is alkyl.
  • Cycloalkyl means a saturated carbocyclic ring, with from three to eight carbons.
  • haloalkyl and haloalkoxy mean alkyl or alkoxy, as the case may be, substituted with one or more halogen atoms.
  • halogen means F, Cl, Br or I.
  • acyl group means -C(O)R, wherein R is an optionally substituted alkyl group or aryl group (e.g., optionally substituted phenyl).
  • R is preferably an unsubstituted alkyl group or phenyl.
  • An "alkylene group” is represented by -[CH 2 ] Z -, wherein z is a positive integer, preferably from one to eight, more preferably from one to four.
  • alkenyl refers to a straight or branched hydrocarbon group that contains one or more double bonds between carbon atoms. Suitable alkenyl groups include, e.g., rc-butenyl, cyclooctenyl and the like. An alkenyl group may be substituted.
  • aryl group used alone or as part of a larger moiety as in “aralkyl”, “aralkoxy”, or “aryloxyalkyl”, includes carbocyclic aromatic rings and heteroaryl rings.
  • aromatic group may be used interchangeably with the terms “aryl”, “aryl ring” “aromatic ring”, “aryl group” and “aromatic group”.
  • An aromatic group typically has six - fourteen ring atoms.
  • a "substituted aryl group” is substituted at any one or more substitutable ring atom.
  • Carbocyclic aromatic rings have only carbon ring atoms (typically six to fourteen) and include monocyclic aromatic rings such as phenyl and fused polycyclic aromatic ring systems in which two or more carbocyclic aromatic rings are fused to one another. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl.
  • heteroaryl refers to aromatic ring groups having five to fourteen ring atoms selected from carbon and at least one (typically 1 -4, more typically 1 or 2) heteroatom (e.g., oxygen, nitrogen or sulfur). They include monocyclic rings and polycyclic rings in which a monocyclic heteroaromatic ring is fused to one or more other carbocyclic aromatic or heteroaromatic rings.
  • Examples of monocyclic heteroaryl groups include furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g., N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl( e.g., 3- isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 2-oxadiazolyl, 5- oxadiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrazolyl (e.g., 3- pyrazolyl, 4-pyrazolyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl
  • Examples of monocyclic six- membered nitrogen-containing heteraryl groups include pyrimidinyl, pyridinyl and pyridazinyl.
  • Examples of polycyclic aromatic heteroaryl groups include carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, or benzisoxazolyl.
  • non-aromatic heterocyclic group used alone or as part of a larger moiety as in “non-aromatic heterocyclylalkyl group”, refers to non-aromatic ring systems typically having five to twelve members, preferably five to seven, in which one or more ring carbons, preferably one or two, are each replaced by a heteroatom such as N, O, or S.
  • a non-aromatic heterocyclic group can be monocyclic or fused bicyclic.
  • a "nitrogen-containing non-aromatic heterocyclic group” is a non- aromatic heterocyclic group with at least one nitrogen ring atom.
  • non-aromatic heterocyclic groups include (tetrahydrofuranyl (e.g., 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl), [1,3]- dioxalanyl, [1,3]-dithiolanyl, [1,3]-dioxanyl, tetrahydrothienyl (e.g., 2- tetrahydrothienyl, 3-tetrahydrothieneyl), azetidinyl (e.g., N-azetidinyl, 1-azetidinyl, 2-azetidinyl), oxazolidinyl (e.g., N-oxazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5- oxazolidinyl), morpholinyl (e.g., N-morpholinyl, 2-morpholinyl, 3-morpholinyl
  • N N-morpholinyl, N-thiomorpholinyl, N-pyrrolidinyl, N-piperazinyl, N-piperidinyl and the like indicates that the non- aromatic heterocyclic group is attached to the remainder of the molecule at the ring nitrogen atom.
  • a “substitutable ring atom” in an aromatic group is a ring carbon or nitrogen atom bonded to a hydrogen atom.
  • the hydrogen can be optionally replaced with a suitable substituent group.
  • substituted ring atom does not include ring nitrogen or carbon atoms which are shared when two aromatic rings are fused.
  • substituted ring atom does not include ring carbon or nitrogen atoms when the structure depicts that they are already attached to a moiety other than hydrogen.
  • An aryl group may contain one or more substitutable ring atoms, each bonded to a suitable substituent.
  • Suitable substituents on a substitutable ring carbon atom of an aryl group include halogen, alkyl, haloalkyl, Ar A , -OR A , -O(haloalkyl), -SR A , -NO 2 , -CN, -N(R B ) 2 , -NR B C(O)R A , -NR B CO 2 R C , -N(R B )C(O)N(R B ) 2 , -C(O)R A , -CO 2 R A , -S(O) 2 R A , -SO 2 N(R B ) 2 , -S(O)R C ,
  • Each V A is independently a Cl-ClO alkylene group.
  • Each V B is independently a C2-C10 alkylene group.
  • Ar A is a monocyclic aromatic group each substituted with zero, one or two groups independently selected from halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy or haloalkyl.
  • Each R A is independently i) hydrogen; ii) an aromatic group substituted with zero, one or two groups represented by halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy or haloalkyl; or iii) an alkyl group optionally substituted with halogen, hydroxyl, alkoxy, nitro, cyano, alkoxycarbonyl, alkylcarbonyl or haloalkoxy.
  • Each R B is independently R A , -CO 2 R A , -SO 2 R A or -C(O)R A ; or -N(R B ) 2 taken together is an optionally substituted non-aromatic heterocyclic group.
  • Each R c is independently: i) an aromatic group substituted with zero, one or two groups represented by halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy or haloalkyl; or ii) an alkyl group optionally substituted with halogen, hydroxyl, alkoxy, nitro, cyano, alkoxycarbonyl, alkylcarbonyl or haloalkoxy.
  • An alkyl or a non-aromatic heterocyclic group may contain one or more substituents.
  • a ring nitrogen atom e.g., N- piperidinyl, N-pyrrolidinyl, N-azepany
  • Each R c is independently selected from hydrogen, an unsubstituted alkyl group or a substituted alkyl group.
  • substituents on the alkyl group represented by R include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
  • Preferred substituents for an alkyl or a ring carbon of a non-aromatic heterocyclic group include C1-C2 alkyl, -OH, N-pyrrolidinyl, N-piperidinyl, N-(4- alkyl)piperazinyl, N-morpholinyl or N-pyrrolyl.
  • substituents on the alkyl group or the phenyl ring represented by R° include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl.
  • Preferred substituents on a substitutable nitrogen atom of a nitrogen-containing heteroaryl or nitrogen- containing non-aromatic heterocyclic group include C1-C2 alkyl, C1-C2 hydroxyalkyl, or benzyl optionally substituted with halogen, nitro, cyano, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
  • the non-aromatic heterocyclic groups each independently are optionally substituted with one or more substituents selected from the group consiting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, (C1-C6 alkoxy)carbonyl, (C1-C6 alkyl)carbonyl, C1-C6 haloalkoxy, amino, (C1-C6 alkyl)amino and (C1-C6 dialkyl)amino.
  • substituents selected from the group consiting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, (C1-C6 alkoxy)carbonyl, (C1-C6 alkyl)carbonyl, C1-C6 haloalkoxy, amino, (C1-C6 alkyl
  • Inhibitors of glucosylceramide synthase can be used to treat diabetes, such as type 2 diabetes (see WO 2006/053043, the entire teachings of which are incorporated herein by reference).
  • the disclosed compounds, which are inhibitors of glucosylceramide synthase can be used to treat diabetes, e.g., type 2 diabetes and renal hypertrophy or hyperplasia associated with diabetic nephropathy, by administration of a therapeutically effective amount of a compound of the invention to a subject in need of such treatment.
  • Inhibitors of glucosylceramide synthase such as GM3 synthase have been shown to be useful for treating lysosomal storage diseases (see, for example, U.S. Patent Nos. 6,569,889; 6,255,336; 5,916,911; 5,302,609; 6,660,749; 6,610,703; 5,472,969; 5,525,616, the entire teachings of which are incorporated herein by reference).
  • the disclosed compounds which are inhibitors of glucosylceramide synthase, can be used to treat lysosomal storage diseases, such as Tay-Sachs, Gaucher's or Fabry's disease, by administration of a therapeutically effective amount of a compound of the invention to a subject in need of such treatment.
  • lysosomal storage diseases such as Tay-Sachs, Gaucher's or Fabry's disease
  • the compounds of the present invention can be used for: treating disorders involving cell growth and division, including cancer, collagen vascular diseases, atherosclerosis, and the renal hypertrophy of diabetic patients (see U.S. Patent Nos. 6,916,802 and 5,849,326, the entire teachings of which are incorporated herein by reference); inhibiting the growth of arterial epithelial cells (see U.S. Patent Nos. 6,916,802 and 5,849,326); treating patients suffering from infections (see Svensson, M.
  • the compounds of the invention can be used for a vaccine-like preparation (see, for example, U.S. Patent Nos. 6,569,889; 6,255,336; 5,916,91 1 ; 5,302,609; 6,660,749; 6,610,703; 5,472,969; 5,525,616).
  • cancer cells are removed from the patient (preferably as completely as possible), and the cells are grown in culture in order to obtain a large number of the cancer cells. The cells are then exposed to the inhibitor for a time sufficient to deplete the cells of their GSLs (generally 1 to 5 days) and are reinjected into the patient. These reinjected cells act like antigens and are destroyed by the patient's immunodefense system.
  • the remaining cancer cells (which could not be physically removed) will also be attacked by the patient's immunodefense system.
  • the patient's circulating gangliosides in the plasma are removed by-plasmapheresis, since the circulating gangliosides would tend to block the immunodefense system.
  • a subject is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, such as a companion animal (e.g., dogs, cats, and the like), a farm animal (e.g., cows, sheep, pigs, horses, and the like) or a laboratory animal (e.g., rats, mice, guinea pigs, and the like).
  • a companion animal e.g., dogs, cats, and the like
  • a farm animal e.g., cows, sheep, pigs, horses, and the like
  • laboratory animal e.g., rats, mice, guinea pigs, and the like.
  • a subject "in need of treatment” includes a subject with chronic renal failure.
  • Treatment or “treating” refers to both therapeutic and prophylactic treatment.
  • an "effective amount" of a pharmaceutical composition disclosed above is a quantity that results in a beneficial clinical outcome of or exerts an influence on, the condition being treated with the pharmaceutical composition compared with the absence of treatment.
  • the administering amount of a pharmaceutical composition disclosed above to the subject will depend on the degree, severity, and type of the disease or condition, the amount of therapy desired, and the release characteristics of the pharmaceutical composition. It will also depend on the subject's health, size, weight, age, sex, and tolerance to drugs.
  • the pharmaceutical compositions of the invention are administered for a sufficient period of time to achieve the desired therapeutic effect. Dosages may range from 0.1 to 500 mg/kg body weight per day. In one embodiment, the dosing range is 1-20 mg/kg/day.
  • the compound of the invention may be administered continuously or at specific timed intervals.
  • the compound of the invention may be administered 1 , 2, 3, or 4 times per day, such as, e.g., a daily or twice-daily formulation.
  • Commercially available assays may be employed to determine optimal dose ranges and/or schedules for administration.
  • assays for measuring blood glucose levels are commercially available (e.g., OneTouch ® Ultra ® , Lifescan, Inc. Milpitas, CA). Kits to measure human insulin levels are also commercially available (Linco Research, Inc. St. Charles, MO).
  • effective doses may be extrapolated from dose- response curves obtained from animal models (see, e.g., Comuzzie et al., Obes. Res. 11 (1 ):75 (2003); Rubino et al., Ann. Surg. 240(2):389 (2004); Gill- Randall et al, Diabet. Med. 21 (7):759 (2004), the entire teachings of which are incorporated herein by reference).
  • Therapeutically effective dosages achieved in one animal model can be converted for use in another animal, including humans, using conversion factors known in the art (see, e.g., Freireich et al., Cancer Chemother. Reports 50(4):219 (1996), the entire teachings of which are incorporarted herein by reference) and Table A below for equivalent surface area dosage factors.
  • the pharmaceutical compositions of the invention can be administered before or after a meal, or with a meal.
  • "before” or “after” a meal is typically within two hours, preferably within one hour, more preferably within thirty minutes, most preferably within ten minutes of commencing or finishing a meal, respectively.
  • the method of the present invention is a mono-therapy where the pharmaceutical compositions of the invention are administered alone. Accordingly, in this embodiment, the compound of the invention is the only pharmaceutically active ingredient in the pharmaceutical compositions.
  • the method of the invention is a co-therapy with other therapeutically active drugs known in the art for treating the desired diseases or indications, such as one or more known drugs for treating, diabetes, lysosomal diseases, tumors, etc.
  • the method of the invention is a combination therapy for treating diabetes, such as Type 2 diabetes.
  • the combination therapy comprise any of the compounds of the invention described herein and at least one other compound suitable for treating diabetes.
  • drugs or compounds used to treat type 2 diabetes include: insulin (e.g., Novolin®, Novolog®, Velosulin®); sulfonylureas (e.g., Diabinese®, Glucotrol®, Glucotrol XL®, (Diabeta®, Amaryl®, Orinase®, Tolinase®, Micronase® and Glynase®); metformin; [alpha] -glucosidase inhibitors (e.g., Glyset®); thiazolidinediones(e.g., Actos® and Avandia®); nateglinide (Starlix®); repaglinide (Prandin®) and combination drugs such as Avandamet® (Avan
  • compositions of the invention optionally include one or more pharmaceutically acceptable carriers and/or diluents therefor, such as lactose, starch, cellulose and dextrose.
  • pharmaceutically acceptable carriers and/or diluents therefor such as lactose, starch, cellulose and dextrose.
  • Other excipients such as flavoring agents; sweeteners; and preservatives, such as methyl, ethyl, propyl and butyl parabens, can also be included. More complete listings of suitable excipients can be found in the Handbook of Pharmaceutical Excipients (5 th Ed., Pharmaceutical Press (2005)).
  • the carriers, diluents and/or excipients are "acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof.
  • the pharmaceutical compositions can conveniently be presented in unit dosage form and can be prepared by any suitable method known to the skilled artisan. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing into association the compounds disclosed herein with the carriers, diluents and/or excipients and then, if necessary, dividing the product into unit dosages thereof.
  • compositions of the invention can be formulated as a tablet, sachet, slurry, food formulation, troche, capsule, elixir, suspension, syrup, wafer, chewing gum or lozenge.
  • a syrup formulation will generally consist of a suspension or solution of the compounds of the invention described herein or salt in a liquid carrier, for example, ethanol, glycerine or water, with a flavoring or coloring agent.
  • a liquid carrier for example, ethanol, glycerine or water
  • a flavoring or coloring agent for example, ethanol, glycerine or water
  • one or more pharmaceutical carriers routinely used for preparing solid formulations can be employed. Examples of such carriers include magnesium stearate, starch, lactose and sucrose.
  • compositions are in the form of a capsule
  • use of routine encapsulation is generally suitable, for example, using the aforementioned carriers in a hard gelatin capsule shell.
  • composition is in the form of a soft gelatin shell capsule
  • pharmaceutical carriers routinely used for preparing dispersions or suspensions can be considered, for example, aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
  • compositions of the invention may also be formulated for rectal administration as a suppository or retention enema, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.
  • pharamceutical compositions of the invention can be formulated for injection, or for transdermal or trnasmucosal administration.
  • Illustrative of various modes of administration methods, vehicles and carriers are those described, for example, in Remington's Pharmaceutical Sciences, 18 th ed. (1990), the disclosure of which is incorporated herein by reference.
  • a general method for the preparation of the compounds of the invention involves the reaction of the amine of type EVII with the appropriate reagent.
  • the amine type EVII such as (IR, 2R)-2-amino-(2,3-dihydrobenzo [ ⁇ ][1,4[dioxin-6-yl)-3- (pyrrolidin-1-yl) propan-1-ol, can be prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference), or by using the general synthetic procedures depicted in schemes 2-5.
  • Final amide compounds, EIX can be prepared by reaction of the amine EVII with the corresponding acylating agent using standard reaction conditions for the formation of an amide.
  • the urea compounds, EIIX can be prepared by reaction of the amine EVII with the corresponding isocyanate.
  • the carbamates, EX can be prepared by reaction of the amine EVII with the corresponding chloroformate.
  • Compound EVII such as (IR, 2R)-2-amino-1-(2,3-dihydro-benzo[1,4] dioxin-6-yl)-3-pyrrolidin-1-yl-propan-1-ol, prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference) or using the methods depicted in schemes 2,3,4 and 5, was coupled with a variety of N-hydroxysuccinamide esters in methylene chloride under an atmosphere of nitrogen, for example, for 18 to 24 hours depending on the ester used.
  • Benzyl (IR, 2R)-1-(2,3-dihydrobenzo[ ⁇ ][1,4]dioxin-6-yl)-1,3- dihydroxypropan-2-ylcarbamate was dissolved in excess pyridine, cooled to -15 °C and one equivalent of methanosulfonyl chloride was added to the mixture. Mixture was stirred about half an hour, and ten equivalents of the amine were added. The reaction mixture was allowed to warm up to room temperature and then heated at 50 °C overnight. The crude was evaporated down and the product was purified by column chromatography using a mixture of methanol/methylene chloride/ammonium hydroxide.
  • the pure compound EVI was then de-protected by hydrolysis in the microwave, using aqueous NaOH (40%in weight)/methanol solution as solvent and heating the mixture to 150 °C for about 15 minutes to give the free amines of the type EVI.
  • the final product was purified by silica-gel column chromatography using a mixture of methanol/methylene chloride/ammonium hydroxide.
  • iiUIR 2R-2-amino-1-(2.3-dihvdrobenzof ⁇ i ⁇ .41dioxin-6-yl)-3-rpiperidin- 1-yl)propan-1-ol.
  • Example IDl Preparation of 3-(4-methoxyphenoxy)propionic acid.
  • Step 1 a mixture of 4-(p-hydroxyphenol)-2-butanone (1.032 g), triton B (400 ⁇ L), acrylonitrile (4 mL) and MeOH (0.8 mL) was heated at 70 °C for 20 hours. The mixture was cooled to room temperature and the solvent was removed to dryness. 3-(4-(3-oxobutyl)phenoxy)propanenitrile was obtained as a white solid (0.572 g) after purification by column chromatography using ethyl acetate/hexane.
  • Step 1 a mixture of 4-(2-methoxy ethyl) phenol (1.547g, 10.3 mmol), propiolic acid tert-butyl ester (1.367g, 10.8 mmol) and N-methyl morpholine (1.18 mL, 10.8 mmol) in CH 2 Cl 2 (15 mL) was stirred at room temperature for 24 hours. The mixture was absorbed on SiO 2 (20 g) and purified by column chromatography using a mixture of methylene chloride/hexane. The product was obtained as a two to one mixture of (E)/ (Z)-tert-butyl 3-(4-(2-methoxyethyl)phenoxy)acrylate isomers (2-0 g).
  • Step 3 (E)/(Z)-3-(4-(2-methoxyethyl)phenoxy)acrylic acid (0.3 g) was dissolved in EtOH (10 mL) and Pd/C (5 %, degussa type ElOl, 40 mg) was added. The mixture was hydrogenated at atmospheric pressure for 2 hours and then filtered and the solvent removed to dryness. After purification by column chromatography using a mixture of hexane/ethyl acetate, 3-(4-(2-methoxyethyl)phenoxy)propanoic acid was obtained as a white solid (0.236 g).
  • Example 1D4 Preparation of 3 -(4-(3-methylbutanoyl)phenoxV)propanoic acid
  • Step 1 3-phenoxypropionic acid (5.0 g, 30 mmol) was dissolved in MeOH (12 mL) and H 2 SO 4 (18 M, 3 drops) was added. The mixture was place in the microwave reactor (T: 140 °C, t: 5 min). The solvent was evaporated, the mixture was partitioned in EtOAc (30 mL) and NaOH (2N, 20 mL). The organic phase was dried over MgSO 4 , filtered, and evaporated to give methyl 3-phenoxypropanoate (5.0 g, 27.7 mmol, 92.5%).
  • Step 2 aluminum chloride (1.1 g, 8.34 mmol) was added to a cold solution (0 0 C) solution of methyl 3-phenoxypropanoate (1.0 g, 5.56 mmol) and tert- butylacetyl chloride (1.25 mL, 8.34 mmol) in CH 2 Cl 2 (9 mL) and the reaction mixture was stirred overnight. The mixture was evaporated and the residue was diluted with EtOAc (30 mL) and then washed with water (2 X 20 mL). The organic phase was removed and purified with silica chromatography using of a gradient hexanes/EtOAc (100:0 ⁇ 0:100) to give methyl 3-phenoxypropanoate (600 mg, 2.27 mmol, 40%).
  • Step 3 a solution of methyl 3-phenoxypropanoate (200 mg, 0.76 mmol) in 2 mL of HCl (37%) was placed in a microwave reactor (T: 120 0 C, t: 5 min). The mixture was poured into iced water (2g) and washed with EtOH (3 X10 mL). The organic phase was combined and evaporated. The crude product was purified with silica gel chromatography using of a gradient hexanes/EtOAc ( 100:0-» 0: 100) to give 3-(4-(3-methylbutanoyl)phenoxy)propanoic acid (120 mg, 0.48 mmol, 63%).
  • Example 2 Preparation of Compounds of the Invention
  • Example 2 The exemplary compounds shown in Example 2 and Tables 1-3 can be prepared by following scheme 1 described above, Detailed synthetic description of certain compounds also are described below as examples.
  • Compound 163 was prepared by following Scheme IA above. 3-(4- methoxyphenoxy)propanoic acid (see Example IDl, 34.47g, 169mmol, 96% purity by HPLC), DCC (34.78g, 169 mmol) and N-hydroxysuccinimide (19.33, 169mmol) were combined as dry powders and methylene chloride (50OmL) was added. The suspension was mechanically stirred overnight, ambient temperature, under a nitrogen atmosphere. HPLC analysis showed complete conversion of the acid to the NHS ester (N-hydroxy succinyl ester).
  • the resultant biphasic solution was poured into an Erlenmeyer flask and cautiously neutralized to a pH of 1.2-1 A with a saturated solution of sodium bicarbonate (approx 20OmL of solution).
  • the organic layer was separated from the aqueous layer, dried over sodium sulfate and evaporated to yield 83.6g of yellow oil (theoretical yield: 77.03g).
  • the oil was dissolved in isopropyl alcohol (50OmL) with heating and transferred to a IL round bottom flask equipped with a mechanical stirrer and heating mantel. The solution was heated to 50°C and the mechanical stirrer was set to a rate of 53-64 rpm. Tartaric acid (25.33g, 168mmol) was dissolved in deionized water (5OmL) and added to the stirred solution at 50°C. Once the solution turned from milky white to clear, seed crystals were added to the mixture and crystallization immediately began (temperature jumped to 56°C). After 20 minutes, the mixture was set to cool to a temperature of 35°C (cooling took 1.15 hours). Heating was removed and the solution was allowed to stir for 12 hours.
  • isopropyl alcohol 50OmL
  • the solution was heated to 50°C and the mechanical stirrer was set to a rate of 53-64 rpm.
  • Tartaric acid 25.33g, 168mmol
  • deionized water 5
  • the resulting thick slurry was filtered on a B ⁇ chner funnel. Any remaining solid in the flask was washed onto the funnel using ice-cold isopropyl alcohol (10OmL). The material was transferred to a drying tray and heated to 48°C under vacuum for 3 days (after two days the material weighed 76g and after three days it weighed 69.3g). The solid was analyzed by LC and shown to be 98.1% pure (AUC), the residual solvent analysis showed the material to possess 3472 ppm of isopropyl alcohol, and the DSC (differnetial scaaning calroimetery) showed a melting point of 134.89°C. A total of 69.3g of white solid was collected (65.7% overall yield).
  • AUC 98.1% pure
  • Compound 247 was prepared by reaction of (IR, 2R)-2-amino-1-(4- methoxyphenyl)-3-(pyrrolidin-1-yl)propan-1-ol as the amine, prepared according to scheme 3 with 3-(4-methylphenoxy)propionic acid using method 1.
  • N,O-dimethylhydroxylamine hydrochloride 45 g, 0.46 mmol, 1.5 eq
  • N- methyl morpholine 84 mL, 0.765 mol, 2.5 eq.
  • CH 2 Cl 2 560 mL
  • EDCI 62 g, 0.323 mol, 1.05 eq
  • Example 2E3 Preparation of Compound 251: N-((1R. 2R)-1-hydroxy- 1 -(4- methoxyphenyl)-3-(pyrrolidin- 1 -yl)propan-2-yl)-2-(4- (trifluoromethyl)phenyl)acetamide.
  • Example 2E Preaparation of Compound 5: N-CClR. 2R.)-1-f2.3- dihydrobenzof ⁇ ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-fpyrrolidin- 1 -yl)propan-2- yPbenzo rblthiophene-2-carboxamide
  • Example 2E7 Preparation of Compound 19: N-((1R. 2R)-1 -(2,3- dihydrobenzo
  • Example 2El Preparation of Compound 27: N-((1R, 2R)-1-(2,3- dihvdrobenzo[ ⁇ ][1,4]dioxin-6-yl)-i-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3- phenoxypropanamide
  • Example 2E21 Preparation of Compound 54: N-((1R. 2R)-1-(2.3- dihvdrobenzo [ ⁇ ] [ 1 ,4]dioxin-6-yl V 1-hydroxy-3 -(pyrrolidin- 1 - vOpropan-2-yl)-3 -(3 - methoxyphenoxy ⁇ propanamide
  • Example 2E25 Preparation of Compound 59: N-(QR. 2R)-1-(2,3- dihvdrobenzo[ ⁇ 1[1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(p- tolyloxy)propanamide
  • Example 2E27 Preparation of Compound 61: N-((1R, 2R)-1-(2,3- dihvdrobenzo[ ⁇ ][1.41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(4- methoxyphenoxy)propanamide
  • Example 2E29 Preparation of Compound 189: N-((1R. 2R)- 1 -(2,3- dihydrobenzo [b] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -Cpyrrolidin- 1 -vQpropan-2-yl)-3 -(4- propionylphenoxy)propanamide C2R, 3R)-2,3-dihydroxysuccinate
  • Example 2E31 Preparation of Compound 202: N-((1R. R)-1-(2.3- dihydrobenzof ⁇ ] [ 1,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl)-3 -(4- (2-methoxyethyl)phenoxy)propanamide (2R, R)-2,3-dihvdroxysuccinate
  • Example 2E32 Preparation of Compound 63: N-fdR. 2R.)-1-f2.3- dihydrobenzo [ ⁇ ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)-2-(3 '- methoxybiphenyl-4-yl)acetamide
  • Example 2E33 Preparation of Compound 127: N-((1R. 2R)-1-(2.3- dihydrobenzo [b] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl)-4-(4- ethoxyphenyl)-4-oxobutanamide
  • Example 2E34 Preparation of Compound 154: N-((1R. 2R)-1-(2.3- dihydrobenzorb] [ 1 ,41dioxin-6-yl)- 1-hvdroxy-3-(pyrrolidin- 1 -yl)propan-2-yl ' )-4-(4- methoxyphenyl)-4-oxobutanamide
  • Example 2E35 Preparation of Compound 181: N-((1R. 2R>l-f2.3- dihydrobenzo FbI [ 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl)-6-(4- isopropoxyphenyl)-6-oxohexanamide
  • Example 2E36 Preparation of Compound 191: N-((1R. 2R)-1-(2.3- dihvdrobenzo[ ⁇ ][1,41dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-5-(4- methoxyphenyl)-5-oxopentanamide (2R,3R * )-2,3-dihydroxysuccinate
  • Example 2E38 Preparation of Compound 267: N-((1R. 2R)-I- (benzo [ ⁇ ] [ 1 ,3 ] dioxol-5-yl )- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)-6-(4- methoxyphenyl)-6-oxohexanamide (2S. 3S)-2,3-dihydroxysuccinate
  • Example 2E39 Preparation of Compound 268: N-((1R. 2R)-1- (benzo[ ⁇ ] [ 1 ,3]dioxol-5-yl)- 1-hvdroxy-3-(pyrrolidin- 1 -yl * )propan-2-vQ-7-(4- isopropoxyphenvO-7-oxoheptanamide (2S, 3S)-2,3-dihydroxysuccinate
  • Example 2E40 Preparation of Compound 197: N-f(lR. 2R)-1-(2.3- dihvdrobenzo[ ⁇ 1[1,41dioxin-6-yl)-1-hydroxy-3-( ' pyrrolidin-1-yl)propan-2-yl)-4-(4- methoxyphenoxy)butanamide (2S, 3S)-2,3-dihydroxysuccinate
  • Example 2E41 Preparation of Compound 187: N-((1R. 2R)-1-(2,3- dihydrobenzo [ ⁇ ] [ 1.4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)-3 -(4- (3-methylbutanoyl)phenoxy)propanamide (2S, 3 S)-2.3-dihydroxysuccinate
  • Example 2E45 Preparation of Compound 280: 2-(3,4-difluorophenvn-N-((lR.2R)- 1 -(2,3-dihydrobenzo[ ⁇ ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)acetamide
  • Example 2E46 Preparation of Compound 103: N-fflR.2RH-f2.3- dihydrobenzo [ ⁇ ] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -f pyrrolidin- 1 -yl)propan-2-yl)-2-(4- (trifluoromethoxy)phenyl)acetamide
  • Example 2E47 Preparation of Compound 90: N-(C !R.2R)-1-f2.3- dihydrobenzo [ ⁇ ] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -f pyrrolidin- 1 - yl)propan-2-yl)-5 - fthiophen-2-yl)isoxazole-3-carboxamide
  • Example 2E48 Preparation of Compound 92: 3-(3-chloro-4-methoxyphenyl)-N- (T 1 R.2R)- 1 -(2.3-dihvdrobenzo[ ⁇ ][ 1 ,41dioxin-6-vn- 1-hydroxy-3-(pyrrolidin- 1 - yl)propan-2-yl)propanamide
  • Example 2E49 Preparation of Compound 96: N-(T 1R.2R)-1 -f 2.3- dihydrobenzo[ ⁇ ] [1 ,4]dioxin-6-y0- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3-(4- (trifluoromethyl)phenyl)propanamide
  • Example 2E50 Preparation of Compound 101: 4-(benzo[d]thiazol-2-yl)-N- (T 1 R.2R)- 1 -(2.3 -dihvdrobenzor ⁇ l ⁇ 1.41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)butanamide
  • Example 2E51 Preparation of Compound 102: N-((lR,2R)-1-(2,3- dihvdrobenzo[ ⁇ ][1.41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-6-(2,3- dihvdrobenzor ⁇ iri.41dioxine-6-sulfonarnido)hexanamide
  • Example 2E54 Preparation of Compound 282: N-((lR.2R)-1-(2.3- dihydrobenzo [ ⁇ l F 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)-5 -(3 A- dimethoxypheny ⁇ -5-oxopentanamide
  • Example 2E56 Preparation of Compound 113: N-((lR.2R)-1-(2.3- dihvdrobenzof ⁇ ][1,4]dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-y ⁇ propan-2-yl ' )-5-oxo- 5 -phenylpentanamide
  • Example 2E58 Preparation of Compound 140: N-((1R.2R)-1 -(2.3- dihydrobenzof ⁇ ] [1 ,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1 -yl)propan-2-yl ' )-6-(4- methoxy-3 ,5 -dimethylphenyl)-6-oxohexanamide
  • Example 2E60 Preparation of Compound 155: 6-(4-tert-butylphenyl)-N-( ⁇ R,2R)- l-(2,3-dihvdrobenzo[ ⁇ iri,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-
  • Example 2E62 Preparation of Compound 144: N-(Yl R.2R)-1 -(2.3- dihydrobenzo ⁇ ] [ 1 ,4]dioxin-6-yl)- 1-hydroxyl)-Cpyrrolidin- 1 -yl)propan-2-yl)-8-(4- methoxyphenyl)-8-oxooctanamide
  • Example 2E63 Preparation of Compound 159: 7-(4-chlorophenvn-N-((lR.2R)-1- (2,3-dihydrobenzo[ ⁇ ] [ 1 ,4]dioxin-6-vQ- 1-hydroxy-3-(py ⁇ Olidin- 1 -yl)propan-2-yl)-7- oxoheptanamide
  • Example 2E64 Preparation of Compound 160: 7-(4-tert-butyrphenyl)-N-((lR,2R)- 1 -(2,3 -dihydrobenzo [ ⁇ ] [ 1 ,41 dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)- 7-oxoheptanamide
  • Example 2E65 Preparation of Compound 168: N-((lR.2R)-1-(2.3- dihydrobenzo [b] [ 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl V7-(4- methoxyphenyl)-7-oxoheptanamide (2S,3SV2,3-dihvdroxysuccinate
  • Example 2E66 Preparation of Compound 162: N-((lR.2R)-1-f2.3- dihydrobenzor ⁇ l ⁇ 1 ,4]dioxin-6-yl)- 1-hydroxy-S-Cpyrrolidin- 1 -yl)propan-2-yl)-4-(4- isopropoxyphenyl)-4-oxobutanamide
  • Example 2E68 Preparation of Compound 65 fGenz-528152-11: 2-(3'- chlorobiphenyl-4-vn-N-(( 1 R.2RH -(2.3-dihvdrobenzor ⁇ l f 1.41dioxin-6-yl)- 1 ⁇ hydroxy-3-Cpyrrolidin- 1 -yl ⁇ )propan-2-vI * )acetamide
  • Example 2E70 Preparation of Compound 270: 5-(4-Isopropoxy-phenyl)-5-oxo- pentanoic acid [2-hvdroxy-2-(4-methoxy-phenyl)- 1 -pyrrolidin- 1 -ylmethyl- ethyll amide
  • Example 2E102 Preparation of Compound 261: N-((1R. 2R)-1-(23- dihvdrobenzo[ ⁇ ][L41dioxin-6-yl)-1-hvdroxy-3-(piperidin-1-yl)propan-2-yl)-3-(4- methoxyphenoxy)propanamide
  • Example 2B8 Preparation of Compound 10: 1-((1R, 2R)- ⁇ -(23- dihvdrobenzo[ ⁇ l[1,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-((S)- 1 -phenylethyl)urea
  • Example 2B9 Preparation of Compound 286: 1-(TlR, 2R)-1-(2,3- dmydroberizo[ ⁇ ][1,4]dioxin-6-yl)-1-hydroxy-3-(pyi ⁇ olidin-1-yl)propan-2-yl)-3-( 1 -phenylethvQurea
  • Example 2B10 Preparation of Compound 69: 1-((1R, 2R)-1-(2,3- dihydrobenzof ⁇ ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3- (naphthalen-2-yl)urea
  • Example 2Bl Preparation of Compound 288: H(IR, 2R)-1-(2,3- dihydrobenzo[ ⁇ 1
  • Example 2B13 Preparation of Compound 70: l-(biphenyl-4-yl)-3-((lR, 2R)-1-(2.3- dihvdrobenzor ⁇ iri,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)urea
  • Example 2B14 Preparation of Compound 81: 1-((1R. 2R)-1-(2,3- dihydrobenzo[ ⁇ ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3-(4- (trifluoromethyl)pheny ⁇ urea
  • Example 2B15 Preparation of Compound 68: 1-((1R, 2R)-1-(2,3- dihvdrobenzo[ ⁇ 1[1,4]dioxin-6-yl)-1-hvdroxy-3-(pyi ⁇ olidin-1-yl)propan-2-yl)-3-(3- (trifluoromethyl)phenyl)urea
  • Example 2B16 Preparation of Compound 82: H(IR. 2R)-1-(2.3- dihvdrobenzo[ ⁇ ][1,4]dioxin-6-yl)-1-hydroxy-3-(pyi ⁇ olidin-1-yl)propan-2-yl)-3-(4- (trifluoromethoxy)phenyl)urea
  • Example 2B19 Preparation of Compound 287: 1-((1R, 2R)-1-C2J- dihydrobenzo [ ⁇ ] [ 1 ,41 dioxin-6-yl)- 1-hvdroxy-3-(pyrrolidin- 1 - yl)propan-2-yl)-3 -(2- (thiophen-2-yl ' )ethyl)urea
  • Example 2B20 Preparation of l-((lR,2R)-1-(4-(4-fluorobutoxy)phenyl)-1-hvdroxy- 3-((R)-3-hydroxypyrrolidin-1-yl)propan-2-yl)-3-(4-methoxybenzyl)urea 2,2,2- trifluoroacetate
  • Example 2B21 Preparation of l-(4-chlorobenzvn-3-((lR,2R)-1-(4-(4- fluorobutoxy)phenyl)- 1-hvdroxy-3-((R)-3-hvdroxypyrrolidin- 1 -yl)propan-2-yl)urea
  • B 16-FO cells from ATCC American Tissue Culture Collection
  • ATCC American Tissue Culture Collection
  • DMEM media Eagle's medium
  • Hyclone Fetal Bovine Serum
  • Pen/Step/Glutamine Biowhittaker
  • 4000 cells per well were plated on collagen coated plates (BD) and allowed to attach for 6 hours in an incubator (37 degrees, 5% CO2). After 6 hours the compounds and controls were added to the wells, the plates mixed and returned to the incubator for 2 days.
  • TBS Tris Buffered Saline
  • 150 ⁇ l of TBS was left in the wells and 50 ⁇ l of goat serum (Invitrogen) was added, the plates mixed and incubated for 1 hour at room temperature.
  • the plates were flicked and the cells incubated with the monoclonal Antibody to GM3 (NeuAc) (Cosmo) for 45 minutes as room temperature.
  • the plates were then washed 3 times with TBS, leaving 150 ⁇ l of TBS in the wells and Peroxidase AffinPure F (ab') 2 frag Gt Anti-mouse IgM, ⁇ Chain Specific (Jackson Immno Research) was added in 50 ⁇ l, the plates mixed and incubated for 45 minutes at room temperature.
  • the plates were washed 3 times with TBS, flicked and blotted and 100 ⁇ l of Quantablu (Pierce) was added to the wells and incubated for 1 hour then read on a Fluorometer at Ex 325 and Em 420. The data was then analyzed using standard programs.
  • IC50 values are indicated as "A,” “B,” C,” “D,” and “E” for those of less than or equal to 0.1 ⁇ m; those of greater than 0.1 ⁇ m, and less than or equal to 1 ⁇ m; those of greater than 1 ⁇ m, and less than or equal to 3 ⁇ m; those of greater than 3 ⁇ m, and less than or equal to 10 ⁇ m; those of greater than 10 ⁇ m, respectively.
  • Tables 1, 2 and 3 numerous compounds of the invention were shown to be inhibitors of GM3.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

A compound is represented by Structural Formula (I): or a pharmaceutically acceptable salt thereof. A pharmaceutical composition comprises a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of treating a subject in need thereof comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. The subject has type 2 diabetes; renal hypertrophy or hyperplasia associated with diabetic nephropathy; Tay-Sachs; Gaucher's; or Fabry's disease. Methods of decreasing plasma TNF-α, lowering blood glucose levels, decreasing glycated hemoglobin levels, inhibiting glucosylceramide synthase, and lowering glycosphingolipid concentrations in a subject in need thereof respectively comprise administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.

Description

2-ACYLAMINOPROPOANOL-TYPE GLUCOSYLCERAMIDE SYNTHASE
INHIBITORS
RELATED APPLICATION(S)
This application claims the benefit of U.S. Provisional Application No. 60/932,370, filed May 31 , 2007 and U.S. Provisional Application No. 60/997,846, filed on October 5, 2007.
The entire teachings of the above applications are incorporated herein by reference.
BACKGROUND OF THE INVENTION
Gangliosides, such as GMl, GM2 and GM3, are glycosphingolipids (GSLs) comprised of ceramide and at least one acidic sugar. Gangliosides are generally found in the outer leaflet of the plasma membrane (Nojri et al., Proc. Natl. Acad. ScL USA 83:782 (1986)). Gangliosides are involved in cell signaling and act as modulators of receptor activity (Yamashita et al., Proc. Natl. Acad. ScL USA
100(6):3445 (2003)). A number of GSLs are derived from glucosylceramide, which is enzymatically formed from ceramide and UDP-glucose. The formation of glucosylceramide is catalyzed by glucosylceramide synthase.
It has been found that the level of GSLs controls a variety of cell functions, such as growth, differentiation, adhesion between cells or between cells and matrix proteins, binding of microorganisms and viruses to cells, and metastasis of tumor cells. In addition, the glucosylceramide precursor, ceramide, may cause differentiation or inhibition of cell growth and be involved in the functioning of vitamin D3, tumor necrosis factor-α, interleukins, and apoptosis. Sphingols, precursors of ceramide, and products of ceramide catabolism have also been shown to influence many cell systems, possibly by inhibiting protein kinase C.
Defects in GSL metabolizing enzymes can cause serious disorders. For example, Tay-Sachs, Gaucher' s, and Fabry's diseases result from enzymatic defects in the GSL degradative pathway and the accumulation of GSL. In particular, GMl accumulates in the nervous system leading to mental retardation and liver enlargement. In Tay-Sachs, GM2 accumulates in brain tissue leading to mental retardation and blindness. These observations suggest that inhibitors of glycosylceramide synthase can be effective in treating lysosomal diseases such as Tay-Sachs, Gaucher' s, and Fabry's diseases. Indeed, glucosylceramide synthase inhibitors have been described for this purpose (see U.S. Patent Nos. 6,569,889; 6,255,336; 5,916,911 ; 5,302,609; 6,660,749; 6610,703; 5,472,969; and 5,525,616). Recently it has been disclosed that the interruption of the insulin induced signaling cascade may be associated with elevated levels of GM3. It has also been suggested that the cytokine tumor necrosis factor-α (TNF-α), implicated in insulin resistance, results in increased expression of GM3 (Tagami et ah, J. Biol. Chem. 277(5):3085 (2002)). Also, it has been disclosed that mutant mice lacking GM3 synthase, and thus lacking in GM3, are protected from insulin resistance caused by a high-fat diet (Yamashita et al, Proc. Natl. Acad. Sc. USA 100:3445-3449 (2003)). These observations suggest that inhibitors of glycosylceramide synthase can be effective in treating diabetes. Indeed, inhibitors of glucosylceramide synthase have been proposed for treating Type 2 diabetes (see WO 2006/053043).
Therefore, agents which inhibit glucosylceramide synthesis, or reduce intracellular content of GSLs, such as GM3, have the potential to treat conditions associated with altered GSL levels and/or GSL precursor levels. There is a need for additional agents which can act as glucosylceramide synthase inhibitors. SUMMARY OF THE INVENTION
It has now been discovered that 2-acylaminopropoanol derivatives represented by Structural Formula (I) below can effectively inhibit glycosphingolipid synthesis, such as GM3 synthesis. As such, these compounds can be used for treating diabetes or lysosomal storage diseases, such as Tay-Sachs,
Gaucher's or Fabry's disease. In addition, a number of these compounds were tested and found to significantly inhibit glycosphingolipid synthesis in animal tissues and to have high metabolic stability at the liver. Based upon this discovery, novel 2-acylaminopropoanol derivatives, pharmaceutical compositions comprising the 2-acylaminopropoanol derivatives, and methods of treatment using the 2-acylaminopropoanol derivatives are disclosed herein.
In one embodiment, the present invention is directed to compounds represented by Structural Formula (I):
Figure imgf000004_0001
and pharmaceutically acceptable salts thereof, wherein: R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group. R2 and R3 are each independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R and R taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring;
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; Alternatively, X is -O-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic group, or substituted or unsubstituted aryl group;
Alternatively, X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen;
Alternatively, X is a covalent bond; and R4 is a substituted or unsubstituted aryl group;
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6;
Each R is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
In another embodiment, the present invention is directed to a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by Structural Formula (1) or a pharmaceutically acceptable salt thereof.
In yet another embodiment, the present invention is directed to a method of treating a subject having type 2 diabetes, comprising administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
A method of treating a subject having renal hypertrophy or hyperplasia associated with diabetic nephropathy is also included in the invention. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
A method of decreasing plasma TNF-α in a subject in need thereof is also included in the present invention. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of lowering blood glucose levels in a subject in need thereof is also included in the present invention. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of decreasing glycated hemoglobin levels in a subject in need thereof is also included in the present invention. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof. A method of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof is also included in the present invention. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
A method of treating a subject with Tay-Sachs, Gaucher's or Fabry's disease is also included in the present invention. The method comprises administering to the subject a therapeutically effective amount of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof.
Also, included in the present invention is the use of a compound represented by Structural Formula (I) or a pharmaceutically acceptable salt thereof for the manufacture of a medicament. The medicament is for treating a subject having type 2 diabetes; for treating a subject having renal hypertrophy or hyperplasia associated with diabetic nephropathy; for decreasing plasma TNF-α in a subject in need thereof; for lowering blood glucose levels in a subject in need thereof; for decreasing glycated hemoglobin levels in a subject in need thereof; for inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof; or for treating a subject with Tay-Sachs, Gaucher's or Fabry's disease.
The compounds of the invention are inhibitors of glucosylceramide synthesis. As such, they can be used for treating various disorders associated with GSL metabolism, including diabetes and lysosomal storage diseases. The compounds of the invention can effectively inhibit glucosylceramide synthesis and at the same time have high metabolic stability at the liver. For example, the compounds of the invention can have a clearance value of less than 50%, and commonly less than 30%, at the liver relative to hepatic blood flow.
DETAILED DESCRIPTION OF THE INVENTION In one embodiment, the invention is directed to a compound represented by
Structural Formula (I), or a pharmaceutically acceptable salt thereof. A first set of values and preferred values for the variables in Structural Formula (I) is provided in the following paragraphs:
R1 is a substituted or unsubstituted aryl group, such as a substituted or unsubstituted phenyl group. Preferably, R1 is an aryl group optionally substituted with one or more substituents selected from halogen, alkyl, haloalkyl, Ar1, -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31)2, -S(O)R32, -SO3R30, -NR31SO2N(R31^, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32, -V0-N(R31)C(O)N(R31)2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R3 ")2-, -V0-S(O)2R30, -VO-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -V0-NR31 SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-Vi-N(R31)2, -N(R31)- V0-Ar1, -N(R31)-Vi-N(R31)2, -NR31C(O)-V0-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R31)2, -C(O)-V0-Ar1, -C(S)-V0-N(R31)2, -C(S)-V0-Ar1, -C(O)O-V,-N(R31)2, -C(O)O-V0-Ar1, -O-C(O)-V1-N(R31)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-V,-N(R31)2, -C(O)N(R31)- V0-Ar1, -S(O)2-VO-N(R31)2, -S(O)2-V0-Ar1, -SO2N(R31)-V1-N(R31),, -SO2N(R31)- V0-Ar1, -S(O)-V0-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V,-N(R31)2, -S(O)2-O-V0-Ar1, -NR31 SO2-V0-N(R31)2, -NR31SO2-V0-Ar1, -0-[CH2]p-0-, -
S-[CH2Jp-S-, or -[CH2Jq- . More preferably, R1 is an aryl group, such as a phenyl group, optionally substituted with one or more halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -V0-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V,-N(R31)2, -N(R31)-V0-Ar', -N(R3 I)-V,-N(R31)2, -0-[CH2Jp-O-, -S-[CH2Jp-S-, or -[CH2]q-. More preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O-, and -[CH2]q-. Even more preferably, R1 is a phenyl group optionally substituted with -OH, -OCH3, -OC2H5 or -O-[CH2]P-O-. Even more preferably, R1 is
Figure imgf000008_0001
where r is 1, 2, 3 or 4, preferably 1 or 2. Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group. Examples of hydrolyzable groups include -C(O)R, -C(O)OR, -C(O)NRR', C(S)R, -C(S)OR, -C(O)SR or -C(S)NRR1. Preferably, Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1; more preferably, -H.
R and R are each independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring. Preferably, R2 and R3 taken together with the nitrogen atom of N(R2R3) form a 5- or 6-membered, optionally-substituted non-aromatic heterocyclic ring . More preferably, -N(R2R3) is an optionally substituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group. Even more preferably, -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, preferably an unsubstituted pyrrolidinyl group.
Suitable substituents for the aliphatic and aryl groups represented by R2 and R3, and suitable substituents for the non-aromatic heterocyclic ring represented by N(R2R3) each independently include halogen, alkyl, haloalkyl, -OR40, -O(haloalkyl), -SR40, -NO2, -CN, -N(R41)2, -NR41C(O)R40, -NR41C(O)OR42, -N(R41)C(O)N(R41)2, -C(O)R40, -C(S)R40, -C(O)OR40, -OC(O)R40, -C(O)N(R41)2, -S(O)2R40, -SO2N(R41)2, -S(O)R42, -SO3R40, Ar2, V2-Ar2, -V2-OR40, -V2-O(haloalkyl), -V2-SR40, -V2-NO2, -V2-CN, -V2-N(R41)2, -V2-NR41C(O)R40, -V2-NR41CO2R42, -V2-N(R41)C(O)N(R41)2, -V2-C(O)R40, -V2-C(S)R40, -V2-CO2R40, -V2-OC(O)R40, -V2-C(O)N(R4 V, -V2-S(O)2R40, -V2-SO2N(R41)2, -V2-S(O)R42, -V2-SO3R40, -0-V2-Ar2 and -S-V2-Ar2. Preferably, suitable substituents for the aliphatic and aryl groups represented by R2 and R3, and suitable substituents for the non-aromatic heterocyclic ring represented by N(R2R3) each independently include halogen, alkyl, haloalkyl, -OR40, -O(haloalkyl), -SR40, -NO2, -CN, -N(R41)2, -C(O)R40, -C(S)R40, -C(O)OR40, -OC(O)R40, -C(O)N(R41)2, Ar2, V2-Ar2, -V2-OR40, -V2-O(haloalkyl), -V2-SR40, -V2-NO2, -V2-CN, -V2-N(R41)2, -V2-C(O)R40, -V2-C(S)R40, -V2-CO2R40, -V2-OC(O)R40, -0-V2-Ar2 and -S-V2-Ar2. More preferably, suitable substituents for the aliphatic and aryl groups represented by R2 and R3, and suitable substituents for the non-aromatic heterocyclic ring represented by N(R2R3) each independently include halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, -0(Cl-ClO alkyl), -O(phenyl), -0(Cl -C 10 haloalkyl), -S(Cl -C 10 alkyl), -S(phenyl), -S(Cl-ClO haloalkyl), -NO2, -CN, -NH(Cl-ClO alkyl), -N(Cl-ClO alkyl)2, -NH(Cl-ClO haloalkyl), -N(Cl-ClO haloalkyl)2, -NH(phenyl), -N(phenyl)2, -C(O)(Cl-ClO alkyl), -C(O)(Cl-ClO haloalkyl), -C(O)(phenyl), -C(S)(Cl-ClO alkyl), -C(S)(Cl-ClO haloalkyl), -C(S)(phenyl), -C(O)O(Cl-ClO alkyl), -C(O)O(Cl-ClO haloalkyl), -C(O)O(phenyl), phenyl, -V2-phenyl, -V2-O-phenyl, -V2-O(Cl-ClO alkyl), -V2-O(Cl-ClO haloalkyl), -V2-S-phenyl, -V2-S(C 1 -C 10 alkyl), -V2-S(C 1 -C 10 haloalkyl), -V2-NO2, -V2-CN, -V2-NH(Cl-ClO alkyl), -V2-N(Cl-ClO alkyl)2, -V2-NH(Cl-ClO haloalkyl), -V2-N(Cl-ClO haloalkyl)2, -V2-NH(phenyl), -V2-N(phenyl)2, -V2-C(O)(Cl-ClO alkyl), -V2-C(O)(Cl-ClO haloalkyl), -V2-C(O)(phenyl), -V2-C(S)(Cl-ClO alkyl), -V2-C(S)(C 1 -C 10 haloalkyl), - V2-C(S)(phenyl), -V2-C(O)O(C 1 -C 10 alkyl), -V2-C(O)O(C 1 -C 10 haloalkyl), -V2-C(O)O(phenyl), -V2-OC(O)(C 1 -C 10 alkyl), -V2-OC(O)(Cl-ClO haloalkyl), -V2-OC(O)(phenyl), -O-V2-phenyl and -S-V2-phenyl. Even more preferably, suitable substituents for the aliphatic and aryl groups represented by R2 and R3, and suitable substituents for the non-aromatic heterocyclic ring represented by N(R2R3) each independently include halogen, Cl- C5 alkyl, C 1 -C5 haloalkyl, hydroxy, C 1 -C5 alkoxy, nitro, cyano, C 1 -C5 alkoxycarbonyl, C1-C5 alkylcarbonyl, C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group. Preferably, Q is -0-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7- or -NR7SO2-. More Preferably, Q is -0-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7- or -OC(O)-. Even more preferably, Q is -0-, -S-, -C(O)- or -C(S)-.
Alternatively, X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic group, or substituted or unsubstituted aryl group.
In another alternative, X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl (e.g., C3-C8) group, or a substituted or unsubstituted cyclic alkenyl (C3-C8) group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen.
In another alternative, X is a covalent bond; and R4 is a substituted or unsubstituted aryl group.
Preferably, R4 is an optionally substituted aliphatic, such as a lower alkyl, or aryl group. More preferably, R4 is an optionally substituted aryl or lower arylalkyl group. Even more preferably, R4 is selected from the group consisting of:
Figure imgf000010_0001
Figure imgf000011_0001
wherein each of rings A-Z5 is optionally and independently substituted; and each x is independently 0 or 1 , specifically x is 0. Even more preferably, R4 is an
optionally substituted
Figure imgf000011_0002
group. Alternatively, R4 is an optionally substituted phenyl group. Alternatively, R4 is an aryl group substituted with Ar3, such as a phenyl group substituted with Ar3. It is noted that, as shown above, rings A-Z5 can be attached to variable "X" of Structural Formula (I) through -(CH2)X- at any ring carbon of rings A-Z5 which is not at a position bridging two aryl groups.
For example, R4 represented by
Figure imgf000011_0003
means that R is attached to variable "X" through either ring J or ring K.
Preferred substituents for each of the aliphatic group and the aryl group represented by R4, including lower alkyl, arylalkyl and rings A-Z5, include halogen, alkyl, haloalkyl, Ar3, Ar3-Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -NCS, -N(R51)2, -NR51C(O)R50, -NR51C(O)OR52, -N(R51)C(O)N(R51)2, -C(O)R50, -C(S)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -S(O)2R50, -SO2N(R51)2, -S(O)R52, -SO3R50, -NR51 SO2N(R51)2, -NR51SO2R52 , -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-NR51CO2R52, -V4-N(R51)C(O)N(R51)2, -V4-C(O)R50, , -V4-C(S)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R51)2-, -V4-S(O)2R50, -V4-SO2N(R51^, -V4-S(O)R52, -V4-SO3R50, -V4-NR51SO2N(R51)2, -V4-NR51SO2R52, -0-V4-Ar3, -O-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R51)- V4-Ar3, -N(R51)- V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R5 ")2, -C(O)-V4-Ar3, -C(S)-V4-N(R51)2,
-C(S)-V4-Ar^, -C(O)O-V5-N(R > 5311)2, -C(O)O-V4-Ar3, -0-C(O)-V5-N(R 531 ')>2, -0-C(O)-V4-Ar3, -C(O)N(R51)-V5-N(R51)2, -C(O)N(R51)- V4- Ar3, -S(O)2-V4-N(R51)2, -S(O)2-V4-Ar3, -SO2N(R51)-V5-N(R51)2, -SO2N(R5I)-V4-Ar3, -S(O)-V4-N(R51)2, -S(O)-V4-Ar3, -S(O)2-O- V5-N(R51)2, -S(O)2-O-V4-Ar3, -NR51 SO2-V4-N(R51)2, -NR51SO2-V4-Ar3, -0-[CH2]P-O-, -S-[CH2]P-S-, and -[CH2]q- . More preferably, substituents for each of the aliphatic group and the aryl group represented by R4, including lower alkyl, arylalkyl and rings A-Z5, include halogen, Cl-ClO alkyl, Cl- ClO haloalkyl, Ar3, Ar3-Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R51)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R51)2-, -0-V4-Ar3,
-0-V5-N(R5 ")2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R51)- V4- Ar3, -N(R51)-V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51)2, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -0-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)- V5-N(R51)2, -C(O)N(R51)- V4-Ar3, -0-[CH2]P-O- and -[CH2],-. More preferably, substituents for each of the aliphatic group and the aryl group represented by R4, including lower alkyl, arylalkyl and rings A-Z5, include halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-IO alkoxy, -0-[CH2]p-0- or -[CH2]q-. Even more preferably, substituents for each of the aliphatic group and the aryl group represented by R4, including lower alkyl, arylalkyl and rings A-Z5, include halogen, cyano, amino, nitro, Ar3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy. Even more preferably, substituents for each of the aliphatic and aryl groups represented by R4, including lower alkyl, arylalkyl and rings A-Z5, include -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-. Preferably, phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, -OR50, -Ar3, -V4-Ar3, -V-OR50, -0(Cl-ClO haloalkyl), -V4-O(Cl-ClO haloalkyl), -0-V4-Ar3, -0-[CH2]p-0- and-[CH2]q-. More preferably, phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-IO alkoxy, -O-[CH2]P-O- and -[CH2]q-. Even more preferably, phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3 and -OC2H5. Specifically, when R4 is phenyl ring A, at least one of the substituents of ring A is at the para position. R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group. Preferably, R5 and R6 are each independently -H; -OH; a halogen; or a lower alkoxy or lower alkyl group. More preferably, R5 and R6 are each independently -H, -OH or a halogen. Even more preferably, R5 and R6 are each independently -H.
Each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom of NR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group. Preferably, each R7 is independently -H, an aliphatic group or phenyl. Even more preferably, each R7 is independently -H or C1-C6 alkyl.
Each n is independently 1, 2, 3, 4, 5 or 6. Preferably, each n is independently 1, 2, 3 or 4. Alternatively, each n is independently 2, 3, 4 or 5.
Each p is independently 1, 2, 3 or 4, preferably 1 or 2.
Each q is independently 3, 4, 5 or 6, preferably 3 or 4. Each p1 is independently 1, 2, 3 or 4, preferably 1 or 2.
Each q1 is independently 3, 4, 5 or 6, preferably 3 or 4.
Each V0 is independently a Cl-ClO alkylene group, preferably C1-C4 alkylene group.
Each Vi is independently a C2-C10 alkylene group, specifically C2-C4 alkylene group.
Each V2 is independently a C1-C4 alkylene group.
Each V4 is independently a Cl-ClO alkylene group, preferably a C1-C4 alkylene group.
Each V5 is independently a C2-C10 alkylene group, preferably a C2-C4 alkylene group.
Each Ar1 is an aryl group optionally and independently substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy and haloalkyl. Preferably, Ar1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl .
More preferably, Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Each Ar2 is an aryl group optionally and independently substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, Cl- C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino. Each Ar3 is independently an aryl group, such as phenyl, each optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy and haloalkyl. Preferably, Ar3 is independently an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, Cl-ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino. Even more preferably, Ar3 is independently an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
Each R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl and alkylcarbonyl. Preferably, each R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C 1 -C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl and Cl -C6 alkylcarbonyl. More preferably, each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl and C1-C6 alkylcarbonyl.
Each R31 is independently R30, -CO2R30, -SO2R30 or -C(O)R30; or -N(R31)2 taken together is an optionally substituted non-aromatic heterocyclic group.
Preferably, each R31 is independently R30, or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
Each R32 is independently an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl and alkylcarbonyl. Preferably, each R32 is independently an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl and Cl -C6 alkylcarbonyl. More preferably, each R32 is independently a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy and C1-C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl-Cl dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, Cl- C6 haloalkoxy, C1-C6 alkoxycarbonyl and C1-C6 alkylcarbonyl.
Each R40 is independently hydrogen; an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, Cl- C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino.
Each R41 is independently R40, -CO2R40, -SO2R40 or -C(O)R40; or -N(R41)2 taken together is an optionally substituted non-aromatic heterocyclic group.
Each R42 is independently an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, Cl- C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino. Each R50 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl. Preferably, each R50 is independently hydrogen; an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, Cl- C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C 1 -C6 haloalkoxy, amino, C 1 -C6 alkylamino and C 1 -C6 dialkylamino.
Each R51 is independently R50, -CO2R50, -SO2R50 or -C(O)R50, or -N(R51)2 taken together is an optionally substituted non-aromatic heterocyclic group. Preferably, each R51 is independently R50, or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
Each R52 is independently an aryl group optionally substituted with one or two substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl. Preferably, each R52 is independently an aryl group, such as a phenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, Cl- C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl, C1-C6 haloalkoxy, amino, C1-C6 alkylamino and C1-C6 dialkylamino.
R and R1 are each independently -H; a lower aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy and aryl; or an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy, lower aliphatic group and lower haloaliphatic group; or R and R' taken together with the nitrogen atom of NRR' form a non-aromatic heterocyclic ring optionally substituted with one or more substituents selected from the group consisting of: halogen; -OH; -CN; -NCS; -NO2; -NH2; lower alkoxy; lower haloalkoxy; lower aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy and aryl; and aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy, lower aliphatic group and lower haloaliphatic group. Preferably, R and R' are each independently -H; a lower aliphatic group; a lower aliphatic group substituted with phenyl; or an aryl group. More preferably, R and R' are each independently -H, Cl- C4 alkyl, phenyl or benzyl.
A second set of values for the variables in Structural Formula (I) is provided in the following paragraphs:
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1, preferably -H. R1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1, -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31)2, -S(O)R32, -SO3R30, -NR31SO2N(R^)2, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32, -V0-N(R31)C(O)N(R31)2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R31)2-, -V0-S(O)2R30, -VO-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -V0-NR31SO2N(R31),, -V0-NR31SO2R32, -0-V0-Ar1, -O-V1-N(R31)2, -S-V0-Ar1, -S-V1 -N(R31)2, -N(R31)-V0-Ar1, -N(R31)-V,-N(R31)2, -NR31C(O)-Vo-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R31)2, -C(O)-V0-Ar1, -C(S)-VO-N(R31)2, -C(S)-V0-Ar1, -C(O)O-V1 -N(R3 1)2, -C(O)O-V0-Ar1, -O-C(O)-V1-N(R31)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-V, -N(R3 ^2, -C(O)N(R31)- V0-Ar1, -S(O)2-V0-N(R31)2, -S(O)2-V0-Ar1, -SO2N(R31)-V1-N(R31),, -SO2N(R31)-Vo-Ar1, -S(O)-VO-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V,-N(R31)2, -S(O)2-O-V0-Ar1, -NR31 SO2-V0-N(R31)2, -NR31SO2-V0-Ar1, -0-[CH2]p-0-, - S-[CH2]p-S- and -[CH2],- . Values and preferred values for the remainder of the variables of Structural
Formula (I) are each independently as described above for the first set of values.
A third set of values for the variables in Structural Formula (I) is provided in the following four paragraphs.
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1, preferably -H. R1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1, -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31)2, -S(O)R32, -SO3R30, -NR31SO2N(R31)2, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32, -V0-N(R31)C(O)N(R31)2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R3 V, -V0-S(O)2R30, -V0-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -V0-NR31SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -O-V1-N(R31)2, -S-V0-Ar1, -S-V1 -N(R31)2, -N(R31)-V0-Ar1, -N(R31)-V,-N(R31)2, -NR31C(O)-VO-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R31)2, -C(O)-V0-Ar1, -C(S)-VO-N(R31)2, -C(S)-V0-Ar1, -C(O)O-V1 -N(R31)2, -C(O)O-V0-Ar1, -O-C(O)-V,-N(R31)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-V1-N(R31);,, -C(O)N(R31)-V0-Ar1, -S(O)2-V0-N(R31),, -S(O)2-V0-Ar1, -SO2N(R31)-V1-N(R31)2, -SO2N(R31)-Vo-Ar1, -S(O)-V0-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V,-N(R31)2, -S(O)2-O-V0-Ar1, -NR31 SO2-V0-N(R31)2, -NR31SO2-V0-Ar1, -O-[CH2]P-O-, - S-[CH2]p-S- and -[CH2]q-. R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring. Examples of suitable substituents for the non-aromatic heterocyclic ring represented by -NR2R3 are as described in the first set of values for Structural Formula (I). Values and preferred values for the remainder of the variables of Structural
Formula (I) are as described above for the first set of values.
A fourth set of values for the variables in Structural Formula (I) is provided in the following paragraphs:
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1, preferably -H. R1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1, -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31):,, -S(O)R32, -SO3R30, -NR31SO2N(R31)2, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32, -VO-N(R31)C(O)N(R31)2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R31)2-, -V0-S(O)2R30, -VO-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -VO-NR31SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -O-Vi-N(R31)2, -S-V0-Ar1, -S-V,-N(R31)2, -N(R31VV0-Ar1, -N(R31)-V,-N(R31)2, -NR3IC(O)-VO-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R31)2, -C(O)-V0-Ar1, -C(S)-V0-N(R31),, -C(S)-V0-Ar1, -C(O)O-V1 -N(R31)2, -C(O)O-V0-Ar1, -O-C(O)-V,-N(R3I)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-V, -N(R31)2, -C(0)N(R31)-V0-Ar', -S(O)2-V0-N(R31),, -S(O)2-V0-Ar1, -SO2N(R31)-V,-N(R31)2, -SO2N(R31)- V0-Ar1, -S(O)-V0-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V,-N(R31)2, -S(O)2-O-V0-Ar1, -NR31SO2-V0-N(R31^, -NR31SO2-V0-Ar1, -0-[CH2]p-0-, - S-[CH2]P-S- and -[CH2]q-.
R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
R5 and R6 are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
Values and preferred values of the remainder of the variables of Structural Formula (I) are each independently as described above for the first set of values. A fifth set of values for the variables in Structural Formula (I) is provided in the following paragraphs:
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR', preferably -H.
R1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1, -OR30,
-O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31)2, -S(O)R32, -SO3R30, -NR31SO2N(R3^2, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR3 ' C(O)R30, -V0-NR3 ' CO2R32, -V0-N(R3 ' )C(0)N(R3 ' )2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R31)2-, -V0-S(O)2R30, -VO-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -VO-NR31SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V, -N(R31)2, -N(R31)-V0-Ar1, -N(R31)-V,-N(R31)2, -NR31C(O)-VO-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R3 !)2, -C(O)-V0-Ar1, -C(S)-VO-N(R31)2, -C(S)-V0-Ar1, -C(O)O-V1 -N(R3 !)2,
-C(O)O-V0-Ar1, -O-C(O)-V,-N(R31)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-Vi -N(R3 !)2, -C(0)N(R31)-V0-Ar1, -S(O)2-V0-N(R31),, -S(O)2-V0-Ar1, -SO2N(R31)-V1-N(R31),, -SO2N(R31)-Vo-Ar', -S(O)-V0-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V,-N(R31)2, -S(O)2-O-V0-Ar1, -NR31 SO2-V0-N(R31)2, -NR31SO2-V0-Ar1, -O-[CH2]P-O-, - S-[CH2]P-S- and -[CH2]q-.
R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring.
R4 is an aliphatic or aryl group each optionally substituted with one or more substituents. Examples of suitable substituents are as described above for the first set of values.
R5 and R6 are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
Values and preferred values of the remainder of the variables of Structural Formula (I) are each independently as described above for the first set of values. A sixth set of values for the variables in Structural Formula (I) is provided in the following paragraphs:
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1, preferably -H. R is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1, -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31)2, -S(O)R32, -SO3R30, -NR31 SO2N(R31)2, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32, -V0-N(R31)C(0)N(R3 ^2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R31),-, -V0-S(O)2R30, -V0-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -V0-NR31 SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V, -N(R31)2, -N(R31)-V0-Ar1,
-N(R31)-V,-N(R31)2, -NR31C(O)- VO-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R31)2, -C(O)-V0-Ar1, -C(S)-VO-N(R31)2, -C(S)-V0-Ar1, -C(O)O-V, -N(R31)2, -C(O)O-V0-Ar1, -0-C(O)-V1-N(R31);,, -0-C(O)-V0-Ar1, -C(O)N(R31)-V, -N(R31)2, -C(O)N(R3^-V0-Ar1, -S(O)2-V0-N(R3 1) -2S,(O)2-V0-Ar1, -SO2N(R31)-V,-N(R31)2, -SO2N(R31)-Vo-Ar1, -S(O)-V0-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V,-N(R31)2, -S(O)2-O-V0-Ar1, -NR31SO2-VO-N(R31)2, -NR31SO2-V0-Ar1, -O-[CH2]P-O-, - S-[CH2]P-S- and -[CH2]q-.
R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring. R4 is an optionally substituted cyclic alkyl group, or an optionally substituted cyclic alkenyl group, an optionally substituted aryl group, -CN, -NCS, -NO2 or a halogen. Examples of suitable substituents are as described above for the first set.
R5 and R6 are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group. Values and preferred values of the remainder of the variables of Structural
Formula (I) are each independently as described above for the first set of values.
A seventh set of values and preferred values for the variables in Structural Formula (I) is provided in the following paragraphs:
Values and preferred values of R1, Y, R2, R3, R5 and R6 are each independently as described above for the sixth set.
R4 is an optionally substituted cyclic alkyl group, or an optionally substituted cyclic alkenyl group, or an optionally substituted aryl group, specifically optionally substituted aryl group. Examples of suitable substituents are as described above for the first set.
Values and preferred values of the remainder of the variables of Structural Formula (I) are each independently as described above for the first set of values.
In a second embodiment, the compound of the invention is represented by Structural Formula (II), (III), (IV), (V), (VI), (VII) or (VIII):
Figure imgf000023_0001
Figure imgf000023_0002
(IV) V)
Figure imgf000024_0001
Figure imgf000024_0002
Figure imgf000024_0003
Figure imgf000024_0004
or a pharmaceutically acceptable salt thereof. A first set of values for the variables of Structural Formulas (II) - (VIII) is provided in the following paragraphs: R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -0-V1-N(R31),, -S-V0-Ar1, -S-V1-N(R31)2, -N(R3 v1 0)--Ar1, -N(R31)-V,-N(R31)2, -O-[CH2]P-O-, -S-[CH2]P-S- and -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O- and -[CH2]q-. Ar1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl. Preferably, R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group. Examples of suitable substituents are as described above in the first set of values for Structural Formula (I).
R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring. Examples of suitable substituents for the non-aromatic heterocyclic ring represented by -NR2R3 are as described above in the first set of values for Structural Formula (I). R4 is an aliphatic or aryl group each optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I).
R5 and R6 for Structural Fomrulas (II), (III) and (V) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
For Structural Formula (VIII), R7 is -H or C1-C6 alkyl, preferably -H. Values and preferred values of the remainder of the variables of Structural
Formulas (II)-(VIII) are each independently as described above in the first set of values for Structural Formula (I).
A second set of values for the variables in Structural Formulas (U)-(VIII) is provided in the following paragraphs: R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-Vi-N(R31)2, -S-V0-Ar1, -S-V1 -N(R31)2, -N(R3^-V0-Ar1, -N(R31)-V,-N(R31)2, -O-[CH2]P-O-, -S-[CH2]P-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O- and -[CH2]q-.
Ar1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
R4 is an aliphatic or aryl group each optionally substituted with one or more substituents. Examples of suitable substituents are described above in the first set of values for Structural Formula (I). R5 and R6 for Structural Fomrulas (II), (III) and (V) are each independently
-H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
For Structural Formula (VIII), R7 is -H or C1-C6 alkyl, preferably -H. Values and preferred values of the remainder of the variables of Structural Formulas (II)-(VIII) are each independently as described above in the first set of values for Structural Formula (I).
A third set of values for the variables in Structural Formulas (H)-(VIII) is provided in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V1-N(R31)2, -S-V0-Ar1, -S-V1 -N(R3 ])2, -N(R31)-V0-Ar1, -N(R31)-V,-N(R31)2, -O-[CH2]P-O-, -S-[CH2Jp-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O- and -[CH2]q-.
Ar1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, C 1 -C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxy carbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 - C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
R4 is an optionally substituted aryl or an optionally substituted lower arylalkyl group. Example of suitable substituents are as described in the first set of values for Structural Formula (I).
R5 and R6 for Structural Fomrulas (II), (III) and (V) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
For Structural Formula (VIII), R7 is -H .
Preferably, Q in Structural Formula (II) is -O- , -S-, -C(O)-, -C(S)-, -NR7(CO)- or -C(O)NR7-
Values and preferred values of the remainder of the variables of Structural Formulas (H)-(VIII) are each independently as described above in the first set of values for Structural Formula (I). Preferably, for Structural Formula (II), Q is -O-, -S-, -C(O)-, -C(S)-, -NR7(C0)- or -C(O)NR7-. A fourth set of values for the variables in Structural Formulas (H)-(VIII) is provided in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V1 -N(R31)2, -N(R31VV0-Ar1, -N(R31)-V,-N(R31)2,
-O-[CH2]P-O-, -S-[CH2]p-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O- and -[CH2]q-.
Ar is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C 1 -C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
R4 is an optionally substituted aryl or an optionally substituted lower arylalkyl group. Examples of suitable substitutents for R4 are as provided above in the first set of values for Structural Formula (I). Preferably, R4 is selected from the group consisting of:
Figure imgf000030_0001
Figure imgf000031_0001
Each of rings A-Z5 is optionally and independently substituted. For Structural Formula (VIII), R7 is -H.
Values and preferred values of the remainder of the variables of Structural Formulas (II)-(VIII) are each independently as described above in the first set of values for Structural Formula (I). When the compound of the invention is represented by Structural Formula (III) or (IV), or a pharmaceutically acceptable salt thereof, n is 1, 2, 3 or 4. Alternatively, when the compound of the invention is represented by Structural Formula (V) or (VI), or a pharamceutically acceptable salt thereof, n is 3, 4 or 5.
A fifth set of values for the variables in Structural Formulas (II)-(VIII) independently is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set of values for the variables for Structural Formula (I). In a third embodiment, the compound of the invention is represented by Structural Formula (IX) or (X):
Figure imgf000032_0001
(IX)
Figure imgf000032_0002
(X)
or a pharmaceutically acceptable salt thereof. A first set of values for the variables in Structural Formulas (IX) and (X) is defined in the following paragraphs: R1 is a phenyl group optionally substituted with one or more substituents.
Examples of suitable substituents include halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V1-N(R31),, -N(R31)- V0- Ar1, -N(R31)-V,-N(R31)2, -O-[CH2]P-O-, -S-[CH2]p-S-, and -[CH2]q-;preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-.
-N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino; preferably, -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
Phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, -OR50, -Ar3, -V4-Ar3, -V-OR50, -0(Cl-ClO haloalkyl), -V4-O(Cl-ClO haloalkyl), -0-V4-Ar3, -O-[CH2]P-O- and -[CH2]q.-.
Ar3 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R5 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
For Structural Formula (IX), n is 1, 2, 3 or 4. For Structural Formula (X), n is 3, 4 or 5.
Values and preferred values of the remainder of the variables of Structural Formulas (IX) and (X) are each independently as defined above in the first set of values for Structural Formula (I).
A second set of values and preferred values for the variables in Structural Formulas (IX) and (X) is as defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-. -N(R2R3) is pyrrolidinyl.
Phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-ClO alkoxy, -O-[CH2]P-O- and -[CH2]q-. Preferably, phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3 or -OC2H5.
For Structural Formula (IX), n is 1, 2, 3 or 4. For Structural Formula (X), n is 3, 4 or 5.
Values and preferred values of the remaining variables of Structural Formulas (IX) and (X) are each independently as described above in the first set of values for Structural Formula (I).
A third set of values for the variables in Structural Formulas (IX) and (X) independently is as defined in the first set, second set, third set, fourth set or fifth set, of values for Structural Formulas (H)-(VIII).
In a fourth embodiment, the compound of the invention is represented by Structural Formula (XI), (XII) or (XIII):
Figure imgf000034_0001
Figure imgf000034_0002
Figure imgf000035_0001
or a pharmaceutically acceptable salt thereof. A first set of values and preferred values for the variables of Structural Formulas (XI)-(XIII) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V1-N(R31)2, -S-V0-Ar1, -S-V1-N(R31),, -N(R31)-V0-Ar1, -N(R31)-V1 -N(R31)2, -O-[CH2]P-O-, -S-[CH2]P-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O- and -[CH2]q-.
Ar1 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C 1 -C6 alkylamino, C 1 -C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl .
Each R31 is independently R30, or -N(R3 !)2 is an optionally substituted non- aromatic heterocyclic group. Examples of suitable substituents are as described above in the first set of values for Structural Formula (I).
R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a 5- or 6- membered, optionally-substituted non-aromatic heterocyclic ring. Examples of suitable substituents for the non-aromatic heterocyclic group represented by -NR R are as described above in the first set of values for Structural Formula (I).
R4 is an optionally substituted aryl group. Examples of suitable substituents for R4 are as provided above in the first set of values for Structural Formula (I). R5 and R6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
Values and preferred values of the remainder of the variables of Structural Formulas (XI)-(XIII) are each independently as described above in the first set of values for Structural Formula (I). A second set of values and preferred values for the variables of Structural
Formulas (XI)-(XIII) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V1-N(R31)2, -S-V0-Ar1, -S-V,-N(R31)2, -N(R31)- V0- Ar1, -N(R31)-V,-N(R31)2,
-O-[CH2]P-O-, -S-[CH2]p-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O-, and -[CH2]q-.
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and
Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
R4 is an optionally substituted aryl group. Suitable substituents and preferred substitutents are as provided above in the first set of values for Structural Formula (I). Preferably, R4 is selected from the group consisting of:
Figure imgf000037_0001
Figure imgf000038_0001
Each of rings A-Z5 is optionally and independently substituted. Preferably, each of rings A-Z5 is optionally and independently substituted with one or more substituents selected from Ar3 and Ar3-Ar3 wherein values and preferred values of Ar3 are as described above for the first set of values for Structural Formula (I). Preferably, Ar3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, C 1 - ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino. More preferably, Ar3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C 1 -C4 haloalkoxy, amino, C 1 -C4 alkylamino and C 1 -C4 dialkylamino.
R5 and R6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
Values and preferred values of the remainder of the variables of Structural Formulas (XI)-(XIII) are each independently as described above in the first set of values for Structural Formula (I).
A third set of values for the variables of Structural Formulas (XI)-(XIII) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -0-V1-N(R31),, -S-V0-Ar1, -S-V,-N(R31)2, -N(R31)-V0-Ar1, -N(R31)-V1 -N(R31)2, -O-[CH2]p-O-, -S-[CH2]p-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C 1 -C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkylamino, C 1 -C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O-, and -[CH2]q-.
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy C 1 -C6 alkoxycarbonyl, C 1 -C6 alkylcarbonyl and C 1 -C6 haloalkyl.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
R4 is a biaryl group, such as a biphenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar3, C 1 -C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkoxy, hydroxy and C 1 -C6 haloalkoxy.
R5 and R6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group, preferably -H.
Values and preferred values of the remainder of the variables of Structural Formulas (XI)-(XIII) are each independently as described above in the first set of values for Structural Formula (I). A fourth set of values values for the variables of Structural Formulas (XI)- (XIII) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-,
Preferably, R1 is
Figure imgf000040_0001
where r is 1, 2, 3 or 4, preferably 1 or 2. -N(R R3) is an unsubstituted pyrrolidinyl group.
R4 is a biaryl group, such as a biphenyl group, optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy.
R5 and R6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group, preferably -H. n is an integer from 1 to 4.
Values and preferred values of the remainder of the variables of Structural Formulas (XI)-(XIII) are each independently as described above in the first set of values for Structural Formula (I).
A fifth set of values preferred values for the variables of Structural Formulas (XI)-(XIII) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-.
Preferably R1 is
Figure imgf000040_0002
where r is 1, 2, 3 or 4, preferably 1 or 2. -N(R2R3) is pyrrolidinyl.
R4 is
Figure imgf000040_0003
optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar3, C1-C6 alkyl, C 1 -C6 haloalkyl, C 1 -C6 alkoxy, hydroxy and C 1 -C6 haloalkoxy. n is 1. R5 and R6 for Structural Formula (XI) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group, preferably -H.
Values and preferred values of the remainder of the variables of Structural Formulas (XI)-(XIII) are each independently as described above in the first set of values for Structural Formula (I).
A sixth set of values values for the variables in Structural Formulas (XI)- (XIII) independently is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set of values for Structural Formula (I).
In a fifth embodiment, the compound of the invention is represented by Structural Formula (XIV) or (XV):
Figure imgf000041_0001
or a pharmaceutically acceptable salt thereof. A first set of values and preferred values for the variables in Structural Formulas (XIV) and (XV) is as defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V, -N(R31)2, -N(R31)-V0-Ar1, -N(R31)-Vi -N(R3 ])2,
-O-[CH2]P-O-, -S-[CH2]P-S-, or -[CH2]q-. Preferably, R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkylamino, C1-C6 dialkylamino, aryl, aryloxy, -OH, C1-C6 alkoxy, -O-[CH2]P-O-, and -[CH2]q-.
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy and C1-C6 haloalkyl.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino. k is O, 1, 2, 3, 4, 5 or 6.
R8 is -H, or an optionally substituted aryl or an optionally substituted lower alkyl group. Examples of suitable substituents are as described for the first set of values for Structural Formula (I). Preferably, R8 is selected from the group consisting of:
Figure imgf000043_0001
Each of rings A-Z5 is optionally and independently substituted. Examples of suitable substituents for R8 are as provided above in the first set of values for R4 in
Structural Formula (I). More preferably, R is
Figure imgf000043_0002
group. Alternatively,
R8 is an aryl group substituted with Ar3, such as a phenyl group substituted with Ar3, where values and preferred values of Ar3 are as described above in Structural
Formula (I).
Values and preferred values of the remainder of the variables of Structural
Formulas (XIV) and (XV) are each independently as described above in the first set of values for Structural Formula (I). A second set of values for the variables in Structural Formulas (XIV) and
(XV) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V-OR30, -V-N(R31)2, -V-Ar1, -O-V-Ar1, -O-V,-N(R31)2, -S-V-Ar1, -S-V1-N(R31)2, -N(R31)-V-Ar\ -N(R31)-V1 -N(R31)2, -O-[CH2]p-O-, -S-[CH2]p-S- and -[CH2]q-.
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl , C 1 -C6 alkylcarbonyl and C 1 - C6 haloalkyl; or an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, Cl- C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Each R31 is independently R30, or -N(R31)2 is an optionally substituted non- aromatic heterocyclic group.
-N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, preferably an unsubstituted pyrrolidinyl group.
Values and preferred values for k and R8 are as provided above in the first set of values for Structural Formulas (XIV) and (XV).
Values and preferred values of the remainder of the variables of Structural Formulas (XIV) and (XV) are each independently as described above in the first set of values for Structural Formula (I).
A third set of values for the variables in Structural Formulas (XIV) and (XV) is defined in the following paragraphs:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-.
Preferably R is
Figure imgf000044_0001
where r is 1, 2, 3 or 4, preferably 1 or 2.
-N(R2R3) is pyrrolidinyl. Values and preferred values for k and R8 are each independently as provided above in the first set of values for Structural Formulas (XIV) and (XV).
Values and preferred values of the remainder of the variables of Structural Formulas (XIV) and (XV) are each independently as described above in the first set of values for Structural Formula (I).
A fourth set of values for the variables in Structural Formulas (XIV)-(XV) is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set for Structural Formula (I).
In a sixth embodiment, the compound of the invention is represented by Structural Formula (XXI):
Figure imgf000045_0001
(XXI)
or a pharmaceutically acceptable salt thereof. A first set of values and preferred values for the variables in Structural Formula (XXI) is as defined in the following paragraphs:
Each of A and B independently is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy. k1 is 0, 1 or 2. k" is 0, 1 or 2. Preferably, k" is 0 or 1. More preferably k" is 1. m' is 0, 1 or 2. Preferably, m' is 1.
Values and preferred values for the remainder of the variables of Structural Formula (XXI) are each independently as described above in the first set of values for Structural Formula (I). A second set of values for the variables in Structural Formula (XXI) is provided in the following paragraphs:
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1, preferably -H. Values and preferred values for A, B, k', k" and m' are each independently as described above in the first set of values for Structural Formula (XXI).
Values and preferred values for the remainder of the variables of Structural Formula (XXI) are each independently as described above in the first set of values for Structural Formula (I).
A third set of values for the variables in Structural Formula (XXI) is provided in the following paragraphs:
R30 is independently hydrogen; an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. More preferably, R30 is independently hydrogen; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Even more preferably, R30 is independently hydrogen, or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 haloalkoxy and hydroxy.
Values and preferred values for A, B, Y, k', k" and m' are each independently as described above in the second set of values for Structural Formula (XXI).
Values and preferred values for the remainder of the variables of Structural Formula (XXI) are each independently as described above in the first set of values for Structural Formula (I).
A fourth set of values for the variables in Structural Formula (XXI) is provided in the following paragraphs:
Y is -H.
Values and preferred values for R3 , A, B, k', k" and m' are each independently as described above in the third set of values for Structural Formula (XXI).
Values and preferred values for the remainder of the variables of Structural Formula (XXI) are each independently as described above in the first set of values for Structural Formula (I).
In a seventh embodiment, the compound of the invention is represented by Structural Formula (XXII), (XXIII), (XXIV), (XXV), (XXVI), (XXVII), (XXVIII), (XXIX), (XXX) or (XXXI):
Figure imgf000047_0001
Figure imgf000048_0001
(XXIII)
Figure imgf000048_0002
(XXIV)
Figure imgf000048_0003
(XXV)
Figure imgf000049_0001
(XXVI)
Figure imgf000049_0002
(XXVIII)
Figure imgf000050_0001
I) or a pharmaceutically acceptable salt thereof. A first set of values and preferred values for the variables in Structural Formulas (XXII) - (XXXI) is as defined in the following paragraphs:
Each of A and B independently is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, R30 is independently hydrogen; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. More preferably, R30 is independently hydrogen, or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 haloalkoxy and hydroxy.
Each k' is independently 0, 1 or 2.
Each k" is independently 0, 1 or 2.
Each m1 is independently 0, 1 or 2. Preferably, each m' is 1.
Each n is independently 1, 2, 3, 4, 5 or 6. Preferably, each n in Structual Formulas (XXV) and (XXVI) is independently 1 , 2, 3 or 4, and each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5.
Values and preferred values for the remainder of the variables of Structural Formulas (XXII) - (XXXI) are each independently as described above in the first set of values for Structural Formula (I). A second set of values for the variables in Structural Formulas (XXII) -
(XXXI) is provided in the following paragraphs:
Each R4 in Structural Formulas (XXII) -(XXVIII) is independently an aliphatic or aryl group each optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I). Preferably, each R4 in Structural Formulas (XXII) -(XXVIII) is independently an optionally substituted aryl or an optionally substituted lower arylalkyl group. Examples of suitable substituents are as described in the first set of values for Structural Formula
(I). Each R4 in Structural Formulas (XXIX) -(XXXI) is independently an aryl group optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I). R5 and R6 in Structural Fomrulas (XXII), (XXIII), (XV) and (XXIX) are each independently -H, -OH, a halogen, a C1-C6 alkoxy group or a C1-C6 alkyl group.
For Structural Formula (XXVIII), R7 is -H or C1-C6 alkyl, preferably -H. Values and preferred values for A, B, R30, k', k", m' and n are each independently as described above in the first set of values for the variables in Structural Formulas (XXII) - (XXXI). Preferably, each n in Structual Formulas (XXV) and (XXVI) is independently 1, 2, 3 or 4, and each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5. Values and preferred values for the remainder of the variables of Structural
Formulas (XXII) - (XXXI) are each independently as described above in the first set of values for Structural Formula (I).
A third set of values for the variables in Structural Formulas (XXII) — (XXXI) is provided in the following paragraphs: Each R4 in Structural Formulas (XXII) -(XXVIII) is independently an optionally substituted aryl or an optionally substituted lower arylalkyl group. Example of suitable substituents are as described in the first set of values for Structural Formula (I). Each R4 in Structural Formulas (XXIX) -(XXXI) is independently an aryl group optionally substituted with one or more substituents described above in the first set of values for Structural Formula (I).
R5 and R6 for Structural Fomrulas (XXII), (XXIII), (XXV) and (XXIX) are each independently -H, -OH, a halogen, a lower alkoxy group or a lower alkyl group.
For Structural Formula (XXVIII), R7 is -H . Q in Structural Formula (XXII) is -O- , -S-, -C(O)-, -C(S)-, -NR7(CO)- or
-C(O)NR7-.
Values and preferred values for A, B, R30, k1, k", m1 and n are each independently as described above in the first set of values for the variables in Structural Formulas (XXII) - (XXXI). Preferably, each n in Structual Formulas (XXV) and (XXVI) is independently 1, 2, 3 or 4, and each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5. Values and preferred values for the remainder of the variables of Structural Formulas (XXII)-(XXXI) are each independently as described above in the first set of values for Structural Formula (I).
A fourth set of values for the variables in Structural Formulas (XXII) - (XXXI) is provided in the following paragraphs:
Each R4 in Structural Formulas (XXII) -(XXVIII) is independently selected from the group consisting of:
Figure imgf000053_0001
wherein each x is independently 0 or 1, and each of rings A-Z5 is optionally and independently substituted.
Each R4 in Structural Formulas (XXIX) -(XXXI) is independently selected from the group consisting of:
Figure imgf000054_0001
wherein each of rings A-Z5 is optionally and independently substituted. Preferably, each R4 in Structural Formulas (XXII) - (XXXI) is independently monocyclic.
Example of suitable substituents for rings A-Z5 are as described in the first set of values for Structural Formula (I).
Preferably, in Structural Formulas (XXIX) - (XXXI), each of rings A-Z5 is optionally and independently substituted with one or more substituents selected from Ar3 and Ar3-Ar3 wherein values and preferred values of Ar are as described above for the first set of values for Structural Formula (I). Preferably, Ar3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, hydroxy, Cl-ClO alkoxy, nitro, cyano, Cl-ClO alkoxycarbonyl, Cl-ClO alkylcarbonyl, Cl-ClO haloalkoxy, amino, Cl-ClO alkylamino and Cl-ClO dialkylamino. More preferably, Ar3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino.
Values and preferred values for R5, R6, R7, R30, Q, k', k", m' and n are each independently as described above in the third set of values for the variables in Structural Formulas (XXII) - (XXXII). Preferably, each n in Structual Formulas (XXV) and (XXVI) is independently 1, 2, 3 or 4, and each n in Structural Formulas (XXIII) or (XXIV) is independently 2, 3, 4 or 5.
Values and preferred values for the remainder of the variables of Structural Formulas (XXII) - (XXXI) are each independently as described above in the first set of values for Structural Formula (I).
A fifth set of values for the variables in Structural Formulas (XXII) - (XXXI) is provided in the following paragraphs:
Each R4 in Structural Formulas (XXII) -(XXVIII) is independently
Figure imgf000055_0001
, wherein x is 0 or 1.
Each R4 in Structural Formulas (XXIX) - (XXXI) is independently
Figure imgf000055_0002
Each ring A is optionally substituted. Example of suitable substituents for rings A are as described in the first set of values for Structural Formula (I). Perferably, ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy. Ar3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C4 alkyl, C1-C4 haloalkyl, hydroxy, C1-C4 alkoxy, nitro, cyano, C1-C4 alkoxycarbonyl, C1-C4 alkylcarbonyl, C1-C4 haloalkoxy, amino, C1-C4 alkylamino and C1-C4 dialkylamino. Values and preferred values for A, B, R5, R6, R7, R30, Q, k', k", nϊ and n are each independently as described above in the fourth set of values for the variables in Structural Formulas (XXII) - (XXXI).
Values and preferred values for the remainder of the variables of Structural Formulas (XXII) - (XXXI) are each independently as described above in the first set of values for Structural Formula (I).
A sixth set of values for the variables other than A, B, k', k" and m' in Structural Formulas (XXII) - (XXXI) is as defined in the first set, second set, third set, fourth set, fifth set, sixth set or seventh set of values for the varibales for Structural Formula (I), and values and preferred values for A, B, k', k" and m' are each independently as described above in the first set of values for the variables in Structural Formulas (XXII) - (XXXI).
In an eighth embodiment, the compound of the invention is represented by Structural Formula (XXXII) or (XXXIII ):
Figure imgf000056_0001
(XXXIII) or a pharmaceutically acceptable salt thereof. A first set of values and preferred values for the variables in Structural Formulas (XXXII) - (XXXIII) is as defined in the following paragraphs:
Each of A and B independently is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C 1 -C6 alkoxy or C 1 -C6 haloalkoxy.
Each R30 is independently hydrogen; a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and Cl- C6 haloalkyl; or a C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl. Preferably, R30 is independently hydrogen; or a Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C 1 -C6 haloalkyl. More preferably, R30 is independently hydrogen, or a C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkoxy, C1-C6 haloalkoxy and hydroxy.
Each k1 is independently 0, 1 or 2.
Each k" is independently 0, 1 or 2.
Each m' is independently 0, 1 or 2.
Each q is independently 0, 1, 2, 3, 4, 5 or 6. Each R8 independently is -H, or an optionally substituted aryl or an optionally substituted lower alkyl group. Examples of suitable substituents are as described for the first set of values for Structural Formula (I). Preferably, each R independently is selected from the group consisting of:
Figure imgf000058_0001
Each of rings A-Z5 is optionally and independently substituted. Examples of suitable substituents for R8 are as provided above in the first set of values for R4 in
Structural Formula (I). More preferably, each R8 is independently a
Figure imgf000058_0002
group. Alternatively, each R8 is independently an aryl group substituted with Ar3, such as a phenyl group substituted with Ar3, where values and preferred values of Ar3 are as described above in Structural Formula (I).
Values and preferred values for the remainder of the variables of Structural Formulas (XXXII) - (XXXIII) are each independently as described above in the first set of values for Structural Formula (I).
In one preferred embodiment, each k' in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1. Preferably, when k' is 1 , each A independently is positioned at a meta position of the phenyl ring.
In another perferred embodiment, each k" in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1 , more preferably 1. In yet another perferred embodiment, each m' in Structural Formulas (XXI) - (XXXIII) is independently 1.
In yet another preferred embodiment, each k' in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1; and each k" in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1 , more preferably 1.
In yet another preferred embodiment, in Structural Formulas (XXI) - (XXXIII):
Each R30 is independently hydrogen or a C1-C6 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C3 alkylamino, C1-C3 dialkylamino, C1-C3 alkoxy, nitro, cyano, hydroxy, C1-C3 haloalkoxy, C1-C3 alkoxycarbonyl and C1-C3 alkylcarbonyl; each k' in Structural Formulas (XXI) - (XXXIV) is independently 0 or 1. Preferably, when k1 is 1, each A independently is positioned at a meta position of the phenyl ring; and each k" in Structural Formulas (XXI) - (XXXIV) is independently 0 or 1, preferably 1.
In yet another preferred embodiment, in Structural Formulas (XXI) - (XXXIII): Each -OR30 is independently -OH or -O-Cl -C6 alkyl optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C3 C1-C3 alkoxy, hydroxy and C1-C3 haloalkoxy; each k1 in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1. Preferably, when k' is 1, each A is independently positioned at a meta position of the phenyl ring; and each k" in Structural Formulas (XXI) - (XXXIII) is independently 0 or 1, preferably 1.
In one more preferred embodiment, the compound of the invention is represented by Structural Formula (XVIA) or (XVIB):
Figure imgf000060_0001
or a pharmaceutically acceptable salt thereof, wherein: Q is -O- , -C(O)- or -NH, specifically, -O- or -C(O)-; r and s are each independently 1, 2, 3 or 4; each n independently is 1, 2, 3, 4, 5 or 6; and R4 has values and preferred values provided above in the fist set of values for Structural Formula (I).
In another more preferred embodiment, the compound of the invention is represented by Structural Formula (XVIC) or (XVID):
Figure imgf000060_0002
or a pharmaceutically acceptable salt thereof, wherein:
Q is -O- , -C(O)- or -NH, specifically, -O- or -C(O)-; r and s are each independently 1, 2, 3 or 4; each n independently is 1, 2, 3, 4, 5 or 6;
R4 has values and preferred values provided above in the fist set of values for Structural Formula (I); and
B is is halogen, hydroxy, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy or C1-C6 haloalkoxy. Preferably, B is halogen, hydroxy, C1-C5 alkoxy or C1-C5 haloalkoxy.
In another more preferred embodiment, the compound of the invention is represented by Structural Formula (XVII), (XVIII), (XIX) or (XIX):
Figure imgf000061_0001
(XVII)
Figure imgf000061_0002
(XVIII)
Figure imgf000062_0001
XIX or
Figure imgf000062_0002
or a pharmaceutically acceptable salt thereof, wherein phenyl ring A is optionally substituted; each n is 1, 2, 3, 4, 5, or 6; and k is 0, 1 or 2. Values and preferred values of suitable substituents of phenyl ring A are as described above in the first set of values for Structural Formula (I).
In all of the embodiments described above for Structural Formulas (XXI) - (XXXIII) and (XVIC) - (XVID), the heterocyclic ring represented by
Figure imgf000062_0003
can be replaced with a bridged heterobicyclic ring comprising 5- 12 ring carbon atoms and 1 or 2 nitrogen atoms. The invention also includes compounds represented by Structural Formulas (XXI) - (XXXIII) and (XVIC) -
(XVID) with this replacement of
Figure imgf000062_0004
with a bridged heterobicyclic ring comprising 5-12 ring carbon atoms and 1 or 2 nitrogen atoms. Values, including preferred values, for the variables other than B, k" and m' in Structural Formulas (XXI) - (XXXIII) and (XVIC) - (XVID) are as defined above with respect to Structural Formulas (XXI) - (XXXIIII) and (XVIC) - (XVID).
Similary, in all of the embodiments described above for Structural Formulas (I) - (XX), the non-aromatic heterocyclic ring represented by -NR2R3 can be a bridged heterobicyclic ring comprising 5-12 ring carbon atoms and 1 or 2 nitrogen atoms.
Examples of bridged eterobicyclic ring comprising 5-12 ring carbon atoms
and 1 or 2 nitrogen atoms include
Figure imgf000063_0001
and
Figure imgf000063_0002
The bridged bicyclic ring carbon atoms can be optionally subsituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-CO alkyl), -O(C1-C6 haloalkyl), -S(Cl-Co haloalkyl), C1-C6 alkyl, C1-C6 haloalkyl, amino, C1-C6 alkylamino and C1-C6 dialkylamino. Alternatively, the bridged bicyclic ring carbon atoms can be optionally subsituted with one or more substituents selected from the group consisting of halogen, -OH, -0(Cl -C6 alkyl) and -O(C1 -C6 haloalkyl). The bridged bicyclic ring nitrogen atoms can be optionally subsituted with one or more substituents selected from the group consisting of C1-C6 alkyl and phenyl, the alkyl being optionally substituted with halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-CO alkyl), -O(C1-C6 haloalkyl), -S(C1-C6 haloalkyl), phenyl, amino, C1-C6 alkylamino and C1-C6 dialkylamino, and the phenyl being optionally substituted with halogen, cyano, nitro, -OH, -SH, -O(C1-C6 alkyl), -S(Cl-Co alkyl), -O(C1-C6 haloalkyl), -S(C1-C6 haloalkyl), C1-C6 alkyl, C1-C6 haloalkyl, amino, C1-C6 alkylamino and C1-C6 dialkylamino. Alternatively, the bridged bicyclic ring nitrogen atoms can be optionally subsituted with C1-C6 alkyl that is optionally substituted with halogen, -OH, -O(C 1 -C6 alkyl) and -0(C 1 -C6 haloalkyl).
In another embodiment, the compound of the invention is represented by a structural formula selected from Structural Formulas (I) - (VIII) and (XI) - (XV), wherein values, including preferred values, of the variables in the structural formulas, other than R30, R31 and R32 for the substituents of R1, are independently as defined in each embodiment described above for Structural Formulas (I) - (VIII) and (XI) - (XV). In this embodiment, each R30 is independently: i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or iii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl, alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl. Each R31 is independently R30, -CO2R30, -SO2R30 or -C(O)R30; or -N(R31)2 taken together is an optionally substituted non- aromatic heterocyclic group. Each R is independently: i) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkylcarbonyl and haloalkoxy and haloalkyl; or ii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl, alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl. Each of the phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl for the substituents of the alkyl group respresented by R30 and R32 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, C1-C5 alkyl, C1-C5 haloalkyl, C1-C5 alkoxy, C1-C5 haloalkoxy, C1-C5 alkylamino, C1-C5 dialkylamino, (C1-C5 alkoxy)carbonyl and (C1-C5 alkyl)carbonyl. Each of the alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl for the substituents of the alkyl group respresented by R30 and R32 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, phenyl, C1-C5 alkoxy, C1-C5 haloalkoxy, phenylamino, C1-C5 alkylamino, C1-C5 dialkylamino, diphenylamino, (C1-C5 alkoxy)carbonyl, (C1-C5 alkyl)carbonyl, benzoyl and phenoxycarbonyl.
Specific examples of the compounds of the invention are shown below: (E3)
(E5 E6)
(E
Figure imgf000065_0001
Figure imgf000066_0001
( )
Figure imgf000067_0001
Figure imgf000068_0001
E(25) and pharmaceutically acceptable salts thereof.
Other specific examples of the compounds of the invention include compounds shown in Tables 1 and 2 and those exemplified in the examples below, stereoisomers thereof, and pharmaceutically acceptable salts thereof.
Also included are solvates, hydrates or polymorphs of the disclosed compounds herein. Thus, it is to be understood that when any compound is referred to herein by name and structure, solvates, hydrates and polymorphs thereof are included.
The compounds of the invention may contain one or more chiral centers and/or double bonds and, therefore, may exist as stereoisomers, such as double-bond isomers (i.e., geometric isomers), enantiomers, or diastereomers. When compounds of the invention are depicted or named without indicating the stereochemistry, it is to be understood that both stereomerically pure forms (e.g. , geometrically pure, enantiomerically pure, or diastereomerically pure) and stereoisomeric mixtures are encompassed. For example, the compound represented by Structural Formula (I) below has chiral centers 1 and 2. Accordingly, the compounds of the invention depicted by Structural Formula (I) include (IR, 2R), (IR, 2S), (IS, 2R) and (IS, 2S) stereoisomers and mixtures thereof.
Figure imgf000068_0002
As used herein, a racemic mixture means about 50% of one enantiomer and about 50% of is corresponding enantiomer relative to all chiral centers in the molecule. The invention encompasses all enantiomerically-pure, enantiomerically- enriched, diastereomerically pure, diastereomerically enriched, and racemic mixtures of the compounds of the invention.
In some preferred embodiments, the compounds of the invention are (IR, 2R) stereoisomers.
Enantiomeric and diastereomeric mixtures can be resolved into their component enantiomers or stereoisomers by well known methods, such as chiral- phase gas chromatography, chiral -phase high performance liquid chromatography, crystallizing the compound as a chiral salt complex, or crystallizing the compound in a chiral solvent. Enantiomers and diastereomers can also be obtained from diastereomerically- or enantiomerically-pure intermediates, reagents, and catalysts by well known asymmetric synthetic methods. Included in the invention are pharmaceutically acceptable salts of the compounds disclosed herein. The disclosed compounds have basic amine groups and therefore can form pharamceutically acceptable salts with pharmaceutically acceptable acid(s). Suitable pharmaceutically acceptable acid addition salts of the compounds of the invention include salts of inorganic acids (such as hydrochloric acid, hydrobromic, phosphoric, metaphosphoric, nitric, and sulfuric acids) and of organic acids (such as, acetic acid, benzenesulfonic, benzoic, citric, ethanesulfonic, fumaric, gluconic, glycolic, isethionic, lactic, lactobionic, maleic, malic, methanesulfonic, succinic, p- toluenesulfonic, and tartaric acids). Compounds of the invention with acidic groups such as carboxylic acids can form pharamceutically acceptable salts with pharmaceutically acceptable base(s). Suitable pharmaceutically acceptable basic salts include ammonium salts, alkali metal salts (such as sodium and potassium salts) and alkaline earth metal salts (such as magnesium and calcium salts). Compounds with a quaternary ammonium group also contain a counteranion such as chloride, bromide, iodide, acetate, perchlorate and the like. Other examples of such salts include hydrochlorides, hydrobromides, sulfates, methanesulfonates, nitrates, maleates, acetates, citrates, fumarates, tartrates [e.g. (+)-tartrates, (-)-tartrates or mixtures thereof including racemic mixtures], succinates, benzoates and salts with amino acids such as glutamic acid.
When the stereochemistry of the disclosed compounds is named or depicted by structure, the named or depicted stereoisomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight pure relative to the other stereoisomers. When a single enantiomer is named or depicted by structure, the depicted or named enantiomer is at least 60%, 70%, 80%, 90%, 99% or 99.9% by weight optically pure. Percent optical purity by weight is the ratio of the weight of the enatiomer over the weight of the enantiomer plus the weight of its optical isomer. As used herein, the term "hydrolyzable group" means an amide, ester, carbamate, carbonate, ureide, or phosphate analogue, respectively, that either: 1) does not destroy the biological activity of the compound and confers upon that compound advantageous properties in vivo, such as improved water solubility, improved circulating half-life in the blood (e.g., because of reduced metabolism of the prodrug), improved uptake, improved duration of action, or improved onset of action; or 2) is itself biologically inactive but is converted to a biologically active compound. Examples of hydrolyzable amides include, but are not limited to, lower alkyl amides, α-amino acid amides, alkoxyacyl amides, and alkylaminoalkylcarbonyl amides. Examples of biohydrolyzable esters include, but are not limited to, lower alkyl esters, alkoxyacyloxy esters, alkyl acylamino alkyl esters, and choline esters. Examples of biohydrolyzable carbamates include, but are not limited to, lower alkylamines, substituted ethylenediamines, aminoacids, hydroxyalkylamines, heterocyclic and heteroaromatic amines, and polyether amines. An "aliphatic group" is non-aromatic, consists solely of carbon and hydrogen and may optionally contain one or more units of unsaturation, e.g., double and/or triple bonds. An aliphatic group may be straight chained, branched or cyclic. When straight chained or branched, an aliphatic group typically contains between about one and about twenty carbon atoms, typically between about one and about ten carbon atoms, more typically between about one and about six carbon atoms. When cyclic, an aliphatic group typically contains between about three and about ten carbon atoms, more typically between about three and about seven carbon atoms. A "substituted aliphatic group" is substituted at any one or more "substitutable carbon atom". A "substitutable carbon atom" in an aliphatic group is a carbon in an aliphatic group that is bonded to one or more hydrogen atoms. One or more hydrogen atoms can be optionally replaced with a suitable substituent group. A "haloaliphatic group" is an aliphatic group, as defined above, substituted with one or more halogen atoms. Suitable substituents on a substitutable carbon atom of an aliphatic group are the same as those for an alkyl group.
The term "alkyl" used alone or as part of a larger moiety, such as "alkoxy", "haloalkyl", "arylalkyl", "alkylamine", "cycloalkyl", "dialkyamine", "alkylamino", "dialkyamino" "alkylcarbonyl", "alkoxycarbonyl" and the like, includes as used herein means saturated straight-chain, cyclic or branched aliphatic group. As used herein, a C1-C6 alkyl group is referred to "lower alkyl." Similarly, the terms "lower alkoxy", "lower haloalkyl", "lower arylalkyl", "lower alkylamine", "lower cycloalkylalkyl", "lower dialkyamine", "lower alkylamino", "lower dialkyamino" "lower alkylcarbonyl", "lower alkoxycarbonyl" include straight and branched saturated chains containing one to six carbon atoms.
The term "alkoxy" means -O-alkyl; "hydroxyalkyl" means alkyl substituted with hydroxy; "aralkyl" means alkyl substituted with an aryl group; "alkoxyalkyl" mean alkyl substituted with an alkoxy group; "alkylamine" means amine substituted with an alkyl group; "cycloalkylalkyl" means alkyl substituted with cycloalkyl; "dialkylamine" means amine substituted with two alkyl groups; "alkylcarbonyl" means -C(O)-R*, wherein R* is alkyl; "alkoxycarbonyl" means -C(O)-OR*, wherein R* is alkyl; and where alkyl is as defined above.
The terms "amine" and "amino" are used interchangeably throughout herein and mean -NH2, -NHR or -NR2, wherein R is alkyl. "Cycloalkyl" means a saturated carbocyclic ring, with from three to eight carbons.
The terms "haloalkyl" and "haloalkoxy" mean alkyl or alkoxy, as the case may be, substituted with one or more halogen atoms. The term "halogen" means F, Cl, Br or I. Preferably the halogen in a haloalkyl or haloalkoxy is F. The term "acyl group" means -C(O)R, wherein R is an optionally substituted alkyl group or aryl group (e.g., optionally substituted phenyl). R is preferably an unsubstituted alkyl group or phenyl. An "alkylene group" is represented by -[CH2]Z-, wherein z is a positive integer, preferably from one to eight, more preferably from one to four.
As used herein, the term "alkenyl" refers to a straight or branched hydrocarbon group that contains one or more double bonds between carbon atoms. Suitable alkenyl groups include, e.g., rc-butenyl, cyclooctenyl and the like. An alkenyl group may be substituted.
The term "aryl group" used alone or as part of a larger moiety as in "aralkyl", "aralkoxy", or "aryloxyalkyl", includes carbocyclic aromatic rings and heteroaryl rings. The term "aromatic group" may be used interchangeably with the terms "aryl", "aryl ring" "aromatic ring", "aryl group" and "aromatic group". An aromatic group typically has six - fourteen ring atoms. A "substituted aryl group" is substituted at any one or more substitutable ring atom.
Carbocyclic aromatic rings have only carbon ring atoms (typically six to fourteen) and include monocyclic aromatic rings such as phenyl and fused polycyclic aromatic ring systems in which two or more carbocyclic aromatic rings are fused to one another. Examples include 1-naphthyl, 2-naphthyl, 1-anthracyl.
The term "heteroaryl", "heteroaromatic", "heteroaryl ring", "heteroaryl group" and "heteroaromatic group", used alone or as part of a larger moiety as in "heteroaralkyl" or "heteroarylalkoxy", refers to aromatic ring groups having five to fourteen ring atoms selected from carbon and at least one (typically 1 -4, more typically 1 or 2) heteroatom (e.g., oxygen, nitrogen or sulfur). They include monocyclic rings and polycyclic rings in which a monocyclic heteroaromatic ring is fused to one or more other carbocyclic aromatic or heteroaromatic rings. Examples of monocyclic heteroaryl groups include furanyl (e.g., 2-furanyl, 3-furanyl), imidazolyl (e.g., N-imidazolyl, 2-imidazolyl, 4-imidazolyl, 5-imidazolyl), isoxazolyl( e.g., 3- isoxazolyl, 4-isoxazolyl, 5-isoxazolyl), oxadiazolyl (e.g., 2-oxadiazolyl, 5- oxadiazolyl), oxazolyl (e.g., 2-oxazolyl, 4-oxazolyl, 5-oxazolyl), pyrazolyl (e.g., 3- pyrazolyl, 4-pyrazolyl), pyrrolyl (e.g., 1-pyrrolyl, 2-pyrrolyl, 3-pyrrolyl), pyridyl (e.g., 2-pyridyl, 3-pyridyl, 4-pyridyl), pyrimidinyl (e.g., 2-pyrimidinyl, 4-pyrimidinyl, 5-pyrimidinyl), pyridazinyl (e.g., 3-pyridazinyl), thiazolyl (e.g., 2-thiazolyl, 4- thiazolyl, 5-thiazolyl), triazolyl (e.g., 2-triazolyl, 5-triazolyl), tetrazolyl (e.g., tetrazolyl) and thienyl (e.g., 2-thienyl, 3-thienyl. Examples of monocyclic six- membered nitrogen-containing heteraryl groups include pyrimidinyl, pyridinyl and pyridazinyl. Examples of polycyclic aromatic heteroaryl groups include carbazolyl, benzimidazolyl, benzothienyl, benzofuranyl, indolyl, quinolinyl, benzotriazolyl, benzothiazolyl, benzoxazolyl, benzimidazolyl, isoquinolinyl, indolyl, isoindolyl, acridinyl, or benzisoxazolyl.
The term "non-aromatic heterocyclic group", used alone or as part of a larger moiety as in "non-aromatic heterocyclylalkyl group", refers to non-aromatic ring systems typically having five to twelve members, preferably five to seven, in which one or more ring carbons, preferably one or two, are each replaced by a heteroatom such as N, O, or S. A non-aromatic heterocyclic group can be monocyclic or fused bicyclic. A "nitrogen-containing non-aromatic heterocyclic group" is a non- aromatic heterocyclic group with at least one nitrogen ring atom.
Examples of non-aromatic heterocyclic groups include (tetrahydrofuranyl (e.g., 2-tetrahydropyranyl, 3-tetrahydropyranyl, 4-tetrahydropyranyl), [1,3]- dioxalanyl, [1,3]-dithiolanyl, [1,3]-dioxanyl, tetrahydrothienyl (e.g., 2- tetrahydrothienyl, 3-tetrahydrothieneyl), azetidinyl (e.g., N-azetidinyl, 1-azetidinyl, 2-azetidinyl), oxazolidinyl (e.g., N-oxazolidinyl, 2-oxazolidinyl, 4-oxazolidinyl, 5- oxazolidinyl), morpholinyl (e.g., N-morpholinyl, 2-morpholinyl, 3-morpholinyl), thiomorpholinyl (e.g., N-thiomorpholinyl, 2-thiomorpholinyl, 3-thiomorpholinyl), pyrrolidinyl (e.g., N-pyrrolidinyl, 2-pyrrolidinyl, 3-pyrrolidinyl) piperazinyl (e.g., N- piperazinyl, 2-piperazinyl), piperidinyl (e.g., N-piperidinyl), 2-piperidinyl, 3- piperidinyl, 4-piperidinyl), thiazolidinyl (e.g., 4-thiazolidinyl), diazolonyl and N- substituted diazolonyl. The designation "N" on N-morpholinyl, N-thiomorpholinyl, N-pyrrolidinyl, N-piperazinyl, N-piperidinyl and the like indicates that the non- aromatic heterocyclic group is attached to the remainder of the molecule at the ring nitrogen atom.
A "substitutable ring atom" in an aromatic group is a ring carbon or nitrogen atom bonded to a hydrogen atom. The hydrogen can be optionally replaced with a suitable substituent group. Thus, the term "substitutable ring atom" does not include ring nitrogen or carbon atoms which are shared when two aromatic rings are fused. In addition, "substitutable ring atom" does not include ring carbon or nitrogen atoms when the structure depicts that they are already attached to a moiety other than hydrogen. An aryl group may contain one or more substitutable ring atoms, each bonded to a suitable substituent. Examples of suitable substituents on a substitutable ring carbon atom of an aryl group include halogen, alkyl, haloalkyl, ArA, -ORA, -O(haloalkyl), -SRA, -NO2, -CN, -N(RB)2, -NRBC(O)RA, -NRBCO2RC, -N(RB)C(O)N(RB)2, -C(O)RA, -CO2RA, -S(O)2RA, -SO2N(RB)2, -S(O)RC,
-NRBSO2N(RB)2, -NRBSO2RC , -VA-ArA, -VA-0RA, -V-O(haloalkyl), -VA-SRA, -VA-NO2, -VA-CN, -VA-N(RB)2, -VA-NRBC(0)RA, -VA-NRBC02RC, -VA-N(RB)C(O)N(RB)2, -VA-C(O)RA, -VA-CO2RA, -VA-S(O)2RA, -VA-SO2N(RB)2, -VA-S(O)RC, -VA-NRBSO2N(RB)2, -VA-NRBSO2RC, -O-VA-ArA, -0-VB-N(RB)2, -S-VA- ArA, -S-VB-N(RB)2, -N(RB)-VB-ArA, -N(RB)-VB-N(RB)2, -NR8C(O)- VA-N(RB)2, -NRBC(O)-VA-ArA, -C(0)-VA-N(RB)2, -C(O)-VA-ArA, -CO2-VB-N(RB)2, -CO2-VA-ArA, -C(0)N(RB)-VB-N(RB)2, -C(O)N(RB)-VA-ArA, -S(O)2- VA-N(RB)2, -S(O)2-VA-ArA, -SO2N(RB)-VB-N(RB)2, -SO2N(R5)- VA-ArA, -S(O)-VA-N(RB)2, -S(O)-VA-ArA, -NR8SO2- VA-N(RB)2 or -NR8SO2- VA-ArA; or two adjacent substituents, taken together, form a methylenedioxy, ethyl enedioxy or -[CH2]4- group.
Each VA is independently a Cl-ClO alkylene group. Each VB is independently a C2-C10 alkylene group. ArA is a monocyclic aromatic group each substituted with zero, one or two groups independently selected from halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy or haloalkyl.
Each RA is independently i) hydrogen; ii) an aromatic group substituted with zero, one or two groups represented by halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy or haloalkyl; or iii) an alkyl group optionally substituted with halogen, hydroxyl, alkoxy, nitro, cyano, alkoxycarbonyl, alkylcarbonyl or haloalkoxy.
Each RB is independently RA, -CO2RA, -SO2RA or -C(O)RA; or -N(RB)2 taken together is an optionally substituted non-aromatic heterocyclic group.
Each Rc is independently: i) an aromatic group substituted with zero, one or two groups represented by halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy or haloalkyl; or ii) an alkyl group optionally substituted with halogen, hydroxyl, alkoxy, nitro, cyano, alkoxycarbonyl, alkylcarbonyl or haloalkoxy.
An alkyl or a non-aromatic heterocyclic group (including, but not limited to, non-aromatic heterocyclic groups represented by -N(R31)2, -N(R41)2, -N(R51)2 and -N(RB)2) may contain one or more substituents. Examples of suitable substituents for an alkyl or a ring carbon of a non-aromatic heterocyclic group include those listed above for a substitutable carbon of an aryl and the following: =O, =S, =NNHRC, =NN(RC)2, =NNHC(O)RC, =NNHCO2 (alkyl), =NNHSO2 (alkyl), =NRC, spiro cycloalkyl group, fused cycloalkyl group or a monocyclic non-aromatic nitrogen-containing heterocyclic group attached by a ring nitrogen atom (e.g., N- piperidinyl, N-pyrrolidinyl, N-azepanyl, N-morpholinyl, N-thiomorphinyl, N- piperazinyl or N-diazepanyl group). Each Rc is independently selected from hydrogen, an unsubstituted alkyl group or a substituted alkyl group. Examples of substituents on the alkyl group represented by R include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyl, alkylaminocarbonyloxy, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl. Preferred substituents for an alkyl or a ring carbon of a non-aromatic heterocyclic group include C1-C2 alkyl, -OH, N-pyrrolidinyl, N-piperidinyl, N-(4- alkyl)piperazinyl, N-morpholinyl or N-pyrrolyl.
Suitable substituents on the nitrogen of a non-aromatic heterocyclic group or heteroaryl group include -RD, -Ν(RD)2, -C(O)R0, -CO2 RD, -C(O)C(O)R0, - C(O)CH2 C(O)R° -SO2 R°, -SO2 N(R°)2, -C(=S)N(RD)2, -C(=NH)-N(RD)2, and - NRD SO2 R°; wherein R° is hydrogen, an alkyl group, a substituted alkyl group, phenyl (Ph), substituted Ph, -O(Ph), substituted -OPh), CH2(Ph), substituted CH2(Ph), or an unsubstituted heteroaryl or heterocyclic ring. Examples of substituents on the alkyl group or the phenyl ring represented by R° include amino, alkylamino, dialkylamino, aminocarbonyl, halogen, alkyl, alkylaminocarbonyl, dialkylaminocarbonyloxy, alkoxy, nitro, cyano, carboxy, alkoxycarbonyl, alkylcarbonyl, hydroxy, haloalkoxy, or haloalkyl. Preferred substituents on a substitutable nitrogen atom of a nitrogen-containing heteroaryl or nitrogen- containing non-aromatic heterocyclic group include C1-C2 alkyl, C1-C2 hydroxyalkyl, or benzyl optionally substituted with halogen, nitro, cyano, C1-C2 alkyl, C1-C2 haloalkyl, C1-C2 alkoxy or C1-C2 haloalkoxy.
In some specific embodiments, non-aromatic heterocyclic groups (including, but not limited to, non-aromatic heterocyclic groups represented by -N(R3 !)2, -N(R41)2, -N(R51)2 and -N(RB)2) each independently are optionally substituted with one or more substituents selected from the group consiting of halogen, =0, =S, =N(C1-C6 alkyl), C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, (C1-C6 alkoxy)carbonyl, (C1-C6 alkyl)carbonyl, C1-C6 haloalkoxy, amino, (C1-C6 alkyl)amino and (C1-C6 dialkyl)amino. In some more specific embodiments, the non-aromatic heterocyclic groups each independently are optionally substituted with one or more substituents selected from the group consiting of halogen, C1-C6 alkyl, C1-C6 haloalkyl, hydroxy, C1-C6 alkoxy, nitro, cyano, (C1-C6 alkoxy)carbonyl, (C1-C6 alkyl)carbonyl, C1-C6 haloalkoxy, amino, (C1-C6 alkyl)amino and (C1-C6 dialkyl)amino. Inhibitors of glucosylceramide synthase can be used to treat diabetes, such as type 2 diabetes (see WO 2006/053043, the entire teachings of which are incorporated herein by reference). As such, the disclosed compounds, which are inhibitors of glucosylceramide synthase, can be used to treat diabetes, e.g., type 2 diabetes and renal hypertrophy or hyperplasia associated with diabetic nephropathy, by administration of a therapeutically effective amount of a compound of the invention to a subject in need of such treatment.
Inhibitors of glucosylceramide synthase, such as GM3 synthase, have been shown to be useful for treating lysosomal storage diseases (see, for example, U.S. Patent Nos. 6,569,889; 6,255,336; 5,916,911; 5,302,609; 6,660,749; 6,610,703; 5,472,969; 5,525,616, the entire teachings of which are incorporated herein by reference). As such, the disclosed compounds, which are inhibitors of glucosylceramide synthase, can be used to treat lysosomal storage diseases, such as Tay-Sachs, Gaucher's or Fabry's disease, by administration of a therapeutically effective amount of a compound of the invention to a subject in need of such treatment.
In an alternative embodiment of the present invention, the compounds of the present invention can be used for: treating disorders involving cell growth and division, including cancer, collagen vascular diseases, atherosclerosis, and the renal hypertrophy of diabetic patients (see U.S. Patent Nos. 6,916,802 and 5,849,326, the entire teachings of which are incorporated herein by reference); inhibiting the growth of arterial epithelial cells (see U.S. Patent Nos. 6,916,802 and 5,849,326); treating patients suffering from infections (see Svensson, M. et al, "Epithelial Glucosphingolipid Expression as a Determinant of Bacterial Adherence and Cytokine Production," Infect, andlmmun., 62:4404-4410 (1994), the entire teachings of which are incorporated herein by reference); preventing the host, i.e., patient, from generating antibodies against the tumor (see Inokuchi, J. et al., "Antitumor Activity in Mice of an Inhibitor of Glycosphingolipid Biosynthesis," Cancer Lett, 38:23-30(1987), the entire teachings of which are incorporated herein by reference); and treating tumors (see Hakomori, S. "New Directions in Cancer Therapy Based on Aberrant Expression of Glycosphingolipids: Anti-adhesion and Ortho-Signaling Therapy," Cancer Cells 3:461-470 (1991), Inokuchi, J. et al, "Inhibition of Experimental Metastasis of Murine Lewis Long Carcinoma by an Inhibitor of Glucosylceramide Synthase and its Possible Mechanism of Action," Cancer Res., 50:6731-6737 (1990) and Ziche, M. et al, "Angiogenesis Can Be Stimulated or Repressed in In Vivo by a Change in GM3 :GD3 Ganglioside Ratio," Lab. Invest., 67:711-715 (1992), the entire teachings of which are incorporated herein by reference).
In an alternative embodiment, the compounds of the invention can be used for a vaccine-like preparation (see, for example, U.S. Patent Nos. 6,569,889; 6,255,336; 5,916,91 1 ; 5,302,609; 6,660,749; 6,610,703; 5,472,969; 5,525,616). Here, cancer cells are removed from the patient (preferably as completely as possible), and the cells are grown in culture in order to obtain a large number of the cancer cells. The cells are then exposed to the inhibitor for a time sufficient to deplete the cells of their GSLs (generally 1 to 5 days) and are reinjected into the patient. These reinjected cells act like antigens and are destroyed by the patient's immunodefense system. The remaining cancer cells (which could not be physically removed) will also be attacked by the patient's immunodefense system. In a preferred embodiment, the patient's circulating gangliosides in the plasma are removed by-plasmapheresis, since the circulating gangliosides would tend to block the immunodefense system.
As used herein a subject is a mammal, preferably a human, but can also be an animal in need of veterinary treatment, such as a companion animal (e.g., dogs, cats, and the like), a farm animal (e.g., cows, sheep, pigs, horses, and the like) or a laboratory animal (e.g., rats, mice, guinea pigs, and the like). Subject and patient are used interchangeably. A subject "in need of treatment" includes a subject with chronic renal failure.
"Treatment" or "treating" refers to both therapeutic and prophylactic treatment.
An "effective amount" of a pharmaceutical composition disclosed above is a quantity that results in a beneficial clinical outcome of or exerts an influence on, the condition being treated with the pharmaceutical composition compared with the absence of treatment. The administering amount of a pharmaceutical composition disclosed above to the subject will depend on the degree, severity, and type of the disease or condition, the amount of therapy desired, and the release characteristics of the pharmaceutical composition. It will also depend on the subject's health, size, weight, age, sex, and tolerance to drugs. Typically, the pharmaceutical compositions of the invention are administered for a sufficient period of time to achieve the desired therapeutic effect. Dosages may range from 0.1 to 500 mg/kg body weight per day. In one embodiment, the dosing range is 1-20 mg/kg/day. The compound of the invention may be administered continuously or at specific timed intervals. For example, the compound of the invention may be administered 1 , 2, 3, or 4 times per day, such as, e.g., a daily or twice-daily formulation. Commercially available assays may be employed to determine optimal dose ranges and/or schedules for administration. For example, assays for measuring blood glucose levels are commercially available (e.g., OneTouch® Ultra®, Lifescan, Inc. Milpitas, CA). Kits to measure human insulin levels are also commercially available (Linco Research, Inc. St. Charles, MO). Additionally, effective doses may be extrapolated from dose- response curves obtained from animal models (see, e.g., Comuzzie et al., Obes. Res. 11 (1 ):75 (2003); Rubino et al., Ann. Surg. 240(2):389 (2004); Gill- Randall et al, Diabet. Med. 21 (7):759 (2004), the entire teachings of which are incorporated herein by reference). Therapeutically effective dosages achieved in one animal model can be converted for use in another animal, including humans, using conversion factors known in the art (see, e.g., Freireich et al., Cancer Chemother. Reports 50(4):219 (1996), the entire teachings of which are incorporarted herein by reference) and Table A below for equivalent surface area dosage factors.
Figure imgf000079_0001
Typically, the pharmaceutical compositions of the invention can be administered before or after a meal, or with a meal. As used herein, "before" or "after" a meal is typically within two hours, preferably within one hour, more preferably within thirty minutes, most preferably within ten minutes of commencing or finishing a meal, respectively.
In one embodiment, the method of the present invention is a mono-therapy where the pharmaceutical compositions of the invention are administered alone. Accordingly, in this embodiment, the compound of the invention is the only pharmaceutically active ingredient in the pharmaceutical compositions.
In another embodiment, the method of the invention is a co-therapy with other therapeutically active drugs known in the art for treating the desired diseases or indications, such as one or more known drugs for treating, diabetes, lysosomal diseases, tumors, etc.
In a particular embodiment, the method of the invention is a combination therapy for treating diabetes, such as Type 2 diabetes. The combination therapy comprise any of the compounds of the invention described herein and at least one other compound suitable for treating diabetes. Examples of drugs or compounds used to treat type 2 diabetes include: insulin (e.g., Novolin®, Novolog®, Velosulin®); sulfonylureas (e.g., Diabinese®, Glucotrol®, Glucotrol XL®, (Diabeta®, Amaryl®, Orinase®, Tolinase®, Micronase® and Glynase®); metformin; [alpha] -glucosidase inhibitors (e.g., Glyset®); thiazolidinediones(e.g., Actos® and Avandia®); nateglinide (Starlix®); repaglinide (Prandin®) and combination drugs such as Avandamet® (Avandia® and metformin).
The pharmaceutical compositions of the invention optionally include one or more pharmaceutically acceptable carriers and/or diluents therefor, such as lactose, starch, cellulose and dextrose. Other excipients, such as flavoring agents; sweeteners; and preservatives, such as methyl, ethyl, propyl and butyl parabens, can also be included. More complete listings of suitable excipients can be found in the Handbook of Pharmaceutical Excipients (5th Ed., Pharmaceutical Press (2005)).
The carriers, diluents and/or excipients are "acceptable" in the sense of being compatible with the other ingredients of the pharmaceutical composition and not deleterious to the recipient thereof. The pharmaceutical compositions can conveniently be presented in unit dosage form and can be prepared by any suitable method known to the skilled artisan. In general, the pharmaceutical compositions are prepared by uniformly and intimately bringing into association the compounds disclosed herein with the carriers, diluents and/or excipients and then, if necessary, dividing the product into unit dosages thereof.
The pharmaceutical compositions of the invention can be formulated as a tablet, sachet, slurry, food formulation, troche, capsule, elixir, suspension, syrup, wafer, chewing gum or lozenge. A syrup formulation will generally consist of a suspension or solution of the compounds of the invention described herein or salt in a liquid carrier, for example, ethanol, glycerine or water, with a flavoring or coloring agent. Where the composition is in the form of a tablet, one or more pharmaceutical carriers routinely used for preparing solid formulations can be employed. Examples of such carriers include magnesium stearate, starch, lactose and sucrose. Where the composition is in the form of a capsule, the use of routine encapsulation is generally suitable, for example, using the aforementioned carriers in a hard gelatin capsule shell. Where the composition is in the form of a soft gelatin shell capsule, pharmaceutical carriers routinely used for preparing dispersions or suspensions can be considered, for example, aqueous gums, celluloses, silicates or oils, and are incorporated in a soft gelatin capsule shell.
Though the above description is directed toward routes of oral administration of pharmaceutical compositions consistent with embodiments of the invention, it is understood by those skilled in the art that other modes of administration using vehicles or carriers conventionally employed and which are inert with respect to the compounds of the invention may be utilized for preparing and administering the pharmaceutical compositions. For example, the pharmaceutical compositions of the invention may also be formulated for rectal administration as a suppository or retention enema, e.g., containing conventional suppository bases such as cocoa butter or other glycerides. Also, the pharamceutical compositions of the invention can be formulated for injection, or for transdermal or trnasmucosal administration. Illustrative of various modes of administration methods, vehicles and carriers are those described, for example, in Remington's Pharmaceutical Sciences, 18th ed. (1990), the disclosure of which is incorporated herein by reference.
The invention is illustrated by the following examples which are not intended to be limiting in any way.
EXEMPLIFICATION
Example 1: General Methods for the Preparation of Compounds of the Invention:
A general method for the synthesis of final compounds is depicted in Scheme
1. A general method for the preparation of the compounds of the invention involves the reaction of the amine of type EVII with the appropriate reagent. The amine type EVII, such as (IR, 2R)-2-amino-(2,3-dihydrobenzo [β][1,4[dioxin-6-yl)-3- (pyrrolidin-1-yl) propan-1-ol, can be prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference), or by using the general synthetic procedures depicted in schemes 2-5. Final amide compounds, EIX can be prepared by reaction of the amine EVII with the corresponding acylating agent using standard reaction conditions for the formation of an amide. The urea compounds, EIIX can be prepared by reaction of the amine EVII with the corresponding isocyanate. The carbamates, EX can be prepared by reaction of the amine EVII with the corresponding chloroformate.
Figure imgf000082_0001
Example IA. Synthesis of the Compounds of the Invention: General Methods for the Preparation of Amide Analogs
Method 1
A mixture of Compound EVII (1 mmol), such as (IR, 2R)-2-amino-1-(2,3- dihydrobenzofβ] [1 ,4]dioxin-6-yl)-3-(pyrrolidin- 1 -yl)propan- 1 -ol, prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference) or using the methods depicted in schemes 2,3,4 and 5, an acid (1.2 mmol), DCC (dicyclohexylcarbodiimide, 1.2 mmol) and HOBT (1-hydroxy benzotriazole, 1.2 mmol) was dissolved in CH2Cl2 (5 ml). The mixture was stirred at room temperature and monitored by TLC (thin liquid chromatography) for completion. After completion the mixture was filtered and purified by column chromatography using, for example, a mixture of (CH2Cl2ZMeOHZNH4OH).
Method 2
A mixture of Compound EVII (1 mmol), such as (IR, 2R)-2-amino-1-(2,3- dihydrobenzo[β][1,4]dioxin-6-yl)-3-(pyrrolidin-1-yl)propan-1-ol, prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference) or using the methods depicted in schemes 2,3,4 and 5, an acid and DCC (dicyclohexylcarbodiimide, 1.2 mmol) was dissolved in CHCl3 (5 ml). The mixture was placed in the microwave reactor (T = 120 °C, time = lmin) and it was then filtered and purified by column chromatography using, for example, a mixture Of (CH2Cl2ZMeOHZNH4OH).
Method 3
A mixture of Compound EVII (1 mmol), such as (IR, 2R)-2-amino-1-(2,3- dihydrobenzo[β] [ 1 ,4]dioxin-6-yl)-3-(pyrrolidin- 1 -yl)propan- 1 -ol, prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference) or using the methods depicted in schemes 2,3,4 and 5, an acid chloride (1.2 mmol) and K2CO3 (2 mmol) was suspended in THF (5 ml). The mixture was stirred at room temperature and monitored by TLC for completion. After completion, the mixture was filtered and purified by column chromatography using, for example, a mixture of (CH2Cl2/MeOH/NH4OH).
Method 4
Compound EVII, such as (IR, 2R)-2-amino-1-(2,3-dihydro-benzo[1,4] dioxin-6-yl)-3-pyrrolidin-1-yl-propan-1-ol, prepared according to the preparation of intermediate 4 of US patent 6,855,830 (the entire teachings of which are incorporated herein by reference) or using the methods depicted in schemes 2,3,4 and 5, was coupled with a variety of N-hydroxysuccinamide esters in methylene chloride under an atmosphere of nitrogen, for example, for 18 to 24 hours depending on the ester used.
Preparation of N-hvdroxysuccinamide esters
Various mono- and di-keto acids were coupled with N-hydroxysuccinamide in the presence of N, N'-dicyclohexylcarbodiimide in ethyl acetate under an atmosphere of nitrogen for 18 hours. The products were filtered to remove the dicyclohexylurea. The identity of these esters was confirmed by 1H NMR and the crude material was then used in the preparation of amide analogs without further purification.
Example IB. Alternative Synthetic Method for the Prepartion of Intermediate EVII. Synthetic Route 1
An alternative general synthesis of Compound EVII is depicted in Scheme 2. Treatment of (R)-2-(benzyloxycarbonylamino)-3-hydroxypropanoic acid with EDCI and N,O-dimethylhydroxyamine gave the weinreb amide EI in excellent yield. The primary alcohol was protected as the TBDMS ether EII in excellent yield by reaction with TBDMSCl in DMF. Reaction of EII with a grignard at low temperature gave EIII in good to excellent yields. Steroselective reduction of EIII and with L-selectride at -70C gave EIV in good to excellent yield and selectivity. Compound EV was obtained in good to excellent yields after deprotection with acetic acid. Reaction with mesylate chloride and a suitable amine produced EVI in good to excellent yield. Finally, deprotection to the primary amine EVII was done in the microwave oven using NaOH aqueous solution in methanol at 150 °C for one to three minutes depending on the specific compound.
HO
Figure imgf000085_0001
Sch
Example IB. Alternative Synthetic Method for the Prepartion of Intermediate EVII. Synthetic Route 2:
An alternative general synthesis of Compound EVII is depicted in Scheme 3. Intermediate AI was obtained with excellent diastereoselectivity (96:4) by reduction of compound A with LiA1H4 followed by reaction with an aldehyde in the presence of CuI and Me2S. Mesylate intermediate AIII was obtained by reaction with Amberlyst 15 followed by reaction with MsCl in pyridine. The final compound EVII was obtained by reaction with pyrrolidine and removal of the CBz by hydrogenation.
Figure imgf000086_0001
Scheme 3
Example IB. Alternative Synthetic Method for the Prepartion of Intermediate EVIL Synthetic Route 3
A general alternative route for synthesis of compound EVII is depicted in
Scheme 4. Intermediate EIV was obtain as shown in Scheme 4 was cycled into oxazolidinone B using sodium hydride in a DMF/THF solution. Deprotection of the primary alcohol by reaction with 11Bu4NF, followed by formation of the tosylate by reaction with tosyl chloride in pyridine, finally, displacement of the tosylate by an appropriate amine afforded compound Bl in good to excellent yield. Hydrolysis of the oxazolidinone with LiOH in a water ethanol mixture gave compound EVII. Scheme 4
Figure imgf000087_0001
Example IB. Alternative Synthetic Method for the Prepartion of Intermediate
EVIL Synthetic Route 4
An alternative general synthesis of Compound EVII is depicted in Scheme 5. An aldehyde (2 equiv) is condensed with the chiral morpholinone in toluene with removal of water to provide the fused cycloadduct 2. Treatment of 2 with hydrogen chloride in an alcohol solvent such as methanol provides amino acid 3. Removal of the N-benzyl functionality can be accomplished with hydrogen in the presence of a palladium catalyst to afford 4. Cyclization of 4 with triphosgene and base provides ester 5. The ester functionality can be reduced with sodium borohydride, and the resulting alcohol converted to an appropriate leaving group (i.e. tosylate or iodide). Reaction of 6 with a suitable amine in the presence of excess base (e.g. K2CO3) in a polar solvent (e.g. DMSO or CH3CN) affords 7. Final deprotection under basic conditions affords Compound EVII analogs suitable for conversion to the desired amide final products.
MeO2 *C- ^ y v R1
R2R3NH1 CO3 DMSO O 3CN
Scheme 5
Figure imgf000088_0001
Example 1C. Preparation of Compound EVII using Scheme 2.
Preparation of EII: (R)-benzyl 3,8,8,9,9-pentamethyl-4-oxo-2,7-dioxa-3-aza-8- siladecan-5-ylcarbamate
Imidazole (1.8 g, 26.5 mmol) was added to a solution of (R)-benzyl 3- hydroxy-1-(methoxy(methyl)amino)-1-oxopropan-2-ylcarbamate (3 g, 10.6 mmol) in DMF (dimethyl formamide, 15 mL) followed by TBDMSiCl (tert- butyldimethylsilyl chloride, 2.4 g, 15.95 mmol). The reaction stirred for 12 hrs at room temperature under nitrogen atmosphere and was quenched with aqueous ammonium chlroride (100 ml). The aqueous layer was extracted with methylene chloride (200 mL) and ethyl acetate (100 mL) and the organic layers were washed with brine and concentrated. The crude product was purified by column chromatography using 10% EtOAc (ethylacetate)-hexanes to give an oil (3 g, 74% yield). 1H NMR (400 MHz, CDCl3) δ= 0 (s, 6H), 0.9 (s, 9H), 3.2 (s, 3H), 3.8 (s, 3H), 3.8-3.9 (m, 2H), 4.8 (broad s, 1H), 5.1 (q, 2H), 5.7 (d, 1H), 7.2-7.4 (m, 5H).
Preparation of EIII: (R)-benzyl 3-(tert-butyldimethylsilyloxy)-1-(2.3- dihydrobenzo[β][1.41dioxin-6-yl)-1-oxopropan-2-ylcarbamate.
(2,3-dihydrobenzo[β][1,4]dioxin-6-yl)magnesium bromide (26 g, 78 mmol) dissolved in 40 mL of THF (tetrahydrofuran) under a nitrogen atmosphere was cooled down to -70 °C and (R)-benzyl 3,8,8,9,9-pentamethyl-4-oxo-2,7-dioxa-3-aza- 8-siladecan-5-ylcarbamate (12.3 g, 31mmol) dissolved in THF (13 ml) were added dropwise. The reaction mixture was allowed to warm up to -15 °C and left to react for 12 hrs followed by stirring at room temperature for 2 hrs. After cooling the reaction mixture to -40 °C it was quenched using aqueous ammonium chloride and the aqueous layer was extracted with EtOAc dried over magnesium sulfate and concentrated. The crude product was purified by column chromatography using 25% EtOAc-hexanes to give pure product (13 g, 88% yield). 1H NMR (400 MHz, CDCl3) δ= 0 (d, 6H), 0.9 (s, 9H), 4.0-4.2 (m, 2H), 4.4 (s, 2H), 4.5 (s, 2H), 5.2 (s, 2H), 5.4 (m, 1H), 6.1 (d, 1H), 7 (d, 1H), 7.4-7.7 (m, 7H).
Preparation of EIV: benzyl (IR. 2R)-3-(tert-butyldimethylsilyloxy)-1-(2.3- dihydrobenzo[βiri,41dioxin-6-yl)-1-hvdroxypropan-2-ylcarbamate.
(R)-benzyl 3-(tert-butyldimethylsilyloxy)- 1 -(2,3- dihydrobenzo[β][1,4]dioxin-6-yl)-1-oxopropan-2-ylcarbamate (3.1g, 6.6 mmol) were dissolved in THF (25 ml) and cooled down to -70 °C under nitrogen atmosphere. L Selectride (13.2 ml of IM solution in THF, 13mmol) was added dropwise while keeping the temperature at -70 °C. After 1 hour, the reaction was quenched with a IM aqueous solution of potassium tartrate (13 ml) and extracted with EtOAc. The organic layer was evaporated down and the product was purified by column chromatography using 2.5%EtOAc-2%acetone-methylene chloride. The desired diastereomer was obtained in 80% yield (2.5 g ). 1H NMR (400 MHz, CDCl3) δ= 0 (d, 6H), 0.9 (s, 9H), 3.5 (broad s, 1H), 3.7-3.9 (m, 2H), 4.2 (s, 4H), 4.9 (broad s, 1H), 5.0 (d, 2H), 5.4 (d, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.2-7.4 (m, 5H). Preparation of EV: benzyl TlR. 2R)-1-(2,3-dihvdrobenzorβiπ,41dioxin-6-yl)-1.3- dihvdroxypropan-2-ylcarbamate.
Benzyl (lR,2R)-3-(tert-butyldimethylsilyloxy)-1-(2,3- dihydrobenzo[β][1,4]dioxin-6-yl)-1-hydroxypropan-2-ylcarbamate (0.5g) was dissolved in a 4 ml mixture of Acetic acid/THF/ water (3/1/1) and left to stir over night. The crude was evaporated down and the product azeotropically dried with EtOAc (10 ml). The crude product was purified by column chromatography using 50%EtOAc-hexane. The pure product was obtained in 74% yield (0.28 g). 1H NMR (400 MHz, CDCl3) δ= 3.4-3.8 (m, 4H), 4.1 (broad s, 4H), 4.8 (s, 1H), 4.9 (broad s, 2H), 5.7 (broad s, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.2-7.4 (m, 5H).
General procedure for preparation of EVI and EVII
Benzyl (IR, 2R)-1-(2,3-dihydrobenzo[β][1,4]dioxin-6-yl)-1,3- dihydroxypropan-2-ylcarbamate was dissolved in excess pyridine, cooled to -15 °C and one equivalent of methanosulfonyl chloride was added to the mixture. Mixture was stirred about half an hour, and ten equivalents of the amine were added. The reaction mixture was allowed to warm up to room temperature and then heated at 50 °C overnight. The crude was evaporated down and the product was purified by column chromatography using a mixture of methanol/methylene chloride/ammonium hydroxide. The pure compound EVI was then de-protected by hydrolysis in the microwave, using aqueous NaOH (40%in weight)/methanol solution as solvent and heating the mixture to 150 °C for about 15 minutes to give the free amines of the type EVI. The final product was purified by silica-gel column chromatography using a mixture of methanol/methylene chloride/ammonium hydroxide.
Examples of EVII compounds
n (IR. 2R)-2-amino-1-(23-dihvdrobenzorβiπ.41dioxin-6-vn-3- morpholinopropan- 1 -ol.
Figure imgf000091_0001
1H NMR (400 MHz, CDCl3) δ= 2.3 (dd, 2H), 2.4 (dd, 2H), 2.5-2.6 (m, 2H), 3.2 (m, 1H), 3.6-3.7 (m, 4H), 4.2 (s, 4H), 4.4 (d, 1H), 6.5-6.9 (m, 3H); MS for C15H22N2O4 m/z 294.8 [M+H].
iiUIR, 2R)-2-amino-1-(2.3-dihvdrobenzofβiπ.41dioxin-6-yl)-3-rpiperidin- 1-yl)propan-1-ol.
Figure imgf000091_0002
1H NMR (400 MHz, CDCl3) δ= 1.4 (broad s, 2H), 1.7 (m, 4H), 2.2-2.6 (m, 6H), 3.2 (m, 1H), 4.2 (s, 4H), 4.5 (s, 1H), 6.7-6.9 (m, 3H).
Example ID. Preparation of Substituted Phenoxy Propionic Acids
Example IDl : Preparation of 3-(4-methoxyphenoxy)propionic acid.
ϊ) 3 -(4-methoxyphenoxy')propionitrile
A 740 g (5.96 mol, 1 eq.) sample of 4-methoxyphenol was charged to a 3 necked 5 L flask under nitrogen. Triton B (50 mL of a 30% wt. solution in methanol) was charged to the flask, and stirring initiated via an overhead stirrer. Acrylonitrile (2365 mL, 35.76 mol, 6 eq.) was then charged to the reaction flask in a single portion, and the reaction mixture heated at 78 °C for 36 h. HPLC analysis indicated that the reaction was complete at this point. Solvents were removed via rotary evaporation, and the resulting oil was chased with toluene to remove excess acrylonitrile. The crude material was recrystallized from TBME (tert-butyl methyl ether) 10 volumes relative to the crude weight), and dried in a vacuum oven to give 945 g of 3-(4-methoxyphenoxy)propionitrile as white crystals (Yield: 89.48 %). 1H NMR (450 MHz, CDCl3): δ = 2.72 (t, 2 H; CH2CN); δ = 3.83 (s, 3 H; OCH3); δ = 4.05 (t, 2H; OCH2); δ = 6.70 (m, 4H; Ar-H); 13C NMR (1 12.5 MHz, CDCl3): d = 18.843 (CH2CN); 55.902 (OCH3); 63.699 (OCH2); 114.947 (CH3OCCH); 116.183 (CH2OCCH); 117.716 (CN); 151.983 (CH3OQ; 154.775 (CH2OQ.
ii) 3-(4-methoxyphenoxy)propionic acid. A 945 g (5.34 mol, 1 eq.) sample of 1 (3-(4-methoxyphenoxy)propionitrile was charged to a 22 L round bottom flask equipped with an overhead stirrer under N2. To the stirred solids, 4 L of concentrated HCl was slowly added, followed by 2 L of H2O. The reaction mixture was heated to 100 °C for 3.5 h, at which point the reaction was complete by HPLC analysis. The reaction was cooled to 10 °C by the addition of ice to the reaction mixture, and was filtered. The dried solids gave 920 g of crude 3-(4-methoxyphenoxy)propionic acid. The crude material was dissolved in 5 L of 6 wt. % sodium carbonate (such that pH = 9), and 2 L of DCM (dichloromethane) was added to the reaction vessel. After stirring thoroughly, the organic layer was separated and discarded via a separatory funnel, and the aqueous layer charged back into the 22 L flask. The pH of the aqueous layer was carefully adjusted to 4.0, by slow addition of 6 M HCl. The precipitated solids were filtered, and dried in a vacuum oven to give 900 g of 3-(4-methoxyphenoxy)propionic acid as a white solid (Yield: 86.04 %). 1H NMR (450 MHz, CDCl3); δ = 2.78 (t, 2H; CH2COOH); 3.70 (s, 3H; OCH3); 4.18 (t, 2H; OCH2); 6.78 (m, 4 H; Ar-H); 13C NMR (112.5 MHz, CDCl3): δ = 34.703 (CH2COOH); 55.925 (OCH3); 64.088
(OCH2); 114.855 (CH3OCCH); 115.984 (CH2OCCH); 152.723 (CH3OQ; 154.302 (CH2OQ; 177.386 (COOH).
Example 1D2: Preparation of S-H-D-oxobutyl)phenoxy^propanoic acid
Figure imgf000093_0001
Step 1 : a mixture of 4-(p-hydroxyphenol)-2-butanone (1.032 g), triton B (400 μL), acrylonitrile (4 mL) and MeOH (0.8 mL) was heated at 70 °C for 20 hours. The mixture was cooled to room temperature and the solvent was removed to dryness. 3-(4-(3-oxobutyl)phenoxy)propanenitrile was obtained as a white solid (0.572 g) after purification by column chromatography using ethyl acetate/hexane.
Step 2: 3-(4-(3-oxobutyl)phenoxy)propanenitrile (0.478g ) was suspended in HCl (37%, 5 mL) and placed in the microwave reactor (T= 110 °C, 5 min). The mixture was poured onto iced water (20 g), filtered, and the solid was washed with water (2 X 5 mL). After column chromatography purification using a mixture of methylene chloride/methanol, 3-(4-(3-oxobutyl)phenoxy)propanoic acid was obtained as a white solid (0.3 g). 1H NMR (CDCl3, 400 mHz, ppm); 2.2 (s, 3H), 2.7 (t, 2H), 2.85 (m, 4H), 4.25 (t, 2H), 6.8 (d, 2H), 7.1 (d, 2H).
Example 1D3: Preparation of 3-(4-(2-methoxyethyl)phenoxy)propanoic acid
Figure imgf000093_0002
Step 1 : a mixture of 4-(2-methoxy ethyl) phenol (1.547g, 10.3 mmol), propiolic acid tert-butyl ester (1.367g, 10.8 mmol) and N-methyl morpholine (1.18 mL, 10.8 mmol) in CH2Cl2 (15 mL) was stirred at room temperature for 24 hours. The mixture was absorbed on SiO2 (20 g) and purified by column chromatography using a mixture of methylene chloride/hexane. The product was obtained as a two to one mixture of (E)/ (Z)-tert-butyl 3-(4-(2-methoxyethyl)phenoxy)acrylate isomers (2-0 g).
Step2: (E)/(Z)-tert-butyl 3-(4-(2-methoxyethyl)phenoxy)acrylate (0.57 g) was suspended in a mixture of THF (5 mL)/HCl (2 M, 5 mL) and placed in the microwave reactor (T = 100 °C, 15 sec). THF was removed by rotary evaporation and the mixture was extracted with CH2Cl2 (1O mL). (E)/(Z)-3-(4-(2- methoxyethyl)phenoxy)acrylic acid was obtained as a white solid after purification by column chromatography using a mixture of hexane/ethyl acetate.
Step 3: (E)/(Z)-3-(4-(2-methoxyethyl)phenoxy)acrylic acid (0.3 g) was dissolved in EtOH (10 mL) and Pd/C (5 %, degussa type ElOl, 40 mg) was added. The mixture was hydrogenated at atmospheric pressure for 2 hours and then filtered and the solvent removed to dryness. After purification by column chromatography using a mixture of hexane/ethyl acetate, 3-(4-(2-methoxyethyl)phenoxy)propanoic acid was obtained as a white solid (0.236 g). 1H NMR (CDCl3, 400 mHz, ppm); 2.85 (t, 4H), 3.35 (s, 3H), 3.55 (t, 2H), 4.25 (t, 2H), 6.85 (d, 2H), 7.1 (d, 2H).
Example 1D4: Preparation of 3 -(4-(3-methylbutanoyl)phenoxV)propanoic acid
Step 1 : 3-phenoxypropionic acid (5.0 g, 30 mmol) was dissolved in MeOH (12 mL) and H2SO4 (18 M, 3 drops) was added. The mixture was place in the microwave reactor (T: 140 °C, t: 5 min). The solvent was evaporated, the mixture was partitioned in EtOAc (30 mL) and NaOH (2N, 20 mL). The organic phase was dried over MgSO4, filtered, and evaporated to give methyl 3-phenoxypropanoate (5.0 g, 27.7 mmol, 92.5%).
Step 2: aluminum chloride (1.1 g, 8.34 mmol) was added to a cold solution (0 0C) solution of methyl 3-phenoxypropanoate (1.0 g, 5.56 mmol) and tert- butylacetyl chloride (1.25 mL, 8.34 mmol) in CH2Cl2 (9 mL) and the reaction mixture was stirred overnight. The mixture was evaporated and the residue was diluted with EtOAc (30 mL) and then washed with water (2 X 20 mL). The organic phase was removed and purified with silica chromatography using of a gradient hexanes/EtOAc (100:0→ 0:100) to give methyl 3-phenoxypropanoate (600 mg, 2.27 mmol, 40%).
Step 3: a solution of methyl 3-phenoxypropanoate (200 mg, 0.76 mmol) in 2 mL of HCl (37%) was placed in a microwave reactor (T: 120 0C, t: 5 min). The mixture was poured into iced water (2g) and washed with EtOH (3 X10 mL). The organic phase was combined and evaporated. The crude product was purified with silica gel chromatography using of a gradient hexanes/EtOAc ( 100:0-» 0: 100) to give 3-(4-(3-methylbutanoyl)phenoxy)propanoic acid (120 mg, 0.48 mmol, 63%). Example 2. Preparation of Compounds of the Invention
The exemplary compounds shown in Example 2 and Tables 1-3 can be prepared by following scheme 1 described above, Detailed synthetic description of certain compounds also are described below as examples.
Example 2El . Preparation of Hemi-Hydrate of Compound 163 N-[2-Hydroxy-2-
(2,3-dihvdrobenzo[β1[1,41dioxin-6-yl)-1-pyrrolidin-1-ylmethyl-ethyll-3-(4- methoxy-phenoxy)-propionamide
Figure imgf000095_0001
(Scheme IA)
Compound 163 was prepared by following Scheme IA above. 3-(4- methoxyphenoxy)propanoic acid (see Example IDl, 34.47g, 169mmol, 96% purity by HPLC), DCC (34.78g, 169 mmol) and N-hydroxysuccinimide (19.33, 169mmol) were combined as dry powders and methylene chloride (50OmL) was added. The suspension was mechanically stirred overnight, ambient temperature, under a nitrogen atmosphere. HPLC analysis showed complete conversion of the acid to the NHS ester (N-hydroxy succinyl ester). To the mixture was added (IR, 2R)-2- amino- 1 -(2,3 -dihydro-benzo [ 1 ,4] dioxin-6-yl)-3 -pyrrolidin- 1 -yl-propan- 1 -ol (5Og, 169mmol) and stirring continued for 2.5 hours. HPLC showed conversion to the product and loss of both the NHS ester and step 5 amine. The reaction mixture was vacuum filtered on a Bϋchner funnel to remove DCC urea. The solid urea was washed with 50OmL of methylene chloride. The organic layers were combined, placed in a separatory funnel, and treated with 50OmL of 1.0M NaOH. The layers were separated, and the cloudy organic layer was recharged into a separatory funnel and treated with a 6% HCl solution (adjusted to pH=0.03-0.34, 10OmL of solution). Two clear layers formed. The resultant biphasic solution was poured into an Erlenmeyer flask and cautiously neutralized to a pH of 1.2-1 A with a saturated solution of sodium bicarbonate (approx 20OmL of solution). The organic layer was separated from the aqueous layer, dried over sodium sulfate and evaporated to yield 83.6g of yellow oil (theoretical yield: 77.03g). The oil was dissolved in isopropyl alcohol (50OmL) with heating and transferred to a IL round bottom flask equipped with a mechanical stirrer and heating mantel. The solution was heated to 50°C and the mechanical stirrer was set to a rate of 53-64 rpm. Tartaric acid (25.33g, 168mmol) was dissolved in deionized water (5OmL) and added to the stirred solution at 50°C. Once the solution turned from milky white to clear, seed crystals were added to the mixture and crystallization immediately began (temperature jumped to 56°C). After 20 minutes, the mixture was set to cool to a temperature of 35°C (cooling took 1.15 hours). Heating was removed and the solution was allowed to stir for 12 hours. The resulting thick slurry was filtered on a Bϋchner funnel. Any remaining solid in the flask was washed onto the funnel using ice-cold isopropyl alcohol (10OmL). The material was transferred to a drying tray and heated to 48°C under vacuum for 3 days (after two days the material weighed 76g and after three days it weighed 69.3g). The solid was analyzed by LC and shown to be 98.1% pure (AUC), the residual solvent analysis showed the material to possess 3472 ppm of isopropyl alcohol, and the DSC (differnetial scaaning calroimetery) showed a melting point of 134.89°C. A total of 69.3g of white solid was collected (65.7% overall yield). 1H NMR (400 MHz, CDCl3) δ= 1.8 (M, 4H), 2.4-2.6 (m, 4H), 2.6 (m, 1H), 2.85 (m, 2H), 3.0 (m, 1H), 3.65 (s, 3H), 3.8 (m, 2H), 3.86 (2, 2H), 4.18 (br s, 5H), 4.6 (s, 1H), 6.6-6.8(m, 7 H), 7.8 (d, 1H); MS for C29H40N2O13 m/z 457.3 [M+H] for main peak (free-base). Example 2E2. Preparation of Compound 247: N-((1R. 2R)- 1-hydroxy- 1 -(4- methoxyphenyl)-3-(pyrrolidin-1-yl)propan-2-yl)-3-(p-tolyloxy)propanamide.
Compound 247 was prepared by reaction of (IR, 2R)-2-amino-1-(4- methoxyphenyl)-3-(pyrrolidin-1-yl)propan-1-ol as the amine, prepared according to scheme 3 with 3-(4-methylphenoxy)propionic acid using method 1.
Preparation of A : (R)-benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate
Figure imgf000097_0001
N,O-dimethylhydroxylamine hydrochloride (45 g, 0.46 mmol, 1.5 eq) and N- methyl morpholine (84 mL, 0.765 mol, 2.5 eq.) were added slowly to a cold (-15 °C ) suspension of d-CBz serine (73.0 g, 0.305 mol) in CH2Cl2 (560 mL) keeping the temperature below —5 °C. The mixture was cooled back to ~ -15 °C and EDCI (62 g, 0.323 mol, 1.05 eq) was added. The mixture was stirred for 5 hours keeping the temperature below 5 °C. The solvent was removed by rotary evaporation and the mixture was partitioned between HCl (1 M, 300 mL)and EtOAc (500 mL).The organic layer was separated and washed with HCl (1 M, 2X 100 mL) and then sat. NaHCO3 (2 X 150 mL). The mixture was dried over MgSO4, filtered and then the solvent was removed by rotary evaporation. (R)-benzyl 3 -hydroxy- 1- (methoxy(methyl)amino)- 1 -oxopropan-2-ylcarbamate was re-dissolved in a mixture of acetone (375 mL) and 2,2-dimethoxy propane (375 mL) and boron trifluoride ethereate (3 mL) was added. The mixture was stirred at room temperature for 5 hours and then triethyl amine (3 mL) was added. The solvent was removed to dryness and (R)-benzyl 4-(methoxy(methyl)carbamoyl)-2,2-dimethyloxazolidine-3- carboxylate was obtained as a white solid (73.0 g, 74 % yield from both steps) after purification by column chromatography using a mixture of hexane/EtO Ac/acetone. 1H NMR (CDCl3, 400 mHz, ppm); 1.5 (s, 2 H), 1.6 (s, 3H), 1.7 (s, 2H), 1.75 (s, 3H), 3.14 (s, 3 H), 3.24 (2 H), 3.4 (3 H), 3.76 (s, 2 H), 4.0 (m, 1.7 H), 4.16 (m, 1 H), 4.2 (m, 1.7), 4.78 (m, 1 H), 4.88 (m, 0.6 H), 5.06 (q, 2 H), 5.18 (q, 1 H), 7.4 (m, 8 H).
Preparation of AI: (R)-benzyl 4-((R)-hydroxy(4-methoxyphenyl)methyl)-2,2- dimethyloxazolidine-3-carboxylate
Figure imgf000098_0001
A solution Of LiALH4 (1 M, 20 mL, 20 mmol) was added dropwise to a cold (-15 °C) solution of (R)-benzyl 4-(methoxy(methyl)carbamoyl)-2,2- dimethyloxazolidine-3-carboxylate (12.2 g, 37.9 mmol) in THF (75 mL). The mixture was stirred for 30 min keeping the temperature below 0 °C. A saturated solution Of KHSO4 (100 mL) was added slowly to the mixture and it was warmed to room temperature. The mixture was filtered and the solvent was removed to dryness. (R)-benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate was obtained as a clear oil (9.161 g, 92 % yield) after purification by column chromatography (SiO2, using a mixture of hexane/EtOAc). 1H NMR (CDCl3, 400 mHz, ppm); 1.7 (m, 6 H), 4.15 (m, 2H), 4.4 (m, 1H), 5.15, (s, 1H), 5.2 (m, 1H), 7.3 (m, 5H), 9.6 (m, 1H).
1 ,2-dibromoethane (0.2 mL) was added slowly to a hot (65 °C) solution of magnesium turnings (0.91 g, 37 mmol) in THF (14 mL), followed by the dropwise addition of a solution of 4-bromo anisole (4 mL, 32 mmol) in THF (14 mL). The mixture was refluxed for 2 hours and then cooled to room temperature. The grignard solution was added dropwise to a suspension of CuI (6.8 g, 36 mmol) in a mixture Of Me2S (20 mL)/THF (100 mL) at -78 °C. The mixture was warmed slowly to -45 °C and stirred for 30 min keeping the temperature between —45 to - 35 °C. The mixture was cooled back to -78 °C , and a solution of the Garner's aldehyde [(R)-benzyl 4-formyl-2,2-dimethyloxazolidine-3-carboxylate ](3.20 g, 12.6 mmol) in THF (15 mL) was added dropwise. The mixture was stirred at low temperature overnight (15 h, T max = 10 °C). The reaction mixture was quenched with NH4Cl (sat. 100 mL) and extracted with EtOAc (50 mL). The solvent was removed to dryness and the mixture was purified by column chromatography (SiO2, using a mixture of hexane/EtOAc/acetone)and the product was obtained as a colorless oil (1.697 g, 36 % yield).
Preparation of All: benzyl (IR, 2R)-1,3-dihvdroxy-1-(4-methoxyphenyl)propan-2- ylcarbamate
Figure imgf000099_0001
A mixture of benzyl 4-(hydroxy-(4-methoxyphenyl)methyl)-2,2- dimethyloxazolidine-3-carboxylate (1.679 g, 4.5 mmol) and amberlyst 15 (1.85 g) in MeOH (20 mL) was stirred at room temperature for 2 days. The mixture was centrifuged and the solid was washed with MeOH (2 X 40 mL). The solvent was removed to dryness and after purification by column chromatography (SiO2 using a mixture of CH2Cl2/Et0Ac) the product was obtained as a white solid (1.26 g, 84 % yield). Preparation of AIV: Synthesis of Compound 289: benzyl (IR, 2R)- 1-hydroxy- 1 -(4- methoxyphenyl)-3-(pyrrolidin- 1 -yl)propan-2-ylcarbamate
Figure imgf000100_0001
Mesityl chloride (0.28 mL, 3.6 mmol) was added slowly to a cold (-10 °C) solution of benzyl (IR, 2R)-1,3-dihydroxy-1-(4-methoxyphenyl)propan-2- ylcarbamate (1.07 g, 3.23 mmol) in pyridine (1.5 mL). The mixture was stirred for 30 min and then pyrrolidine (2.7 mL, 33 mmol) was added slowly to the mixture. The mixture was heated to 45 °C for 6 hours and then the solvent was removed to dryness. After purification by column chromatography (SiO2, using a mixture of CH2Cl2, MeOH, NH4OH), the product was obtained as a clear oil (0.816 g, 66 % yield).
Preparation of EVII: ( 1 R, 2R)-2-amino- 1 -(4-methoxyphenyl)-3 -(pyrrolidin- l-yl)propan-1-ol as the amine was prepared by the procedures described below:
Figure imgf000100_0002
A mixture of benzyl (IR, 2R)-I -hydroxy- l-(4-methoxyphenyl)-3- (pyrrolidin-1-yl)propan-2-ylcarbamate (0.10 g, 0.26 mmol) and Pd/C (5 %, 21 mg) in EtOH (1 mL)/HCl (1 M, 50 μL) was degassed and hydrogen gas was added. The mixture was hydrogenated at atmospheric pressure for two hours. The mixture was filtered over celite and the solvent was removed to dryness. The product was obtained as a colorless oil (63.5 mg, 85 % yield).
Figure imgf000101_0001
Preparation of Compound 247: N-((1R, 2R)-1-hydroxy- l-(4-methoxyphenyl)-3- (pyrrolidin- 1 -yl)propan-2-yl)-3-(p-tolyloxy)propanamide.
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.3 (s, 3H), 2.65 (br, 6H), 2.85 (m, 2H), 3.75 (s, 3H), 4.1 (m, 2H), 4.25 (m, 1H), 5.05 (sd, 1H), 6.5 (br, 1H), 6.8 (m, 4H), 7.1 (d, 2H), 7.2 (d, 2H). M/Z for C24H32N2O4 [M-H]- = 413.
Example 2E3. Preparation of Compound 251: N-((1R. 2R)-1-hydroxy- 1 -(4- methoxyphenyl)-3-(pyrrolidin- 1 -yl)propan-2-yl)-2-(4- (trifluoromethyl)phenyl)acetamide.
Figure imgf000101_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.55 (br, 4H), 2.85 (m, 2H), 3.5 (s, 2H), 3.8 (s, 3H), 4.2 (m, 1H), 5.05 (sd, 1H), 5.8 (d, 1H), 6.8 (d, 2H), 7.1 (d, 2H), 7.2 (d, 2H), 7.55 (d, 2H). M/Z for C23H27F3N2O3 [M-H]- = 437.
Example 2E4. Preaparation of Compound 5: N-CClR. 2R.)-1-f2.3- dihydrobenzofβ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-fpyrrolidin- 1 -yl)propan-2- yPbenzo rblthiophene-2-carboxamide
Figure imgf000102_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.7 (br, 4H), 3.0 (m, 2H),
4.25 (s, 4H), 4.45 (m, 1H), 5.05 (sd, 1H), 6.6 (br, 1H), 6.85 (s, 2H), 6.95 (s, 1H), 7.4 (m, 2H), 7.7 (s, 1H), 7.85 (m, 2H). M/Z for C24H26N2O4S [M-H]- - 439.
Example 2E5. Preparation of Compound 11: N-((1R. 2R)-1 -(2.3- dihydrobenzofβ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-2- (phenylthio^acetamide
Figure imgf000102_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.5 (br, 4H), 2.8 (br, 2H),
3.6 (q, 2H), 4.1.5 (m, 1H), 4.2 (s, 4H), 5.9 (sd, 1H), 6.7 (m, 2H), 6.8 (s, 1H), 7.2 (m, 7H). M/Z for C23H28N2O4S [M-H]- = 429. Example 2E6. Preparation of Compound 12: N-(QR, 2R)-1 -(2,3- dihydrobenzorβi [ 1 ,41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl-)propan-2- yl)biphenyl-4-carboxamide
Figure imgf000103_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.7 (br, 4H), 3.0 (m, 2H), 4.25 (s, 4H), 4.4 (br, 1H), 5.05 (sd, 1H), 6.6 (sd, 1H), 6.85 (m, 2H), 6.95 (s, 1H), 7.45 (m, 3H), 7.6 (m, 4H), 7.75 (m, 2H). M/Z for C28H30N2O4 [M-H]- = 459.
Example 2E7. Preparation of Compound 19: N-((1R. 2R)-1 -(2,3- dihydrobenzo |~βl [ 1 ,4-|dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)benzorblthiophene-5-carboxamide
Figure imgf000103_0002
1H NMR (d6-dmso, 400 mHz, ppm); 1.6 (br, 4H), 2.4 (br, 5H), 2.65 (m, 1H), 4.15 (s, 4H), 4.25 (m, 1H), 4.75 (sd, 1H), 5.6 (br, 1H), 6.7 (m, 3H), 7.5 (sd, 1H), 7.7 (sd, 1H), 7.8 (sd, 1H), 7.85 (sd, 1H), 8.0 (sd, 1H), 8.2 (s, 1H). M/Z for C24H26N2O4S [M-H]- = 439. Example 2E8. Preparation of Compound 23: 2-(biphenyl-4-yl)-N-(T IR. 2R.)-1-f2.3- dihydrobenzofβif 1.41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2- vQacetamide
Figure imgf000104_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.5 (br, 4H), 2.8 (d, 2H), 3.55 (s, 2H), 4.2 (m, 5H), 4.85 (sd, 1H), 5.95 (br, 1H), 6.6 (m, 1H), 6.75 (m, 2H), 7.2 (sd, 2H), 7.4 (m, 1H), 7.5 (st, 2H), 7.6 (m, 4H). M/Z for C29H32N2O4 [M-H]- 473.
Example 2E9. Preparation of Compound 24: N-f(lR. 2R)-1-(2.3- dihydrobenzo[βl [ 1 ,41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yPpropan-2-yl)-2-(4- phenoxyphenyl)acetamide
Figure imgf000104_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.6 (br, 4H), 2.8 (sd, 2H), 3.45 (s, 2H), 4.15 (m, 1H), 4.25 (s, 4H), 4.85 (sd, 1H), 5.9 (br, 1H), 6.6 (m, 1H), 6.7 (s, 1H), 6.8 (m, 1H), 7.15 (m, 7H), 7.4 (m, 2H). M/Z for C29H32N2O5 [M-H]- - 489. Example 2E10. Preparation of Compound 25: TSVN-((1R, 2R)-1-(2,3- dihydrobenzo [β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl>2- hydroxy-3 -phenylpropanamide
Figure imgf000105_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.65 (br, 7H), 3.1 (dd, 2H), 4.2 (m, 6H), 4.8 (sd, 1H), 6.6 (m, 1H), 6.8 (m, 3H), 7.3 (m, 5H). M/Z for C24H30N2O5 [M-H]- = 427.
Example 2El 1. Preparation of Compound 27: N-((1R, 2R)-1-(2,3- dihvdrobenzo[β][1,4]dioxin-6-yl)-i-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3- phenoxypropanamide
Figure imgf000105_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.7 (br, 6H), 2.9 (m, 2H), 4.2 (m, 7H), 4.95 (sd, 1H), 6.45 (m, 1H), 6.75 (s, 1H), 6.85 (m, 3H), 6.95 (t, 1H), 7.2 (m, 3H). M/Z for C24H30N2O5 [M-H]- = 427. Example 2E12. Preparation of Compound 31: N-(HR, 2R)-1-(2,3- dihydrobenzorβl f 1.4]dioxin-6-yl)- 1-hydroxy-S-Cpyrrolidin- 1 -yl)propan-2-yl)-2-oxo- 2-phenylacetamide
Figure imgf000106_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.8 (br, 4H), 3.0 (m, 2H), 4.2 (s, 4H), 4.3 (m, 1H), 5.05 (sd, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.35 (m, 1H), 7.45 (t, 2H), 7.6 (t, 1H) 8.2 (d, 2H). M/Z for C23H26N2O5 [M-H]- = 411.
Example 2E13. Preparation of Compound 32: N-((1R. 2R)-M2.3- dihydrobenzo[β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3- (phenylthio)propanamide
Figure imgf000106_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.4 (t, 2H), 2.7 (br, 4H), 2.8 (m, 2H), 3.1 (m, 2H), 4.2 (m, 5H), 4.9 (sd, 1H), 5.95 (br, 1H), 6.8 (m, 3H), 7.2 (m, 1H), 7.3 (m, 3H). M/Z for C24H30N2O4S [M-H]- = 443. Example 2E14. Preparation of Compound 35: N-((1R. 2R)-1-(2.3- dihydrobenzorβirL41dioxin-6-yl)-1-hvdroxy-3-('pyrrolidin-1-ylN)propan-2-yl)-2-o- tolylacetamide
Figure imgf000107_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.1 (s, 3H), 2.5 (br, 4H), 2.75 (m, 2H), 3.5 (s, 2H), 4.1 (m, 1H), 4.25 (s, 4H), 4.8 (sd, 1H), 5.75 (br, 1H), 6.5 (d, 1H), 6.65 (s, 1H), 6.75 (d, 1H), 7.1 (d, 1H), 7.2 (m, 3H). M/Z for C24H30N2O4 [M-H]- = 411.
Example 2E15. Preparation of Compound 36: N-((1R. 2R)-M2.3- dihydrobenzo FbI [ 1.4] dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2- yl)-2-m- tolylacetamide
Figure imgf000107_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.35 (s, 3H), 2.5 (br, 4H), 2.75 (m, 2H), 3.45 (s, 2H), 4.1 (m, 1H), 4.25 (s, 4H), 4.85 (sd, 1H), 5.8 (br, 1H), 6.55 (d, 1H), 6.75 (m, 2H), 6.9 (d, 2H), 7.1 (sd, 1H), 7.2 (m, 1H). M/Z for C24H30N2O4 [M-H]- = 411. Example 2E16. Preparation of Compound 39: 2-(benzylthioVN-(YlR. 2R)-1-(2,3- dihydrobenzo[βl [ 1 ,41dioxin-6-yl)- 1-hydroxy-S-Cpyrrolidin- 1 -yl)propan-2- vQacetamide
Figure imgf000108_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.7 (br, 4H), 2.9 (m, 2H), 3.0 (m, 2H), 3.3 (d, 1H), 3.55 (d, 1H), 4.2 (m, 5H), 5.05 (sd, 1H), 6.85 (s, 2H), 6.9 (s, 1H), 7.1 (sd, 2H), 7.3 (m, 3H). M/Z for C24H30N2O4S [M-H]- = 443.
Example 2E17. Preparation of Compound 47: N-((1R. 2R)-1-(2,3- dihydrobenzo[β1[1.41dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-2-(4- (pyridin-3 -yl)phenyl)acetamide
Figure imgf000108_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.6 (br, 4H), 2.8 (sd, 2H), 3.55 (s, 2H), 4.15 (m, 1H), 4.2 (s, 4H), 4.85 (sd, 1H), 5.85 (br, 1H), 6.6 (d, 1H), 6.75 (m, 2H), 7.25 (d, 3H), 7.4 (m, 1H), 7.6 (sd, 2H), 7.9 (sd, 1H), 8.6 (sd, 1H), 8.85 (s, 1H). M/Z for C28H31N3O4 [M-H]- = 474. Example 2El 8. Preparation of Compound 48: 2-(4'-chlorobiphenyl-4-yl)-N-((lR. 2R)- 1 -(2,3-dihydrobenzo[β] [ 1 ,4]dioxin-6-vQ- 1-hvdroxy-3-(pyrrolidin- 1 -yl)propan- 2-yl)acetamide
Figure imgf000109_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.55 (br, 4H), 2.8 (sd, 2H), 3.55 (s, 2H), 4.15 (m, 1H), 4.2 (s, 4H), 4.85 (sd, 1H), 5.8 (br, 1H), 6.6 (d, 1H), 6.75 (m, 2H), 7.2 (d, 2H), 7.4 (m, 2H), 7.55 (sd, 4H). M/Z for C29H31ClN2O4 [M-H]- = 508.
Example 2E19. Preparation of Compound 51: N-((1R. 2R)-1-(2,3- dihydrobenzo[β][1,4]dioxin-6-yl')-1-hydroxy-3-('pyrrolidin-1-yl)propan-2-yl)-2-(3-
(trifluoromethyl)phenyl)acetamide
Figure imgf000109_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.55 (br, 4H), 2.8 (sd, 2H), 3.55 (s, 2H), 4.15 (m, 1H), 4.25 (s, 4H), 4.85 (sd, 1H), 5.8 (br, 1H), 6.6 (d, 1H), 6.75 (m, 2H), 7.35 (d, 1H), 7.45 (m, 2H), 7.55 (sd, 1H). M/Z for C24H27F3N2O4 [M-H]- = 465. Example 2E20. Preparation of Compound 53: N-((1R. 2R)-1 -(2.3- dihydrobenzorβ] [1.4]dioxin-6-ylV 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-2-(3- fluorophenyl)acetamide
Figure imgf000110_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.55 (br, 4H), 2.8 (sd, 2H), 3.50 (s, 2H), 4.15 (m, 1H), 4.25 (s, 4H), 4.85 (sd, 1H), 5.8 (br, 1H), 6.6 (d, 1H), 6.75 (m, 1H), 6.8 (d, 1H), 6.85 (d, 1H), 6.9 (d, 1H), 7.0 (t, 1H), 7.3 (sq, 1H). M/Z for C23H27FN2O4 [M-H]- = 415.
Example 2E21. Preparation of Compound 54: N-((1R. 2R)-1-(2.3- dihvdrobenzo [β] [ 1 ,4]dioxin-6-yl V 1-hydroxy-3 -(pyrrolidin- 1 - vOpropan-2-yl)-3 -(3 - methoxyphenoxy^propanamide
Figure imgf000110_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.65 (br, 6H), 2.85 (m, 2H), 3.80 (s, 3H), 4.2 (m, 7H), 4.95 (sd, 1H), 6.45 (m, 4H), 6.75 (s, 2H), 6.85 (s, 1H), 7.2 (t, 1H). M/Z for C25H32N2O6 [M-H]- = 457. Example 2E22. Preparation of Compound 55: 3-(2,5-dichlorophenoxy)-N-((lR, 2R)-I -(2,3-dihydrobenzo[β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan- 2-yl)propanamide
Figure imgf000111_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.65 (br, 6H), 2.8 (m, 2H), 4.1 (m, 1H), 4.25 (m, 6H), 4.95 (sd, 1H), 6.3 (br, 1H), 6.75 (s, 2H), 6.8 (s, 1H), 6.9 (m, 2H), 7.25 (m, 1H). M/Z for C24H28Cl2N2O5 [M-H]- = 496.
Example 2E23. Preparation of Compound 57: 3-f4-chlorophenoxy)-N-((lR, 2R)-I- (2,3-dihvdrobenzo[β][1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2- yl)propanamide
Figure imgf000111_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.65 (br, 6H), 2.8 (m, 2H),
4.2 (m, 7H), 4.95 (sd, 1H), 6.3 (br, 1H), 6.8 (m, 5H), 7.2 (m, 2H). M/Z for C24H29ClN2O5 [M-H]- = 461. Example 2E24. Preparation of Compound 58: N-((1R, 2RM -(2,3- dihydrobenzo|-β1 [ 1 ,4]dioxin-6-yI)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3-(4- fluorophenoxy)propanamide
Figure imgf000112_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.65 (br, 6H), 2.8 (m, 2H), 4.2 (m, 7H), 4.95 (sd, 1H), 6.4 (br, 1H), 6.8 (m, 5H), 7.0 (m, 2H). M/Z for C24H29FN2O5 [M-H]- = 445.
Example 2E25. Preparation of Compound 59: N-(QR. 2R)-1-(2,3- dihvdrobenzo[β1[1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(p- tolyloxy)propanamide
Figure imgf000112_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.3 (s, 3H), 2.65 (br, 6H), 2.8 (m, 2H), 4.2 (m, 7H), 4.95 (sd, 1H), 6.45 (br, 1H), 6.75 (m, 4H), 6.85 (s, 1H), 7.1 (m, 2H). M/Z for C25H32N2O5 [M-H]- = 441. Example 2E26. Preparation of Compound 60: N-((1R. 2R)-1-(2,3- dihvdrobenzo[β][1,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(2- fluorophenoxy)propanamide
Figure imgf000113_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.65 (br, 6H), 2.75 (m, 2H), 4.2 (m, 7H), 4.95 (sd, 1H), 6.35 (br, 1H), 6.7 (s, 2H), 6.85 (s, 1H), 6.95 (m, 2H), 7.05 (m, 2H). M/Z for C24H29FN2O5 [M-H]- = 445.
Example 2E27. Preparation of Compound 61: N-((1R, 2R)-1-(2,3- dihvdrobenzo[β][1.41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(4- methoxyphenoxy)propanamide
Figure imgf000113_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.75 (br, 4H), 2.65 (br, 6H), 2.75 (m, 2H), 3.8 (s, 3H), 4.1 (m, 2H), 4.2 (br, 5H), 4.95 (sd, 1H), 6.45 (br, 1H), 6.8 (m, 7H). M/Z for C25H32N2O6 [M-H]- = 457. Example 2E28. Preparation of Compound 188: N-((1R. 2R)-1-(2,3- dihydrobenzo [bi |- 1 ,4]dioxin-6-yl)- 1-hvdroxy-3 -Cpyrrolidin- 1 -yl)propan-2-yl)-3 -(4- ethylphenoxy)propanamide (2R, 3R)-2,3-dihvdroxysuccinate
Figure imgf000114_0001
1H NMR (D2O, 400 mHz, ppm); 0.93 (t, 3H), 1.75 (br, 2H), 1.86 (br, 2H), 2.35 (q, 2H), 2.4 (br, 2H), 2.9 (br, 2H), 3.25 (m, 2H), 3.4 (br, 2H), 3.9 (br, 6H), 4.3 (br, 3H), 4.6 (br, 1H), 6.6 (m, 5H), 7.0 (d, 2H). M/Z for C26H34N2O5 C4H6O6 [M- H]- = 454.
Example 2E29. Preparation of Compound 189: N-((1R. 2R)- 1 -(2,3- dihydrobenzo [b] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -Cpyrrolidin- 1 -vQpropan-2-yl)-3 -(4- propionylphenoxy)propanamide C2R, 3R)-2,3-dihydroxysuccinate
Figure imgf000114_0002
1H NMR (D2O, 400 mHz, ppm); 0.93 (t, 3H), 1.75 (br, 2H), 1.86 (br, 2H),
2.45 (br, 2H), 2.8 (q, 2H), 2.9 (br, 2H), 3.25 (m, 2H), 3.4 (br, 2H), 3.9 (br, 6H), 4.3 (br, 3H), 4.6 (br, 1H), 6.5 (d, 1H), 6.5 (d, 2H), 6.7 (d, 2H), 7.7 (d, 2H). M/Z for C27H34N2O6 C4H6O6 [M-H]- = 483.
Example 2E30. Preparation of Compound 193: N-((1R, 2R)-1-(2.3- dihvdrobenzo[bl[1,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(4- (3-oxobuty0phenoxy)propanamide (2R, 3R)-2,3-dihydroxysuccinate
Figure imgf000115_0001
1H NMR (D2O, 400 mHz, ppm); 1.75 (br, 2H), 1.86 (br, 2H), 1.94 (s, 3H),
2.45 (br, 2H), 2.6 (m, 4H), 2.9 (br, 2H), 3.25 (m, 2H), 3.4 (br, 2H), 3.9 (br, 6H), 4.3 (br, 3H), 4.6 (br, 1H), 6.6 (m, 5H), 7.0 (d, 2H). M/Z for C28H36N2O6 C4H6O6 [M- H]- = 497.
Example 2E31. Preparation of Compound 202: N-((1R. R)-1-(2.3- dihydrobenzofβ] [ 1,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl)-3 -(4- (2-methoxyethyl)phenoxy)propanamide (2R, R)-2,3-dihvdroxysuccinate
Figure imgf000115_0002
1H NMR (D2O, 400 mHz, ppm); 1.75 (br, 2H), 1.86 (br, 2H), 2.45 (br, 2H), 2.62 (t, 2H), 2.9 (br, 2H), 3.1 (s, 3H), 3.25 (m, 2H), 3.4 (br, 4H), 3.9 (br, 6H), 4.3 (br, 3H), 4.6 (br, 1H), 6.6 (m, 5H), 7.0 (d, 2H). M/Z for C27H36N2O6 C4H6O6 [M-H]- = 485.
Example 2E32. Preparation of Compound 63: N-fdR. 2R.)-1-f2.3- dihydrobenzo [β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)-2-(3 '- methoxybiphenyl-4-yl)acetamide
Figure imgf000116_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.7 (br, 4H), 2.5 (br, 4H), 2.75 (m, 2H), 3.5 (br, 2H), 3.9 (sd, 3H), 4.2 (m, 5H), 4.95 (sd, 1H), 5.9 (br, 1H), 6.5-7.6 (m, HH). M/Z for C30H34N2O5 [M-H]- = 503.
Example 2E33. Preparation of Compound 127: N-((1R. 2R)-1-(2.3- dihydrobenzo [b] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl)-4-(4- ethoxyphenyl)-4-oxobutanamide
Figure imgf000116_0002
1H NMR (CDCl3, 400 mHz, ppm); 1.4 (t, 3H), 1.8 (br, 4H), 2.7 (br, 6H), 3.2 (m, 2H), 4.05 (q, 2H), 4.2 (m, 2H), 4.25 (m, 5H), 4.95 (sd, 1H), 6.05 (br, 1H), 6.9 (m, 5H), 7.95 (d, 2H). M/Z for C27H34N2O6 [M-H]- = 483.
Example 2E34. Preparation of Compound 154: N-((1R. 2R)-1-(2.3- dihydrobenzorb] [ 1 ,41dioxin-6-yl)- 1-hvdroxy-3-(pyrrolidin- 1 -yl)propan-2-yl')-4-(4- methoxyphenyl)-4-oxobutanamide
Figure imgf000117_0001
1H NMR (CDCl3, 400 mHz, ppm); 1.8 (br, 4H), 2.7 (br, 6H), 3.2 (m, 1H),
3.45 (s, 3H), 3.9 (s, 3 H), 4.2 (m, 5H), 4.95 (sd, 1H), 6.05 (br, 1H), 6.9 (m, 5H), 7.95 (d, 2H). M/Z for C26H32N2O6 [M-H]* = 469.
Example 2E35. Preparation of Compound 181: N-((1R. 2R>l-f2.3- dihydrobenzo FbI [ 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl)-6-(4- isopropoxyphenyl)-6-oxohexanamide
Figure imgf000117_0002
1H NMR (CDCl3, 400 rnHz, ppm); 1.4 (d, 6H), 1.8 (br, 8H), 2.15 (br, 2H), 2.8 (br, 10H), 4.25 (m, 5H), 4.65 (m, 1H), 4.95 (sd, 1H), 6.05 (br, 1H), 6.9 (m, 5H), 7.95 (d, 2H). M/Z for C30H40N2O6 [M-H]' = 525.
Example 2E36. Preparation of Compound 191: N-((1R. 2R)-1-(2.3- dihvdrobenzo[β][1,41dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1-yl)propan-2-yl)-5-(4- methoxyphenyl)-5-oxopentanamide (2R,3R*)-2,3-dihydroxysuccinate
Figure imgf000118_0001
1H NMR (D2O, 400 mHz, ppm); 1.40 (br, 1H), 1.53 (br, 1H), 1.75 (br, 2H), 1.91 (br, 2H), 1.98 (m, 1H), 2.15 (m, 1H) 2.45 (m, 2H), 2.95 (m, 2H), 3.35 (dd, 2H), 3.4 (m, 2H), 3.68 (br, 5H), 3.77 (br, 2H), 4.3 (br, 3H), 4.68 (br, 1H), 6.47 (d, 1H), 6.65 (d, 2H), 6.85 (d, 2H), 7.63 (d, 2H). M/Z for C27H34N2O6 C4H6O6 [M-H] = 483.
Example 2E37. Preparation of Compound 265: N-((1R. 2R)-I- (benzo|-δ][1,3]dioxol-5-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-5-(4- isopropoxyphenyl)-5-oxopentanamide (2S. 3S)-2.3-dihydroxysuccinate
Figure imgf000119_0001
1H NMR (400MHz, CD3OD) δ 1.30 (sd, 6H), 1.70-1.85 (m, 2H), 2.04 (br, 4H), 2.09-2.26 (m, 2H), 2.64-2.82 (m, 2H), 3.31-3.48 (m, 5H), 4.37 (s, 2H), 4.43 (br, 1H), 4.68 (m, 1H), 4.71 (sd, 1H), 5.76 (s, 2H), 6.66 (d, 1H), 6.82-6.95 (m, 4H), 7.84 (d, 2H); MS for C28H36N2O6 C4H 6O6: [M-H]- 645.
Example 2E38. Preparation of Compound 267: N-((1R. 2R)-I- (benzo [δ] [ 1 ,3 ] dioxol-5-yl )- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)-6-(4- methoxyphenyl)-6-oxohexanamide (2S. 3S)-2,3-dihydroxysuccinate
Figure imgf000119_0002
1H NMR (400MHz, CD3OD) δ 1.49 (br, 4H), 2.03 (br, 4H), 2.89 (t, 2H), 3.33-3.46 (m, 6H), 3.84 (s, 3H), 4.37 (s, 2H), 4.43 (d, 1H), 4.76 (br, 1H), 5.81 (s, 2H), 6.68 (d, 1H), 6.81 (d, 1H), 6.88 (s, 1H), 6.96 (d, 2H), 7.92 (d, 2H); MS for C27H34N2O6-C4H 6O6: [M-H]- 633.
Example 2E39. Preparation of Compound 268: N-((1R. 2R)-1- (benzo[δ] [ 1 ,3]dioxol-5-yl)- 1-hvdroxy-3-(pyrrolidin- 1 -yl*)propan-2-vQ-7-(4- isopropoxyphenvO-7-oxoheptanamide (2S, 3S)-2,3-dihydroxysuccinate
Figure imgf000120_0001
1H NMR (400MHz, CD3OD) δ 1.15-1.18 (m, 2H), 1.30 (d, 6H), 1.40-1.45 (m, 2H), 1.57-1.65 (m, 2H), 2.03 (br, 4H), 2.12-2.17 (m, 2H), 2.88 (t, 2H), 3.33-3.48 (m, 5H), 4.38 (s, 2H), 4.42 (d, 1H), 4.67 (m, 1H), 4.78 (d, 1H), 5.83 (d, 2H), 6.71 (d, 1H), 6.82 (d, 1H), 6.89 (s, 1H), 6.92 (d, 2H), 7.90 (d, 2H); MS for C30H40N2O6-C4H 6O6: [M-H]- 675.
Example 2E40. Preparation of Compound 197: N-f(lR. 2R)-1-(2.3- dihvdrobenzo[β1[1,41dioxin-6-yl)-1-hydroxy-3-('pyrrolidin-1-yl)propan-2-yl)-4-(4- methoxyphenoxy)butanamide (2S, 3S)-2,3-dihydroxysuccinate
Figure imgf000120_0002
1H NMR (400MHz, CD3OD) δ 1.78-1.91 (m, 2H), 2.00 (br, 4H), 2.32 (t,
2H), 3.33-3.47 (m, 6H), 3.69 (s, 3H), 3.72 (t, 2H), 4.11 (br, 4H), 4.37 (s, 2H), 4.41 (d, 1H), 4.72 (d, 1H), 6.69-6.86 (m, 7H); MS for C26H34N2O6 C4H 6O6: [M-H]- 621.
Example 2E41. Preparation of Compound 187: N-((1R. 2R)-1-(2,3- dihydrobenzo [β] [ 1.4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)-3 -(4- (3-methylbutanoyl)phenoxy)propanamide (2S, 3 S)-2.3-dihydroxysuccinate
Figure imgf000121_0001
1H NMR (400MHz, CD3OD) δ 0.95 (d, 6H), 2.00 (br, 4H), 2.17 (m, 2H), 2.66 (t, 2H), 2.78 (d, 2H), 3.34-3.44 (m, 5H), 4.12-4.17 (m, 6H), 4.40 (s, 2H), 4.45 (d, 1H), 4.73 (sd, 1H), 6.67 (d, 1H), 6.79 (d, 1H), 6.86 (s, 1H), 6.93 (d, 2H), 7.91 (d, 2H); MS for C29H38N2O6- C4H 6O6: [M-H]- 661.
Example 2E42. Preparation of Compound 83: 2-(4-chlorophenoxy)-N-((lR,2R)-1- (2,3-dihydrobenzo|'βl|'1,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2- yl)acetamide
Figure imgf000121_0002
1H NMR (400MHz, CDCl3) δ 1.76 (br, 4H), 2.63 (br, 4H), 2.78 (dd, 1H), 2.89 (dd, 1H), 4.24 (s, 4H), 4.27 (br, 1H), 4.36 (q, 2H), 4.94 (d, 1H), 6.71 (d, 1H), 6.77-6.82 (m, 4H), 6.86 (d, 1H), 7.24 (s, 1H); MS for C23H27ClN2O5: [M-H]- 447.
Example 2E43. Preparation of Compound 87: 2-(3,4-dichlorophenoxy)-N-((lR,2R)- l-(2,3-dihvdrobenzo[β][1,4]dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl')propan-2- yl)acetamide
Figure imgf000122_0001
1H NMR (400MHz, CDCl3) δ 1.78 (br, 4H), 2.67 (br, 4H), 2.79 (dd, 1H), 2.92 (dd, 1H), 4.25 (br, s, 5H), 4.35 (q, 2H), 4.95 (d, 1H), 6.71-6.84 (m, 5H), 7.01 (d, 1H), 7.34 (d, 1H); MS for C23H26Cl2N2O5: [M-H]- 482.
Example 2E44. Preparation of Compound 86: N-(Q R,2R)-1 -(2.3- dihydrobenzo Fb] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- y D-2-(3 - phenoxyphenyPacetamide
Figure imgf000122_0002
1H NMR (400MHz, CDCl3) δ 1.72 (br, 4H), 2.57 (br, 4H), 2.75-2.80 (m, 2H), 3.45 (s, 2H), 4.11-4.13 (m, 1H), 4.23 (s, 4H), 4.84 (d, 1H), 5.86 (d, 1H), 6.55 (dd, 1H), 6.71 (d, 1H), 6.74 (d, 1H), 6.80 (br, 1H), 6.85 (dd, 1H), 6.92 (dd, 1H), 6.98 (d, 1H), 7.14 (t, 1H), 7.28-7.36 (m, 2H); MS for C29H32N2O5: [M-H]- 489.
Example 2E45. Preparation of Compound 280: 2-(3,4-difluorophenvn-N-((lR.2R)- 1 -(2,3-dihydrobenzo[β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)acetamide
Figure imgf000123_0001
1H NMR (400MHz, CDCl3) δ 1.80 (br, 4H, 2.68 (br, 4H), 2.84 (d, 2H), 3.45 (s, 2H), 4.17 (m, 1H), 4.25 (s, 4H), 4.88 (d, 1H), 5.88 (d, 1H), 6.65 (d, 1H), 6.79 (d, 1H), 6.95 (m, 1H), 6.95 (t, 1H), 7.13 (q, 1H); MS for C23H26F2N2O4: [M-H]- 434.
Example 2E46. Preparation of Compound 103: N-fflR.2RH-f2.3- dihydrobenzo [β] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -f pyrrolidin- 1 -yl)propan-2-yl)-2-(4- (trifluoromethoxy)phenyl)acetamide
Figure imgf000123_0002
1H NMR (400MHz, CDCl3) δ 1.65 ( br, 4H), 2.48 (br, 4H), 2.69 (d, 2H), 3.40 (s, 2H), 4.08 (m, 1H), 4.17 (s, 4H), 4.80 (s, 1H), 5.84 (t, 1H), 6.55 (d, 1H), 6.66 (s, 1 H), 6.70 (d, 1 H), 7.10 (t, 3H); MS for C24H27F3N2O5 : [M-H]* 481.
Example 2E47. Preparation of Compound 90: N-(C !R.2R)-1-f2.3- dihydrobenzo [β] [ 1 ,4] dioxin-6-yl)- 1-hydroxy-3 -f pyrrolidin- 1 - yl)propan-2-yl)-5 - fthiophen-2-yl)isoxazole-3-carboxamide
Figure imgf000124_0001
1H NMR (400MHz, CDCl3) δ 1.82 (br, 4H), 2.73-2.81 (m, 4H), 2.89-2.93 (m, 1H), 3.02-3.07 (m, 1H), 4.23 (s, 4H), 4.41 (br, 1H), 5.07 (s, 1H), 5.30 (d, 1H), 6.74 (s, 1H), 6.83 (t, 2H), 6.90 (s, 1H), 7.12-7.14 (m, 2H), 7.47 (d, 1H), 7.52 (d, 1H); MS for C23H25N3O5S: [M-H]- 456.
Example 2E48. Preparation of Compound 92: 3-(3-chloro-4-methoxyphenyl)-N- (T 1 R.2R)- 1 -(2.3-dihvdrobenzo[β][ 1 ,41dioxin-6-vn- 1-hydroxy-3-(pyrrolidin- 1 - yl)propan-2-yl)propanamide
Figure imgf000124_0002
1H NMR (400MHz, CDCl3) δ 1.77 (br, 4H), 2.38 (t, 2 H), 2.60 (br, 4H), 2.8 (m, 4H), 3.86 (s, 3H), 4.20 (br, 1H), 4.24 (s, 4H), 4.87 (s, 1H), 5.80 (d, 1H), 6.66 (d, 1H), 6.8 (m, 3H), 7.00 (d, 1H), 7.18 (s, 1H); MS for C25H31ClN2O5: [M-H]- 475.
Example 2E49. Preparation of Compound 96: N-(T 1R.2R)-1 -f 2.3- dihydrobenzo[β] [1 ,4]dioxin-6-y0- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3-(4- (trifluoromethyl)phenyl)propanamide
Figure imgf000125_0001
1H NMR (400MHz, CDCl3) δ 1.73 (br, 4H), 2.4 (m, 2H), 2.53 (m, 4H), 2.7 (m, 2H), 2.90-2.97 (m, 2H), 4.17 (br, 1H), 4.23 (s, 4H), 4.89 (s, 1H), 5.83 (br, 1H), 6.68 (d, 1H), 6.79 (d, 2H), 7.24 (d, 2H), 7.50 (d, 2H); MS for C25H29F3N2O5: [M-H]- 479.
Example 2E50. Preparation of Compound 101: 4-(benzo[d]thiazol-2-yl)-N- (T 1 R.2R)- 1 -(2.3 -dihvdrobenzorβl \ 1.41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)butanamide
Figure imgf000125_0002
1H NMR (400MHz, CDCl3) δ 1.77 (br, 4H), 2.10-2.15 (m, 2H), 2.24-2.27
(m, 2H), 2.64-2.67 (m, 4H), 2.79-2.83 (m, 2H), 3.02 (t, 2H), 4.18 (s, 4H), 4.26 (br, 1H), 4.92 (d, 1H), 6.12 (br, 1H), 6.75-6.81 (m, 2H), 6.86 (s, 1H), 7.37 (t, 1H), 7.45 (t, 1H), 7.85 (d, 1H), 7.92 (d, 1H); MS for C26H3iN3O4S: [M-H]- 482.
Example 2E51. Preparation of Compound 102: N-((lR,2R)-1-(2,3- dihvdrobenzo[β][1.41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-6-(2,3- dihvdrobenzorβiri.41dioxine-6-sulfonarnido)hexanamide
Figure imgf000126_0001
1H NMR (400MHz, CDCl3) δ 1.15-1.20 (m, 2H), 1.38-1.50 (m, 4H), 1.77 (br, 4H), 2.08 (q, 2H), 2.63-2.66 (m, 4H), 2.79 (d, 2H), 2.87 (t, 2H), 4.2 (m, 9H), 4.91 (br, 1H), 5.93 (br, 1H), 6.77 (q, 2H), 6.84 (s, 1H), 6.93 (d, 1H), 7.31 (d, 1H), 7.37 (s, 1H); MS for C29H39N3O8S: [M-H]- 590.
Example 2E52. Preparation of Compound 104: N-(5-((lR.2R)-1-(2.3- dihydrobenzo [βl [ 1 ,41 dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-ylamino)- 5 -oxopentyl)benzamide
Figure imgf000126_0002
1H NMR (400MHz, CDCl3) δ 1.47-1.52 (m, 2H), 1.59-1.69 (m, 2H), 1.77 (br, 4H), 2.15-2.21 (m, 2H), 2.62-2.65 (m, 4H), 2.81 (br, 2H), 3.30-3.42 (m, 2H), 4.19-4.23 (m, 5H), 4.94 (br, 1H), 5.98 (br, 1H), 6.76 (br, 1H), 6.78-6.86 (m, 3H), 7.40-7.50 (m, 3H), 7.80 (d, 2H); MS for C27H35N3O5: [M-H]- 482. Example 2E53. Preparation of Compound 281: Nl-((lR,2R)-1-(2,3- dihvdrobenzorβiri,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-N5- (thiazol-2-yl)glutar amide
Figure imgf000127_0001
1H NMR (400MHz, CDCl3) δ 1.74 (br, 4H), 1.97-2.03 (m, 2H), 2.20-2.26 (m, 2H), 2.40-2.45 (m, 2H), 2.64-2.68 (m, 5H), 2.88 (m 1H), 4.20 (s, 4H), 4.26-4.29 (m, 1H), 4.83 (d, 1H), 6.12 (br, 1H), 6.74-6.79 (m, 2H), 6.85 (s, 1H), 6.95 (d, 1H), 7.41 (d, 1H); MS for C23H30N4O5S: [M-H]- 475.
Example 2E54. Preparation of Compound 282: N-((lR.2R)-1-(2.3- dihydrobenzo [βl F 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2- yl)-5 -(3 A- dimethoxyphenyπ-5-oxopentanamide
Figure imgf000127_0002
1H NMR (400MHz, CDCl3) δ 1.76 (br, 4H), 1.92-2.00 (m, 2H), 2.21-2.26 (m, 2H), 2.60-2.65 (m, 4H), 2.70-2.95 (m, 4H), 3.93 (d, 6H), 4.17-4.23 (m, 5H), 4.90 (d, 1H), 5.96 (br, 1H), 6.75-6.79 (m, 2H), 6.85 (s, 1H), 6.87 (d, 1H), 7.50 (s, 1H), 7.55 (d, 1H); MS for C28H36N2O7: [M-H]- 513. Example 2E55. Preparation of Compound 283: N-f(lR.2R)-1-(Z3- dihydrobenzorbl F 1 ,41dioxin-6-vQ- 1-hydroxy-3-(pyrrolidin- 1 -vQpropan-Σ-vO-S-oxo- 5 -p-tol ylpentanamide
Figure imgf000128_0001
1H NMR (400MHz, CDCl3) δ 1.77 (br, 4H), 1.96-2.02 (m, 2H), 2.21-2.26 (m, 2H), 2.40 (s, 3H), 2.63-2.80 (m, 4H), 2.82-2.95 (m, 4H), 4.18-4.23 (m, 5H), 4.91 (d, 1H), 5.94 (br, 1H), 6.74-6.77 (m, 2H), 6.85 (s, 1H), 7.26 (d, 2H), 7.81 (d, 2H); MS for C27H34N2O5: [M-H]- 467.
Example 2E56. Preparation of Compound 113: N-((lR.2R)-1-(2.3- dihvdrobenzofβ][1,4]dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yπpropan-2-yl')-5-oxo- 5 -phenylpentanamide
Figure imgf000128_0002
1H NMR (400MHz, CDCl3) δ 1.76 (br, 4H), 1.95-2.01 (m, 2H), 2.22-2.25 (m, 2H), 2.62-2.63 (m, 4H), 2.78-2.95 (m, 4H), 4.17-4.22 (m, 5H), 4.91 (sd, 1H), 5.99 (br, 1H), 6.77 (st, 2H), 6.85 (s, 1H), 7.44-7.58 (m, 3H), 7.92 (d, 2H); MS for C26H32N2O5: [M-H]- 453. Example 2E57. Preparation of Compound 284: N-((1R.2R)-1-r2,3- dihydrobenzo[β][1,4]dioxin-6-Vl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-5-(4- i sopropoxyphenyl)-5 -oxopentanamide
Figure imgf000129_0001
1H NMR (400MHz, CDCl3) δ 1.36 (d, 6H), 1.75 (br, 4H), 1.90-2.02 (m, 2H), 2.20-2.25 (m, 2H), 2.60-2.66 (m, 4H), 2.70-2.86 (m, 4H), 4.17 (s, 4H), 4.22 (br, 1H), 4.62-4.65 (m, 1H), 4.89 (sd, 1H), 6.07 (d, 1H), 6.77 (s, 2H), 6.85 (s, 1H), 6.87 (d, 2H), 7.86 (d, 2H); MS for C29H38N2O6: [M-H]- 511.
Example 2E58. Preparation of Compound 140: N-((1R.2R)-1 -(2.3- dihydrobenzofβ] [1 ,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin-1 -yl)propan-2-yl')-6-(4- methoxy-3 ,5 -dimethylphenyl)-6-oxohexanamide
Figure imgf000129_0002
1H NMR (400MHz, CDCl3) δ 1.61-1.63 (m, 4H), 1.77 (br, 4H), 2.16 (t, 2H), 2.32 (s, 6H), 2.61-2.67 (m, 4H), 2.74-2.89 (m, 2H), 2.91 (t, 2H), 3.75 (s, 3H), 4.21 (br, 5H), 4.90 (sd, 1H), 5.93 (br, 1H), 6.75-6.82 (m, 2H), 6.85 (sd, 1H), 7.61 (s, 2H); MS for C30H40N2O6: [M-H]- 525. Example 2E59. Preparation of Compound 141: N-((1 R.2R)-1 -(2,3 - dihydrobenzo[β][1.41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-6-(4- methoxyphenyl)-6-oxohexanamide
Figure imgf000130_0001
1H NMR (400MHz, CDCl3) δ 1.62-1.64 (m, 4H), 1.76 (br, 4H), 2.17 (t, 2H), 2.61-2.65 (m, 4H), 2.72- 2.79 (m, 2H), 2.89 (t, 2H), 3.86 (s, 3H), 4.20 (br, 5H), 4.89 (d, 1H), 6.01 (br, 1H), 6.77 (q, 2H), 6.85 (s,1H), 6.91 (d, 2H), 7.90 (d, 2H); MS for C28H36N2O6: [M-H]- 497.
Example 2E60. Preparation of Compound 155: 6-(4-tert-butylphenyl)-N-(πR,2R)- l-(2,3-dihvdrobenzo[βiri,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-
6-oxohexanamide
Figure imgf000130_0002
1H NMR (400MHz, CDCl3) δ 1.34 (s, 9H), 1.63-1.65 (m, 4H), 1.77 (br, 4H), 2.17 (t, 2H), 2.64-2.66 (br, 4H), 2.75 (dd, 1H), 2.2.81 (dd, 1H), 2.91 (t, 2H), 4.20 (br, 5H), 4.90 (d, 1H), 6.02 (br, 1H), 6.77-6.82 (q, 2H), 6.85 (d, 1H), 7.46 (d, 2H), 7.86 (d, 2H); MS for C31H42N2O5: [M-H]- 523.
Example 2E61. Preparation of Compound 156: N-((lR,2R)-1-(2.3- dihydrobenzof β] [1 ,4]dioxin-6-yl)-1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-7-(4- methoxvphenyl)-7-oxoheptanamide
Figure imgf000131_0001
1H NMR (400MHz, CDCl3) δ 1.25-1.30 (m, 2H), 1.55-1.70 (m, 4H), 1.77 (br, 4H), 2.13 (t, 2H), 2.61-2.66 (m, 4H), 2.74- 2.82 (m, 2H), 2.88 (t, 2H), 3.86 (s, 3H), 4.20 (br, 5H), 4.90 (d, 1H), 5.93 (br, 1H), 6.78 (q, 2H), 6.85 (s, 1H), 6.91 (d, 2H), 7.92 (d, 2H); MS for C29H38N2O6: [M-H]- 511.
Example 2E62. Preparation of Compound 144: N-(Yl R.2R)-1 -(2.3- dihydrobenzoφ] [ 1 ,4]dioxin-6-yl)- 1-hydroxyl)-Cpyrrolidin- 1 -yl)propan-2-yl)-8-(4- methoxyphenyl)-8-oxooctanamide
Figure imgf000131_0002
1H NMR (400MHz, CDCl3) δ 1.25-1.33 (m, 4H), 1.54 (m, 2H), 1.68 (t, 2H), 1.78 (br, 4H), 2.11 (br, 2H), 2.65 (br, 4H), 2.76-2.1 1 (m, 4H), 3.86 (s, 3H), 4.21 (br, 5H), 4.90 (br, 1H), 6.02 (d, 1H), 6.78-6.84 (m, 3H), 6.91 (d, 2H), 7.92 (d, 2H); MS for C30H40N2O6: [M-H]- 525.
Example 2E63. Preparation of Compound 159: 7-(4-chlorophenvn-N-((lR.2R)-1- (2,3-dihydrobenzo[β] [ 1 ,4]dioxin-6-vQ- 1-hydroxy-3-(pyπOlidin- 1 -yl)propan-2-yl)-7- oxoheptanamide
Figure imgf000132_0001
1H NMR (400MHz, CDCl3) δ 1.26-1.37 (m, 2H), 1.57 (m, 2H), 1.68 (m, 2H), 1.77 (br, 4H), 2.13 (t, 2H), 2.62-2.65 (m, 4H), 2.76-2.82 (m, 2H), 2.90 (t, 2H), 4.20 (br, 5H), 4.90 (d, 1H), 5.93 (d, 1H), 6.78 (q, 2H), 6.85 (s, 1H), 7.42 (d, 2H), 7.87 (d, 2H); MS for C28H35 ClN2O5: [M-H]- 515.
Example 2E64. Preparation of Compound 160: 7-(4-tert-butyrphenyl)-N-((lR,2R)- 1 -(2,3 -dihydrobenzo [β] [ 1 ,41 dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)- 7-oxoheptanamide
Figure imgf000132_0002
1H NMR (400MHz, CDCl3) δ 1.27-1.34 (m, HH), 1.56-1.71 (m, 4H), 1.77 (br, 4H), 2.13 (t, 2H), 2.63-2.66 (m, 4H), 2.76-2.819 (m, 2H), 2.91 (t, 2H), 4.20 (br, 5H), 4.90 (sd, 1H), 5.90 (d, 1H), 6.81 (q, 2H), 6.85 (s, 1H), 7.46 (d, 2H), 7.88 (d, 2H); MS for C32H44N2O5: [M-H]' 537.
Example 2E65. Preparation of Compound 168: N-((lR.2R)-1-(2.3- dihydrobenzo [b] [ 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 - yl)propan-2-yl V7-(4- methoxyphenyl)-7-oxoheptanamide (2S,3SV2,3-dihvdroxysuccinate
Figure imgf000133_0001
1H NMR (400MHz, CD3OD) δ 1.15-1.19 (m, 2H), 1.40-1.47 (m, 2H), 1.60 (m, 2H), 2.02 (br, 4H), 2.09-2.21 (m, 2H), 2.90 (t, 2H), 3.35-3.49 (m, 5H), 3.83 (s, 3H), 4.12 (br, 4H), 4.38 (s, 2H), 4.43 (m, 1H), 4.74 (sd, 1H), 6.71 (d, 1H), 6.79 (dq, 1H), 6.86 (sd, 1H), 6.96 (d, 2H), 7.92 (d, 2H); MS for C29H38N2O6- C4H 6O6: [M-H]- 661 .
Example 2E66. Preparation of Compound 162: N-((lR.2R)-1-f2.3- dihydrobenzorβl \ 1 ,4]dioxin-6-yl)- 1-hydroxy-S-Cpyrrolidin- 1 -yl)propan-2-yl)-4-(4- isopropoxyphenyl)-4-oxobutanamide
Figure imgf000133_0002
1H NMR (400MHz, CDCl3) δ 1.35 (d, 6H), 1.77 (br, 4H), 2.52-2.56 (m, 2H),
2.64-2.83 (m, 6H), 3.09-3.36 (m, 2H), 4.22( br, 5H), 4.63-4.66 (m, 1H), 4.89 (sd, 1H), 6.13 (d, 1H), 6.78 (s, 2H), 6.88 (t, 3H), 7.90 (d, 2H); MS for C28H36N2O6: [M- H]- 497.
Example 2E67. Preparation of Compound 176: N-((lR,2R)-1-(2,3- dihydrobenzo[β] [ 1 ,41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-4-oxo- 4-(4-(trifluoromethyl)phenyl)butanamide (2S,3S)-2,3-dihydroxysuccinate
Figure imgf000134_0001
1H NMR (400MHZ, CD3OD) δ 2.08 (br, 4H), 2.54-2.72 (m, 2H), 3.24-3.48 (m, 6H), 4.19 (s, 4H), 4.29 (m, 4H), 4.74 (sd, 1H), 6.76 (d, 1H), 6.86 (d, 1H), 6.92 (s, 1H), 7.81 (d, 2H), 8.13 (d, 2H); MS for C26H29F3N2O5- C4H 6O6: [M-H]' 657.
Example 2E68. Preparation of Compound 65 fGenz-528152-11: 2-(3'- chlorobiphenyl-4-vn-N-(( 1 R.2RH -(2.3-dihvdrobenzorøl f 1.41dioxin-6-yl)- 1 ■ hydroxy-3-Cpyrrolidin- 1 -yl~)propan-2-vI*)acetamide
Figure imgf000134_0002
1H NMR (400MHz, CDCl3) δ 1.70 (br, 4H), 2.54 (br, 4H), 2.72-2.81 (m, 2H), 3.53 (s, 2H), 4.12-4.23 (m, 5H), 4.85 (d, 1H), 5.82 (d, 1H), 6.58 (dd, 1H), 6.70 (sd, 1H), 6.73 (d, 1H), 7.19 (d, 1H), 7.32-7.34 (m, 1H), 7.38 (t, 1H), 7.46-7.49 (m, 1H), 7.52 (d, 2H), 7.59 (d, 1H); C29H31ClN2O4: [M-H]- 507.
Example 2E69. Preparation of Compound 262: JV-[2-Hvdroxy-2-(4-methoxy- phenyl)- 1 -pyrrolidin- 1 -ylmethyl-ethvn-3-(4-methoxy-phenoxyVpropionamide OH
Figure imgf000135_0001
1H NMR (CDCl3 400 rnHz, ppm); 1.75 (m, 4H), 2.55 (m, 2H), 2.65 (m, 4H), 2.85 (m, 2H), 3.8 (s, 6H), 4.1 (m, 2H), 4.25 (m, 1H), 5.0 (d, 1H), 6.5 (br. d, 1H), 6.8 (m, 4H), 7.25 (m, 4H). M/Z for C24H32N2O5 [M-H]+ 429.
Example 2E70. Preparation of Compound 270: 5-(4-Isopropoxy-phenyl)-5-oxo- pentanoic acid [2-hvdroxy-2-(4-methoxy-phenyl)- 1 -pyrrolidin- 1 -ylmethyl- ethyll amide
OH
Figure imgf000135_0002
1H NMR (CDCl3 400 mHz, ppm); 1.4 (d, 6H), 1.8 (m, 4H), 2.0 (m, 2H), 2.2 (m, 2H), 2.6 (m, 4H), 2.8 (m, 4H), 3.75 (s, 3H), 4.25 (m, 1H), 4.65 (m, 1H), 5.0 (d, 1H), 5.95 (br. d, 1H), 6.85 (m, 4H), 7.25 (m, 2H), 7.9 (m,2H). M/Z for C24H32N2O5 [M-H]+ 483.3. Example 2E71. Preparation of Compound 285: 7-(4-Methoxy-phenyl)-7-oxo- heptanoic acid |-2-hvdroxy-2-(4-methoxy-phenyl)- 1 -pyrrolidin- 1 -ylmethyl-ethyll- amide
Figure imgf000136_0001
1H NMR (CDCl3 400 mHz, ppm); 1.25 (m, 2H), 1.6 (m, 4H), 1.8 (m, 4H), 2.15 (m, 2H), 2.65 (m, 4H), 2.85 (m, 4H), 3.75 (s, 3H), 3.9 (s, 3H), 4.2 (m, 1H), 5.0 (d, 1H), 5.9 (br. d, 1H), 6.85 (d, 2H), 6.95 (d, 2H), 7.2 (d, 2H), 7.95 (d, 2H). M/Z for C24H32N2O5 [M-H]+ 483.3
Example 2E72. Preparation of Compound 262: JV-[2-Hydroxy-2-(4-methoxy- phenyl)- 1 -pyrrolidin- 1 -ylmethyl-ethyl1-3-(4-methoxy-phenoxy)-propionamide
Figure imgf000136_0002
1H NMR (CDCl3 400 mHz, ppm); 1.75 (m, 4H), 2.55 (m, 2H), 2.65 (m, 4H), 2.85 (m, 2H), 3.8 (s, 6H), 4.1 (m, 2H), 4.25 (m, 1H), 5.0 (d, 1H), 6.5 (br. d, 1H), 6.8 (m, 4H), 7.25 (m, 4H). M/Z for C24H32N2O5 [M-H]+ 429.
Example 2E73. Preparation of Compound 270: 5-(4-Isopropoxy-phenyl)-5-oxo- pentanoic acid [2-hvdroxy-2-(4-methoxy-phenyl)- 1 -pyrrolidin- 1 -ylmethyl- ethyll amide
Figure imgf000137_0001
1H NMR (CDCl3 400 mHz, ppm); 1.4 (d, 6H), 1.8 (m, 4H), 2.0 (m, 2H), 2.2 (m, 2H), 2.6 (m, 4H), 2.8 (m, 4H), 3.75 (s, 3H), 4.25 (m, 1H), 4.65 (m, 1H), 5.0 (d, 1H), 5.95 (br. d, 1H), 6.85 (m, 4H), 7.25 (m, 2H), 7.9 (m,2H). M/Z for C24H32N2O5 [M-H]+ 483.3.
Example 2E74. Preparation of Compound 305
OH
Figure imgf000138_0001
1H NMR (CDCl3 400 mHz, ppm); 1.25 (m, 14 H), 1.6 (m, 4H), 1.8 (m, 4H), 2.1 (t, 2H), 2.6 (t, 2H), 2.8 (m, 6H), 4.2 (m, 5H), 4.9 (d, 1H), 6.0 (br d, 1H), 6.8 (m, 3H), 7.2 (m, 1H), 7.5 (m, 1H), 8.4 (m, 2H). M/Z for C24H32N2O5 [M-H]+ 538.
Example 2E75. Preparation of Compound 320: Octanoic acid r2-hydroxy-2(4- methoxy-phenyl)- 1 -Pyrrolidinl -ylmethyl -ethyl] -amide
Figure imgf000138_0002
1H NMR (CDCl3 400 mHz, ppm); 0.9 (t, 3H), 1.2 (m, 8H), 1.5 (m, 2H), 1.8 (m, 4H), 2.1 (t, 2H), 2.65 (m, 4H), 2.8 (d, 2H), 3.8 (s, 3H), 4.2 (m, 1H), 4.95 (d, 1H), 5.9 (br d, 1H), 6.9 (2s, 2H), 7.25 (m, 2H). M/Z for C22H36N2O3 [M-H]+ 377.4. Example 2E76. Preparation of Cyclic Amide Analogs
Figure imgf000139_0001
(Scheme 6)
Cyclic amide analogs were prepared according to Scheme 6. 2-Amino-1- (2,3-dihydro-benzo[1,4] dioxin-6-yl)-3-pyrrolidin-1-yl-propan-1-ol was prepared according to the preparation of intermediate 4 of US patent 6,855,830 B2. This amine was coupled with various nitriles in potassium carbonate and glycerol, under an atmosphere of nitrogen, for example, at 1 15°C for 18 hours. Compound 323 characterized by the following structural formula was prepared by following Scheme 6. Compound 323 was purified by column chromatography using a mixture of methanol and methylene chloride.
Figure imgf000139_0002
1H NMR (CDCl3 400 mHz, ppm); 0.95 (t, 3H), 1.35 (m, 2H), 1.6 (m, 2H), 1.8 (m, 4H), 2.7 (m, 6H), 2.8 (m, 2H), 4.2 (m, 5H), 5.4 (d, 1H), 6.85 (m, 3H), 7.2 (m, 2H), 7.9 (d, 2H). M/Z for C24H32N2O5 [M-H]+ 421.54. Example 2E77. Preparation of N-(TlR,2R)-1-(23-dihvdrobenzorbiri.41dioxin-6- vQ- 1-hvdroxy-3-(-pyrrolidin- 1 -yl)propan-2-vQ-5-(4-(2-methoxyethoxy)phenyl)-5- oxopentanamide:
Figure imgf000140_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.25 (t, 3H), 1.8 (br, 4H), 1.95 (m, 2H), 2.05 (t, 3H), 2.25 (m, 2H), 3.65 (m, 4H), 2.90 (m, 4H), 3.4 (s, 4H), 3.8 (m, 2H), 4.15 (m, 9H), 4.95 (br, 1H), 5.95 (br, 1H), 6.88-6.95 (m, 5H), 7.9 (m, 2H). M/Z for C29H38N2O7 [M+H] - 527.
Example 2E78. Preparation of N-fdR. 2R)-1-(4-chlorophenyl)-1-hvdroxy-3- (pyrrolidin- 1 -yl)propan-2-yl)-3-(4-methoxyphenoxy)propanamide
Figure imgf000140_0002
1H NMR (CDCl3, 400 mHz, ppm): 1.76 (br, 4H), 2.52-2.57 (sq, 2H), 2.60-2.73 (br, 4 H), 2.88-2.96 (st, 2H), 3.8 (s, 3H), 3.96-4.0 (m, 1H), 4.06-4.11 (1H), 4.21-4.24 (m, 1H), 5.07 (d, 1H), 6.57 (bd, 1H), 6.77-6.87 (sq, 4H), 7.20-7.27 (sd, 6H). M/Z for C23H29ClN2O4 [M+H] = 433. Example 2E79. Preparation of N-((1R, 2R)-1-(4-chlorophenvn-1-hydroxy-3- (pyrrolidin-1-yl)propan-2-yl)-6-(4-methoxyphenyl)-6-oxohexanamide:
OH
Figure imgf000141_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.54-1.62 (br, 4H), 1.79 (br, 4H), 2.14 (t, 2H), 2.63-2.69 (br, 4H), 2.83-2.89 (m, 4H), 3.88 (s, 3H), 4.24 (br, 1H), 5.03 (d, 1H), 5.93 (d, 1H), 6.93 (d, 2H), 7.26-7.32 (m, 4H), 7.93 (d, 2H). M/Z for C26H33ClN2O4 [M+H] = 473.
Example 2E80. Preparation of N-((1R. 2R)-I -hydroxy- l-(4-methoxy-3- methylphenyl)-3 -(pyrrolidin- 1 -yl)propan-2-yl)-6-(4-methoxyphenyl)-6- oxohexanamide:
OH
Figure imgf000141_0002
1H NMR (CDCl3, 400 mHz, ppm): 1.77 (br, 4H), 1.91-2.0 (m, 2H), 2.18 (s, 3H), 2.2- 2.25 (m, 2H), 2.62-2.69 (m, 4H), 2.77-2.89 (m, 4H), 3.75 (s, 3H), 3.88 (s, 3H), 4.23 (m, 1H), 4.96 (sd, 1H), 5.93 (br, 1H), 6.75 (br, 1H), 6.94 (d, 2H), 7.1 (br, 2H), 7.88 (m, 2H). M/Z for C28H38N2O5 [M+H] = 483.
Example 2E81. Preparation of N-((1R. 2R)-1-hydroxy- l-(4-methoxy-3- methylphenyl)-3-(pyrrolidin- 1 -yl)propan-2-yl)-2-(4- (trifluoromethoxy'jphenyl)acetamide:
Figure imgf000142_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.73 (br, 4H), 2.20 (s, 3H), 2.55 (br, 4H), 2.81 (st, 2H), 3.46 (s, 2H), 3.82 (s, 3H), 4.15 (m, 1H), 4.92 (sd, 1H), 5.85 (br, 1H), 672 (d, 1H), 6.95 (sd, 1H), 7.00 (br, 1H), 7.2 (m, 4H). M/Z for C24H29F3N2O4 [M+H] = 467.
Example 2E82. Preparation of N-(QR. 2R)-1-hvdroxy-3-(pyrrolidin-1-vn-1- (2.2.3,3-tetrafluoro-2,3-dihydrobenzo[b1|'1.41dioxin-6-yl)propan-2-yl')octanamide:
Figure imgf000142_0002
1H NMR (CDCl3, 400 mHz, ppm): 0.9 (t, 3H), 1.2 (rm, 11H), 1.5 (bm, 8H), 1.8 (br, 4H), 2.1 (m, 2H), 2.65 (m, 4 H), 2.90 (m, 2H), 4.2 (m, 1H), 5.05 (d, 1H), 5.85 (br, 1H), 7.2 (m, 3H). M/Z for C23H32F4N2O4 [M+H] = 477. Example 2E83. Preparation of N-(YlR. 2R)-1-(2.2-difluorobenzo[diπ.31dioxol-5- yl)-1-hydroxy-3-('pyrrolidin-1-yl)propan-2-yl)-2-(4- (trifluoromethoxy)phenyl)acetamide:
OH
Figure imgf000143_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.75 (br, 4H), 2.55 (br, 4H), 2.85 (m, 2H), 3.45 (s, 2H), 4.1 (m, 1H), 5.0 (d, 1H), 5.85 (br, 1H), 6.8-6.95 (3H), 7.1-7.20 (4H). M/Z for C23H23F5N2O5 [M+H] = 503.
Example 2E84. Preparation of N-((1R, 2R)-1-hydroxy- 1-(4-(2- phenoxyethoxy)phenyl)-3-(pynolidin-1-yl)propan-2-yl)-6-(4-methoxyphenyl)-6- oxohexanamide :
Figure imgf000143_0002
1H NMR (CDCl3, 400 mHz, ppm): 1.6 (m, 4H), 1.8 (m, 4H), 2.15 (t, 2H), 2.7 (m, 4H), 2.85 (m, 4H), 3.8 (s, 3H), 4.25 (m, 1H), 4.3 (s, 3H), 5.0 (d, 1H), 5.95 (br, 1H), 6.9 (m, 7H), 7.2 (m, 4H), 7.95 (m, 2H). M/Z for C34H42N2O6 [M+H] = 575.
Example 2E85. Preparation of N-((1R, 2R)-1-(4-(cyclobutylmethoxy)phenyl)-1- hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yP-6-(4-methoxyphenyl)-6-oxohexanami de
Figure imgf000144_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.6 (br, 4H), 1.9 (m, 9H), 2.05 (m, 5H), 2.75-3.0 (m, 9H), 3.8 (m, 5H), 4.3 (m, 1H), 5.0 (m, 1H), 6.2 (br, 1H), 6.9 (m, 4H), 7.25 (m, 2H), 7.9 (m, 2H). M/Z for C3IH42N2O5 [M+H] = 523.
Example 2E86. Preparation of N-((1R, 2R)-1-(4-(4-fluorobutoxy)phenvn-1- hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-6-(4-methoxyphenyl)-6-oxohexanamide:
Figure imgf000144_0002
1H NMR (CDCl3, 400 mHz, ppm): 1.6 (m, 8H), 1.8 (m, 10H), 2.15 (t, 2H), 2.65 (m, 4H), 2.8 (d, 2H), 2.9 (m, 5H), 2.95 (s, 3H), 4.0 (t, 2H), 4.15 (m, 1H), 4.45 (t, 1H), 4.55 (t, 1H), 4.95 (br, 2H), 5.9 (br, 1H), 6.90 (m, 4H), 7.20 (m, 2H), 7.95 (m, 2H), 8.05 (br, 1H). M/Z for C30H4IFN2O5 [M+H] = 529.
Example 2E87. Preparation of N-((1R. 2R)-1-hvdroxy-3-(pyrrolidin-1-yiyi-(4-C3- Cp-tolyloxy)propoxy)phenyl)propan-2-yl)-6-C4-methoxyphenyl)-6-oxohexanamide:
Figure imgf000145_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.65 (m, 4H), 1.8 (m, 4H), 2.15 (t, 2H), 2.25 (t, 2H), 2.3 (s, 3H), 2.65 (m, 4H), 2.8 (m, 2H), 2.9 (t, 2H), 3.85 (s, 3H), 4.15 (m, 4H), 4.25 (m, 1H), 4.95 (br, 1H), 6.85 (br, 1H), 6.8-6.95 (m, 6H), 7.05 (m, 2H), 7.2 (m, 2H), 7.95 (2H). M/Z for C36H46N2O6 [M+H] = 603.
Example 2E88. Preparation of N-(QR, 2R)- l-(4-butoxyphenyl)-l -hydroxy- 3- (pyrrolidin-1-yl)propan-2-yl)-6-(4-methoxyphenyl)-6-oxohexanamide:
OH
Figure imgf000145_0002
1H NMR (CDCl3, 400 mHz, ppm): 1.0 (t, 3H), 1.5 (m, 2H), 1.65 (m, 4H), 1.8 (m, 6H), 2.15 (t, 2H), 2.65 (m, 4HO, 2.8 (m, 2H), 2.9 (t, 2H), 3.85 (s, 3H), 3.9 (t, 2H), 4.15 (m, 1H), 4.95 (br, 1H), 5.90 (br, 1H), 6.8-6.95 (m, 4H), 7.2 (br ,2H), 7.90 (br, 2H). M/Z for C30H42N2O5 [M+H] = 511.
Example 2E89. Preparation QfN-((1R. 2R)-1-(4-fhexyloxy)phenyl)-1-hvdroxy-3- (pyrrolidin-1-yl)propan-2-yl)-5-(4-(2-methoxyethoxy)phenyl)-5-oxopentanamide:
Figure imgf000146_0001
1H NMR (CDCl3, 400 mHz, ppm): 0.95 (t, 3H), 1.35 (m, 4H), 1.45 (m, 2H), 1.7 (m, 6H), 1.95 (m, 2H), 2.20 (m, 2H), 2.65 (m, 4H), 2.85 (m, 4H), 3.45 (s, 3H), 3.75 (m, 2H), 3.90 (t, 2H), 4.15 (m, 2H), 4..25 (m, 1H), 4.95 (m, 1H), 6.0 (br, 1H), 6.8 (m, 2H), 6.9 (m, 2H), 7.2 (m, 2H), 7.90 (m, 2H). M/Z for C33H48N2O6 [M+H] = 569.
Example 2E90. Preparation of N-((1R,2 Ryi-(4-(hexyloxy)phenyl)-1-hvdroxy-3- (YSV3 -hydroxypyrrolidin- 1 -yl)propan-2-yl)-3 -(4-methoxyphenoxy)propanamide
OH
Figure imgf000146_0002
1H NMR (CDCl3, 400 mHz, ppm): 0.95 (t, 3H), 1.35 (m, 4H), 1.45 (m, 2H), 1.75 (m, 3H), 2.1 (m, 1H), 2.4 (m, 1H), 2.55 (t, 2H), 2.75 (m, 3H), 2.85 (m, 1H), 3.0 (m, 1H), 3.75 (s, 3H), 3.90 (t, 2H), 4.05 (m, 2H), 4.1 (m, 1H), 4.15 (m, 1H), 5.0 (br, 1H), 6.6 (br, 1H), 6.8 (m, 6H), 7.2 (m, 2H). M/Z for C29H42N2O6 [M+H] = 515.
Example 2E91. Preparation of 2-(4'-chlorobiphenyl-4-yl)-N-(αR, 2R)-3-(YR)-3- fluoropyrrolidin- 1 - yl)- 1-hydroxy- 1 -(4-isopropoxyphenyl)propan-2-vQacetamide : OH
Figure imgf000147_0001
1H NMR (CDCl3, 400 mHz, ppm): 1.15 (m, 6H), 2.10 (m, 2H), 2.4 (q, 1H), 2.5-2.75 (m, 4H), 2.95 (m, 2H), 3.55 (d, 2H), 4.15 (m, 1H), 4.45 (m, 1H), 4.85 (br, 1H), 5.10 (m, 1H), 5.9 (br, 1H), 6.75 (m, 2H), 7.05 (br, 2H), 7.20 (m, 2H), 7.4 (m, 2H), 7.5 (m, 4H). M/Z for C30H34ClFN2O3 [M+H] = 528.
Example 2E92. Preparation of N-((1R, 2R)-1-hvdroxy-3-((S)-3-hydroxypyrrolidin- 1 -vQ- 1 -(4-isopropoxyphenyl)propan-2-yiy3-(4-methoxyphenoxy)propanamide:
Figure imgf000147_0002
1H NMR (CDCl3, 400 mHz, ppm): 1.35 (d, 6H), 1.7 (m, 1H), 2.1(m, 1H), 2.45 (m, 1H), 2.55 (t, 2H), 2.7-2.9 (m, 4H), 3.0 (m, 1H), 3.8 (s, 3H), 4.05 (m, 1H), 4.15 (m, 1H), 4.20 (m, 1H), 4.35 (m, 1H), 4.5 (m, 1H), 4.95 (d, 1H), 6.55 (br, 1H), 6.75-6.85 (m, 6H), 7.2 (m, 2H). M/Z for C26H36N2O6 [M+H] = 473.
Example 2E93. Preparation of N-((1 R,2R)-1 -(4-(4-fluorobutoxy)phenyl)- 1-hydroxy-
3-C(R)-3-hydroxypyrrolidin-1-yπpropan-2-yl)-5-C4-methoxyphenyl)-5- oxopentanamide
Figure imgf000148_0001
1H NMR (400 MHz, CDCl3) 5=1.7-2.2 (m, 12 H), 2.4 (dd, 1H), 2.65-2.9 (m, 6H), 3.0(dd, 1H), 3.90 (s, 3H), 3.91(dd, 2H), 4.1-4.22 (m, 1H), 4.3-4.4 (m,1H), 4.4(dd, 1H), 4.6 (dd, 1H), 4.91 (d, 1H), 6.19(d, 1H), 6.83(d, 2H), 6.92 (d, 2H), 7.22(d, 2 H), 7.9 (d, 2H); MS for C29H39FN2O6 m/z 531 [M+H].
Example 2E94. Preparation of N-(C 1 R.2R)- 1 -(4-('4-fluorobutoxy>)phenyl)- 1 - hvdroxy-3-((R)-3-hydroxypyrrolidin-1-yl)propan-2-yl)-8-methoxyoctanamide
Figure imgf000148_0002
1H NMR (400 MHz, CDCl3) 6=1.2-1.34 (m, 6H), 1.45-1.6 (m, 4H), 1.7-1.8(m, 1H), 1.86-1.95 (m, 4H), 2.0-2.2 (m, 4), 2.4-2.5 (m, 2H), 2.7-2.8 (m, 4H), 2.98 (dd, 1H), 3.3 (s, 3H), 3.53 (dd, 1H), 4.0 (dd, 2H), 4.1-4.2 (m, 1H), 4.3-4.4 (m, 1H), 4.5 (dd, 1H), 4.58 (dd,1H), 4.9(d, 1H), 5.9 (d, 1H), 6.85 (d, 2H), 7.22 (d, 2H) ; MS for C26H43FN2O5 m/z 483 [M+H]
Example 2E95. Preparation of N-(C 1 R.2R)- 1 -(4-(4-fluorobutoxy)phenvn- 1 - hvdroxy-3-((R)-3-hvdroxypyrrolidin- 1 -vOpropan-2-vO-4-(4- methoxyphenoxy)butanamide
Figure imgf000149_0001
1H NMR (400 MHz, CDCl3) 6=1.6-2.2 (m, 9H), 2.3-2.5 (m, 4H), 2.6-2.8 (m, 5), 2.9 (dd, 1H), 3.7 (s, 3H), 3.85 (dd, 2H), 3.95 (dd, 2H), 4.2-4.3 (m, 2H), 4.5 (dd, 1H), 4.6 (dd, 1H), 4.9 (d, 1H), 6.0 (d, 1H), 6.7-7 (m, 6H), 7.1-7.2 (d, 2H); MS for C28H39FN2O6 m/z 519[M+H].
Example 2E96. Preparation of N-(T 1 R.2R)- 1 -(4-(4-fluorobutoxy)phenvn- 1 - hvdroxy-3-((R)-3-hvdroxypyrrolidin-1-yl)propan-2-yl)-3-(4- methoxyphenoxy)propanamide
Figure imgf000149_0002
1H NMR (400 MHz, CDCl3) δ=1.6-1.7 (m, 1H), 1.8-2 (m, 4H), 2.1-2.2 (m, 1), 2.4- 2.5(m, 1H), 2.6(t, 2H), 2.7-2.85 (m, 4H), 3.0 (dd, 1H), 3.7 (s, 3H), 4.0 (t, 2H), 4.1- 4.3 (m, 4H), 4.5 (dd, 1H), 4.6 (dd, 1H) 4.98 (d, 1H), 6.6 (d, 1H), 6.7-6.9 (m, 6H), 7.1-7.22 (d, 2H); MS for C27H37FN2O6 m/z 505[M+H]. Example 2E97. Preparation of N-(αR,2RH-(4-(4-fluorobutoxy)phenyl)-1-hvdroxy- 3-((R)-3-hvdroxypyπ^lidin-1-y0propan-2-yl)-7-(4-methoxyphenyl)-7- oxoheptanamide
Figure imgf000150_0001
1H NMR (400 MHz, CDCl3) δ=l .l-1.4( m, 3H), 1.5-2.0( m, 12H), 2.1-2.2 (dd, 4H), 2.4-2.90(m, 10H), 3.0(dd, 1H), 3.75 (s, 3H), 3.9 (dd, 2H), 4.1-4.2 (m, 1H), 4.3-4.4.5 (m, 2H), 4.57 (dd, 1H), 4.9 (d, 1H), 5.9 (d, 1H), 6.8 (d, 2H), 6.9 (d, 2H), 7.2 (d, 2H), 7.9 (d, 2H); MS for C31H43FN2O6 m/z 559[M+H].
Example 2E98. Preparation of N-(( 1 R.2R)- 1 -(4-(4-fluorobutoxy)phenyl> 1 - hydroxy-3 -((R)-3 -hvdroxypyrrolidin- 1 -yl)propan-2-yl)-6-(4-methoxyphenyl)- 6- oxohexanamide
Figure imgf000150_0002
1H NMR (400 MHz, CD3OD) 5=1.4-1.6 (m, 4H), 1.6-1.8 (m, 5H), 2.0-2.2 (m, 1H), 2.2-2.3(m, 2H),2.4-2.6 (m, 3H), 2.7-3.0 (m, 5H), 3.8 (s, 3H), 3.9 (dd, 1H), 4.1-4.25 (m, 1H), 4.3-4.38(m, 1H), 4.4 (dd, 1H), 4.5 (dd, 1H), 6.8 (d, 2H), 7.1(d, 2H), 7.2(d, 2H), 8 (d, 2H); MS for C30H4IFN2O6 m/z 545[M+H] Example 2E99. Preparation of N-(αS,2Ryi-f5-chlorothiophen-2-yl)-1-hvdroxy-3- (pyrrolidin- 1 -yl)propan-2-y0-3-(4-methoxyphenoxy)propanamide
Figure imgf000151_0001
1H NMR (400 MHz, CDCl3) δ=1.7 (broad s, 4H), 2.5-2.7 (m, 7H), 2.8 (dd, 1H), 2.94 (dd, 1H), 3.77 (s, 3H) 4.1-4.2(m, 2H), 4.3-4.35( m, 1H), 5.18 (d, 1H), 6.55 (d, 1H), 6.66 (d, 1H), 6.67 (d, 1H), 6.7-6.9 (m, 4H);MS for C2IH27ClN2O4S m/z 439[M+H].
Example 2E100. Preparation of N-(αS,2R)-1-hvdroxy-1-f3-methyrthiophen-2-vn- 3-(pyrrolidin-1-vOpropan-2-yl)-3-(4-methoxyphenoxy)propanamide 2,2,2- trifluoroacetate
Figure imgf000151_0002
1H NMR (400 MHz, CD3OD) δ= 1.8-2.2 (m, 4H), 2.24 (s, 3H) 2.5-2.8(m, 2H), 3.0- 3.2 (m, 2H), 3.5 (dd, 2H), 3.7 (s, 3H), 3.6-3.8 (m, 2H), 4.0-4.2(m, 2H), 4.5 (dd, 1H), 5.2 (s, 1H), 6.8 (d, 1H), 6.84 (broad s, 4H), 7.2 (d, 1H);MS for C22H30N2O4S m/z 419[M+H]. Example 2E101. Preparation of Compound 257: N-fflR. 2R)-l-(23- dihvdrobenzo[β][1,41dioxin-6-yl)-1-hvdroxy-3-morpholinopropan-2-yl)-3-(4- methoxyphenoxy)propanamide
Figure imgf000152_0001
1H NMR (400 MHz, CDCl3) δ= 2.4-2.6 (m, 7H), 2.7 (dd, 1H), 3.5-3.7 (m, 4H), 3.8 (s, 3H), 4-4.2 (m, 2H), 4.2 (s, 4H), 4.2-4.3 (m, 1H), 4.9 (d, 1H), 6.5 (d, 1H), 6.7-6.9 (m, 7H); MS for C25H32N2O7 m/z 473.1 [M+H].
Example 2E102. Preparation of Compound 261: N-((1R. 2R)-1-(23- dihvdrobenzo[β][L41dioxin-6-yl)-1-hvdroxy-3-(piperidin-1-yl)propan-2-yl)-3-(4- methoxyphenoxy)propanamide
Figure imgf000152_0002
1H NMR (400 MHz, CDCl3) δ= 1.4 (br, 2H), 1.6 (br, 4H), 2.2-2.8 (m, 6H), 3.8 (s, 3H), 4.0-4.2 (m, 2H), 4.2 (s, 4H), 4.2-4.3 (m, 1H), 4.9 (s, 1H), 6.4 (d, 1H), 6.7-6.9 (m, 7H); MS for C25H34N2O6 m/z 471.1 [M+H]. Example 2Bl. Preparation of Compound 6: l-benzyl-3-(dR,2R)-1-(2,3- dihydrobenzorβir 1 ,4]dioxin-6-vQ- 1-hvdroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)urea
Figure imgf000153_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.4-2.6 (m, 5H), 2.6-2.7 (dd, 1H), 4.0 (m, 1H), 4.2 (s, 4H), 4.3 (m, 2H), 4.8 (d, 1H), 4.86 (d, 1H), 5.0 (br, 1H), 6.6-6.9 (m, 3H), 7.2-7.4 (m, 5 H); MS for C23H29N3O4 m/z 412.2 [M+H].
Example 2B2. Preparation of Compound 17: 1-((1R, 2R)-\-(23- dihydrobenzofβ] [ 1 ,4]dioxin-6-yP- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3-(4- fluorobenzyl)urea
Figure imgf000153_0002
1H NMR (400 MHz, CDCl3) δ= 1.6 (s, 4H), 2.4-2.6 (m, 6H), 3.9 (m, 1H), 4.0-4.1 (m, 2H), 4.13 (s, 4H), 4.7 (d, 1H), 5.4 (d, 1H), 6.6-7.1 (m, 7H); MS for C23H28FN3O4 m/z 430.2 [M+H].
Example 2B3. Preparation of Compound 40: l-(4-bromobenzyl)-3-((lR, 2R)-1-(2,3- dihydrobenzo FBI \ 1.41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)urea
Figure imgf000154_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.4-2.8 (m, 6H), 4.0 (m, 1H), 4.1-4.2 (m, 2H) 4.2 (s, 4H), 4.8 (d, 1H), 5.3 (d, 1H), 5.6-5.8 (br, 1H), 6.8-7.0 (m, 3H), 7.0 (d, 2H), 7.4 (d, 2H); MS for C23H28BrN3O4 m/z 490 [M], 491 [M+H], 492 [M+2].
Example 2B4. Preparation of Compound 41: 1-((1R, 2R)-1-(2,3- dihydrobenzo[β][1,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-(4- methoxybenzyl)urea
Figure imgf000154_0002
1H NMR (400 MHz, CDCl3) δ= 1.6 (s, 4H), 2.4-2.6 (m, 6H), 3.7 (s, 3H), 3.9 (m, 1H), 4.1 (d, 2H), 4.2 (s, 4H), 4.7 (d, 1H), 5.2 (d, 1H), 5.5-5.7 (br, 1H), 6.6-6.8 (m, 5H), 7.1 (d, 2H); MS for C24H31N3O5 m/z 442.2 [M+H].
Example 2B5. Preparation of Compound 80: 1-((1R, 2R)-1-(2,3- dihydrobenzo[β] [ 1.4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin-l -yl)propan-2-yl)-3-(3- methoxybenzyl)urea
Figure imgf000155_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.4-2.6 (m, 6H), 3.8 (s, 3H), 4.0 (m, 1H), 4.1-4.2 (s, 6H), 4.8 (d, 1H), 5.1 (d, 1H), 5.2-5.4 (br, 1H), 6.6-6.8 (m, 6H), 7.2 (dd, 1H); MS for C24H3iN3O5 m/z 442.2 [M+H].
Exampl 2B6. Preparation of Compound 42: H(IR. 2R)-1-(2,3- dihvdrobenzo[βl|-1,41dioxin-6-yl)-1-hvdroxy-3-(rpyrrolidin-1-yl)propan-2-yl)-3-('4- methylbenzyl)urea
Figure imgf000155_0002
1H NMR (400 MHz, CDCl3) δ= 1.6 (s, 4H), 2.3 (s, 3H), 2.4-2.6 (m, 6H), 4.0 (m, 1H), 4.2 (d, 2H), 4.21 (s, 4H), 4.7 (d, 1H), 5.2 (d, 1H), 5.4-5.6 (br, 1H), 6.7-7.1 (m, 7H); MS (for C24H31N3O4 m/z 426.2 [M+H].
Exampl 2B7. Preparation of Compound 43: 1-(4-ChIOrObBnZvI)-S-((1R, 2R)-1-(2.3- dihydrobenzorβl [ 1 ,41dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-vOurea
Figure imgf000156_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.5-2.7 (m, 6H), 4.0 (m, 1H), 4.2 (s, 6H), 4.8 (d, 1H), 5.2 (d, 1H), 5.4-5.5 (br, 1H), 6.7-6.9 (m, 3H), 7.1 (d, 2H), 7.3 (d, 2H); MS for C23H28N3ClO4 m/z 446 [M+H], 447.5 [M+2].
Example 2B8. Preparation of Compound 10: 1-((1R, 2R)-\-(23- dihvdrobenzo[βl[1,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)-3-((S)- 1 -phenylethyl)urea
Figure imgf000156_0002
1H NMR (400 MHz, CDCl3) δ= 1.4 (d, 3H), 1.6 (s, 4H), 2.2-2.5 (m, 4H), 2.5 (dd, 1H), 2.6 (dd, 1H), 3.9 (m, 1H), 4.2 (s, 4H), 4.5 (m, 1H), 4.8 (d, 1H), 5.0 (d, 1H), 5.1-5.3 (br, 1H), 6.6-6.9 (m, 3H), 7.2-7.4 (m, 5H); MS for C24H31N3O4 m/z 426.2 [M+H].
Example 2B9. Preparation of Compound 286: 1-(TlR, 2R)-1-(2,3- dmydroberizo[β][1,4]dioxin-6-yl)-1-hydroxy-3-(pyiτolidin-1-yl)propan-2-yl)-3-( 1 -phenylethvQurea
Figure imgf000157_0001
1H NMR (400 MHz, CDCl3) δ= 1.3 (d, 3H), 1.7 (s, 4H), 2.2-2.6 (m, 6H), 3.9 (m, 1H), 4.2 (s, 4H), 4.6-4.7 (m, 2H), 5.3 (d, 1H), 5.6-5.7 (br, 1H), 6.6 (d, 1H), 6.7 (d, 1H), 6.8 (s, 1H), 7.2-7.4 (m, 5H); MS for C24H3iN3O4 m/z 426.0 [M+H].
Example 2B10. Preparation of Compound 69: 1-((1R, 2R)-1-(2,3- dihydrobenzofβ] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3- (naphthalen-2-yl)urea
Figure imgf000157_0002
1H NMR (400 MHz, CDCl3) δ= 1.6 (s, 4H), 2.4-2.8 (m, 6H), 4.1 (s, 5H), 4.8 (s, 1H), 6.0 (d, 1H), 6.7 (s, 2H), 6.9 (s, 1H), 7.1-7.8 (m, 7H); MS for C26H29N3O4 m/z 448.1 [M+H].
Example 2Bl 1. Preparation of Compound 288: H(IR, 2R)-1-(2,3- dihydrobenzo[β1|-1,41dioxin-6-yπ-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yπ-3- (naphthalen- 1 -yl)urea
Figure imgf000158_0001
1H NMR (400 MHz, CDCl3) δ= 1.6 (s, 4H), 2.4 (s, 4H), 2.6 (d, 2H), 4.1 (m, 1H), 4.2 (s, 4H), 4.8 (d, 1H), 5.4 (d, 1H), 6.5 (d, 1H), 6.6 (d, 1H), 6.7 (s, 1H), 7.2-7.6 (m, 3H), 7.7 (d, 1H), 7.8 (d, 1H), 8.0 (d, 1H); MS for C26H29N3O4 m/z 448.1 [M+H].
Example 2B12. Preparation of Compound 71: 1-(QR, 2R)-1 -(2.3- dihydrobenzo [β] [ 1 ,41dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl*)-3 -((S)-
1 -(naphthalen- 1 -yl)ethyl)urea
Figure imgf000158_0002
1H NMR (400 MHz, CDCl3) δ= 1.4 (s, 4H), 1.5 (d, 3H), 2.3 (s, 4H), 2.4 (dd, 1H), 2.6 (dd, 1H), 3.9 (br, 1H), 4.2 (s, 4H), 4.7 (s, 1H), 5.0 (d, 1H), 5.3 (br, 1H), 5.5 (br, 1H), 6.6 (m, 3H), 7.4-7.6 (m, 4H), 7.7 (d, 1H), 7.8 (d, 1H), 8.1 (d, 1H); MS for C28H33N3O4 m/z 476.2 [M+H].
Example 2B13. Preparation of Compound 70: l-(biphenyl-4-yl)-3-((lR, 2R)-1-(2.3- dihvdrobenzorβiri,41dioxin-6-yl)-1-hvdroxy-3-(pyrrolidin-1-yl)propan-2-yl)urea
Figure imgf000159_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.6-2.8 (m, 6H), 4.1 (br, 1H), 4.2 (s, 4H), 4.9 (br, 1H), 5.9 (d, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.2-7.6 (m, 9H); for C28H31N3O4 m/z 474.1 [M+H].
Example 2B14. Preparation of Compound 81: 1-((1R. 2R)-1-(2,3- dihydrobenzo[β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3-(pyrrolidin- 1 -yl)propan-2-yl)-3-(4- (trifluoromethyl)phenyπurea
Figure imgf000159_0002
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.4-2.7 (m, 6H), 4.0 (br, 1H), 4.2 (s, 4H), 4.8 (br, 1H), 5.9 (br, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.3 (d, 2H), 7.5 (d, 2H); MS for C23H26F3N3O4 m/z 465.97 [M+H].
Example 2B15. Preparation of Compound 68: 1-((1R, 2R)-1-(2,3- dihvdrobenzo[β1[1,4]dioxin-6-yl)-1-hvdroxy-3-(pyiτolidin-1-yl)propan-2-yl)-3-(3- (trifluoromethyl)phenyl)urea
Figure imgf000160_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.5-2.9 (m, 6H), 4.0 (br, 1H), 4.2 (s, 4H), 4.8 (br, 1H), 5.9 (br, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.2-7.6 (m, 4H); MS for C23H26F3N3O4 m/z 466.0 [M+H].
Example 2B16. Preparation of Compound 82: H(IR. 2R)-1-(2.3- dihvdrobenzo[β][1,4]dioxin-6-yl)-1-hydroxy-3-(pyiτolidin-1-yl)propan-2-yl)-3-(4- (trifluoromethoxy)phenyl)urea
Figure imgf000160_0002
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.4-2.7 (m, 6H), 4.0 (br, 1H), 4.2 (s, 4H), 4.8 (br, 1H), 5.9 (br, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.0 (d, 2H), 7.2 (d, 2H); MS for C23H26F3N3O5 m/z 481.5 [M], 482.5 [M+H].
Exampl 2Bl 7. Preparation of Compound 133: 1-((1R, 2RH -(2,3- dihydrobenzo [β] [ 1 ,4]dioxin-6-yl)- 1-hydroxy-3 -(pyrrolidin- 1 -yl)propan-2-yl)-3 -(4-
(2-methylthiazol-4-yl)phenyl)urea
Figure imgf000161_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.4-2.7 (m, 6H), 2.7 (s, 3H), 4.1 (br, 1H), 4.2 (s, 4H), 4.8 (br, 1H), 5.9 (d, 1H), 6.8 (s, 2H), 6.9 (s, 1H), 7.2 (s, 1H), 7.3 (d, 2H), 7.7 (d, 2H); MS for C26H30N4O4S m/z 494.9 [M+H].
Example 2B18. Preparation of Compound 7: 1-((1R. 2R)-1-(2,3- dihvdrobenzo[β][1.41dioxin-6-yl)-1-hydroxy-3-fpyrrolidin-1-yl)propan-2-yl)-3- dodecylurea
Figure imgf000161_0002
1H NMR (400 MHz, CDCl3) δ= 0.9 (t, 3H), 1.3 (br, 18H), 1.4 (m, 2H), 1.8 (s, 4H), 2.5-2.7 (m, 6H), 3.1 (q, 2H), 4.0 (m, 1H), 4.3 (s, 4H), 4.4 (br, 1H), 4.76 (d, 1H), 4.8 (d, 1H), 6.7-6.8 (dd, 2H), 6.9 (s, 1H); MS for C28H47N3(M m/z 489.7 [M+H], 490.9 [M+2].
Example 2B19. Preparation of Compound 287: 1-((1R, 2R)-1-C2J- dihydrobenzo [β] [ 1 ,41 dioxin-6-yl)- 1-hvdroxy-3-(pyrrolidin- 1 - yl)propan-2-yl)-3 -(2- (thiophen-2-yl')ethyl)urea
Figure imgf000162_0001
1H NMR (400 MHz, CDCl3) δ= 1.7 (s, 4H), 2.5-2.7 (m, 6H), 3.0 (t, 2H), 3.8 (q, 2H), 4.0 (m, 1H), 4.2 (s, 4H), 4.8 (d, 2H), 4.9 (d, 1H), 6.7-6.8 (m, 3H), 6.9 (d, 1H), 6.9 (dd-1H), 7.1 (d, 1H); MS for C22H29N3O4S m/z 432.1 [M+H].
Example 2B20. Preparation of l-((lR,2R)-1-(4-(4-fluorobutoxy)phenyl)-1-hvdroxy- 3-((R)-3-hydroxypyrrolidin-1-yl)propan-2-yl)-3-(4-methoxybenzyl)urea 2,2,2- trifluoroacetate
Figure imgf000162_0002
1H NMR (400 MHz, CD3OD) δ= 1.8-2.2 (m, 6H), 3.2-3.3 (dd, 2H), 3.4-3.7 (m, 3H), 3.8 (s, 3H), 3.82-4.1 (m, 4H), 4.3 (dd, 2H), 4.4 (dd, 1H), 4.5 (dd, 2H), 4.8 (dd, 1H), 6.8 (d, 2H), 6.9 (d, 2H), 7 (m, 2H), 7.3 (d, 2H); MS for C26H36FN3O5 m/z 491 [M+H].
Example 2B21. Preparation of l-(4-chlorobenzvn-3-((lR,2R)-1-(4-(4- fluorobutoxy)phenyl)- 1-hvdroxy-3-((R)-3-hvdroxypyrrolidin- 1 -yl)propan-2-yl)urea
Figure imgf000163_0001
1H NMR (400 MHz, CDCl3) δ=1.6-1.8(m, 3H), 1.8-2 (m, 5H), 2-2.2 (m, 2H), 2.2- 2.3 (m, 2H), 2.8-2.4 (m, 5H), 2.9 (m, 1H), 3.9-4.0 (m, 3), 4.1-4.4 (m, 3H),4.5 (t, 1H), 4.6-4.7 (m, 1H), 4.75 (d, 1H),6.8 (d, 2H), 7.1 (d, 2H), 7.15-7.3 (m, 4H); MS for C25H33ClFN3O4 m/z 494[M+H].
Example 3; GM3 Elisa Assay
B 16-FO cells from ATCC (American Tissue Culture Collection) were grown in DMEM media (ATCC) with 10% Fetal Bovine Serum (Hyclone) and Pen/Step/Glutamine (Biowhittaker). 4000 cells per well were plated on collagen coated plates (BD) and allowed to attach for 6 hours in an incubator (37 degrees, 5% CO2). After 6 hours the compounds and controls were added to the wells, the plates mixed and returned to the incubator for 2 days. Day of assay the cells were fixed for 20 minutes with 1% formaldehyde and then washed with Tris Buffered Saline (TBS) 3 times, 150 μl of TBS was left in the wells and 50 μl of goat serum (Invitrogen) was added, the plates mixed and incubated for 1 hour at room temperature. The plates were flicked and the cells incubated with the monoclonal Antibody to GM3 (NeuAc) (Cosmo) for 45 minutes as room temperature. The plates were then washed 3 times with TBS, leaving 150 μl of TBS in the wells and Peroxidase AffinPure F (ab') 2 frag Gt Anti-mouse IgM, μ Chain Specific (Jackson Immno Research) was added in 50 μl, the plates mixed and incubated for 45 minutes at room temperature. The plates were washed 3 times with TBS, flicked and blotted and 100 μl of Quantablu (Pierce) was added to the wells and incubated for 1 hour then read on a Fluorometer at Ex 325 and Em 420. The data was then analyzed using standard programs.
The results of the GM3 Elisa assay are summarized in Tables 1 and 2. In Tables 1 and 2, IC50 values are indicated as "A," "B," C," "D," and "E" for those of less than or equal to 0.1 μm; those of greater than 0.1 μm, and less than or equal to 1 μm; those of greater than 1 μm, and less than or equal to 3 μm; those of greater than 3 μm, and less than or equal to 10 μm; those of greater than 10 μm, respectively. As shown in Tables 1, 2 and 3, numerous compounds of the invention were shown to be inhibitors of GM3.
Figure imgf000164_0001
Figure imgf000165_0001
Figure imgf000166_0001
Figure imgf000167_0001
Figure imgf000168_0001
Figure imgf000169_0001
Figure imgf000170_0001
Figure imgf000171_0001
Figure imgf000172_0001
Figure imgf000173_0001
Figure imgf000174_0001
Figure imgf000175_0001
Figure imgf000176_0001
Figure imgf000177_0001
Figure imgf000178_0001
Figure imgf000179_0001
Figure imgf000180_0001
Figure imgf000181_0001
Figure imgf000182_0001
Figure imgf000183_0001
Figure imgf000184_0001
Figure imgf000185_0001
Figure imgf000186_0001
Figure imgf000187_0001
Figure imgf000188_0001
Figure imgf000189_0001
Figure imgf000190_0001
Figure imgf000191_0001
Figure imgf000192_0001
Figure imgf000193_0001
Figure imgf000194_0001
Figure imgf000195_0001
Table 2. IC 50 Values from GM3 Elisa Assay
Figure imgf000196_0001
Figure imgf000197_0001
Figure imgf000198_0001
Figure imgf000199_0001
Figure imgf000200_0001
Figure imgf000201_0001
Figure imgf000202_0001
Figure imgf000203_0001
Figure imgf000204_0001
Figure imgf000205_0001
Figure imgf000206_0001
Figure imgf000207_0001
Figure imgf000208_0001
Table 3: IC 50 Values
Figure imgf000209_0001
Figure imgf000210_0001
Figure imgf000210_0002
Figure imgf000210_0003
B 348
Figure imgf000210_0004
Figure imgf000211_0001
Figure imgf000211_0002
Figure imgf000211_0003
Figure imgf000211_0004
B 353
Figure imgf000211_0005
Figure imgf000212_0001
Figure imgf000212_0002
Figure imgf000212_0003
K
B 357
Figure imgf000212_0004
Figure imgf000213_0001
Figure imgf000213_0002
Figure imgf000213_0003
361
Figure imgf000213_0004
Figure imgf000214_0001
Figure imgf000214_0002
Figure imgf000214_0003
Figure imgf000214_0004
Figure imgf000214_0005
Figure imgf000215_0001
Figure imgf000215_0002
Figure imgf000215_0003
370
Figure imgf000215_0004
Figure imgf000216_0001
Figure imgf000216_0002
Figure imgf000216_0003
374
Figure imgf000216_0004
Figure imgf000217_0001
Figure imgf000217_0002
Figure imgf000217_0003
Figure imgf000217_0004
Figure imgf000218_0001
Figure imgf000218_0002
Figure imgf000218_0003
B 384
Figure imgf000218_0004
Figure imgf000219_0001
Figure imgf000219_0002
Figure imgf000219_0003
388
Figure imgf000219_0004
Figure imgf000220_0001
Figure imgf000220_0002
Figure imgf000220_0003
Figure imgf000220_0004
D 393
Figure imgf000220_0005
Figure imgf000221_0001
Figure imgf000221_0002
Figure imgf000221_0003
398
Figure imgf000221_0004
Figure imgf000222_0001
Figure imgf000222_0002
Figure imgf000222_0003
Figure imgf000222_0004
Figure imgf000223_0001
Figure imgf000223_0002
Figure imgf000223_0003
D 406
Figure imgf000223_0004
Figure imgf000224_0001
Figure imgf000224_0002
Figure imgf000224_0003
D 410
Figure imgf000224_0004
Figure imgf000225_0001
Figure imgf000225_0002
Figure imgf000225_0003
Figure imgf000225_0004
Figure imgf000226_0001
Figure imgf000226_0002
418
Figure imgf000226_0003
Figure imgf000227_0001
Figure imgf000227_0002
Figure imgf000227_0003
Figure imgf000227_0004
Figure imgf000228_0001
Figure imgf000228_0002
Figure imgf000228_0003
428
Figure imgf000228_0004
Figure imgf000229_0001
Figure imgf000229_0002
Figure imgf000229_0003
432
Figure imgf000229_0004
Figure imgf000230_0001
Figure imgf000230_0002
Figure imgf000230_0003
Figure imgf000230_0004
Figure imgf000231_0001
Figure imgf000231_0002
Figure imgf000231_0003
440
Figure imgf000231_0004
Figure imgf000232_0001
Figure imgf000233_0001
Figure imgf000234_0001
Figure imgf000235_0001
Figure imgf000236_0001
Figure imgf000237_0001
Figure imgf000238_0001
Figure imgf000239_0001
Figure imgf000240_0001
Figure imgf000241_0001
Figure imgf000242_0001
Figure imgf000243_0001
Figure imgf000244_0001
Figure imgf000245_0001
Figure imgf000246_0001
Figure imgf000247_0001
Figure imgf000248_0001
Figure imgf000249_0001
Figure imgf000250_0001
Figure imgf000251_0001
Figure imgf000252_0001
Figure imgf000253_0001
Figure imgf000254_0001
Figure imgf000255_0001
Figure imgf000256_0001
Figure imgf000257_0001
Figure imgf000258_0001
Figure imgf000259_0001
Figure imgf000260_0001
Figure imgf000261_0001
Figure imgf000262_0001
Figure imgf000263_0001
Figure imgf000264_0001
Figure imgf000265_0001
Figure imgf000266_0001
Figure imgf000267_0001
Figure imgf000268_0001
Figure imgf000269_0001
Figure imgf000270_0001
Figure imgf000271_0001
Figure imgf000272_0001
Figure imgf000273_0001
Figure imgf000274_0001
Figure imgf000275_0001
Figure imgf000276_0001
Figure imgf000277_0001
Figure imgf000278_0001
Figure imgf000279_0001
Figure imgf000280_0001
Figure imgf000281_0001
Figure imgf000282_0001
Figure imgf000283_0001
Figure imgf000284_0001
Figure imgf000285_0001
Figure imgf000286_0001
Figure imgf000287_0001
Figure imgf000288_0001
Figure imgf000289_0001
Figure imgf000290_0001
Figure imgf000291_0001
Figure imgf000292_0001
Figure imgf000293_0001
Figure imgf000294_0001

Claims

What is claimed is:
1. A compound represented by the following structural formula:
Figure imgf000295_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R2 and R3 are each independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -O-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic group, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom of NR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
2. The compound of Claim 1, wherein:
R1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1 , -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS,
-N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31)2, -S(O)R32, -SO3R30, -NR31 SO2N(R31)2, -NR31SO2R32 , -V0-Ar1, -V0-OR30, -Vo-O(haloalkyl), -V0-SR30, -V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32,
-VO-N(R3 I)C(O)N(R31)2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R3 V, -V0-S(O)2R30, -V0-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -VO-NR31SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -0-V1-N(R31):., -S-V0-Ar1, -S-V, -N(R31)2, -N(R3 1)-v0-Ar1, -N(R31)-V,-N(R31)2, -NR31 C(O)-V0-N(R31)2,
-NR31C(O)-V0-Ar1, -C(O)-V0-N(R31)2, -C(O)-V0-Ar1, -C(S)-VO-N(R31)2, -C(S)-V0-Ar1, -C(O)O- V, -N(R31)2, -C(O)O-V0-Ar1, -O-C(O)-V,-N(R31)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-V1-N(R31)2, -C(O)N(R3 ^-V0-Ar1, -S(O)2-VO-N(R31)2, -S(O)2-V0-Ar1, -SO2N(R3I)-V,-N(R31)2, -SO2N(R3 ^-V0-Ar1,
-S(O)-VO-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V1-N(R31),, -S(O)2-O-V0-Ar1, -NR31SO2- VO-N(R31)2, -NR31SO2-V0-Ar1, -O-[CH2]P-O-, -S-[CH2]p-S- and -[CH2],,- ; each V0 is independently a Cl-ClO alkylene group; each Vi is independently a C2-C10 alkylene group; Ar1 is an aryl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; and each R is independently i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or iii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; and each R31 is independently R30, -CO2R30, -SO2R30 or -C(O)R30; or
-N(R31)2 taken together is an optionally substituted non-aromatic heterocyclic group; and each R32 is independently: i) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkylcarbonyl and haloalkoxy and haloalkyl; or ii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkylcarbonyl and haloalkoxy and haloalkyl; and each p is independently 1 , 2, 3 or 4; and each q is independently 3, 4, 5 or 6.
3. The compound of Claim 2, wherein:
Y is -H, -C(O)R, -C(O)OR or -C(O)NRR1; and R and R' are each independently -H; a lower aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy and aryl; or an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy, lower aliphatic group and lower haloaliphatic group; or
R and R' taken together with the nitrogen atom of NRR1 form a non-aromatic heterocyclic ring optionally substituted with one or more substituents selected from the group consisting of: halogen; -OH; -CN; -NCS; -NO2; -NH2; lower alkoxy; lower haloalkoxy; lower aliphatic group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy and aryl; and aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, -OH, -CN, -NCS, -NO2, -NH2, lower alkoxy, lower haloalkoxy, lower aliphatic group and lower haloaliphatic group.
4. The compound of Claim 3, wherein:
-N(R2R3) is a 5- or 6-membered non-aromatic nitrogen- containing heterocyclic group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, -OR40, -O(haloalkyl), -SR40, -NO2, -CN, -N(R4I)2, -NR41C(O)R40, -NR41C(O)OR42, -N(R41)C(O)N(R41)2, -C(O)R40, -C(S)R40, -C(O)OR40, -OC(O)R40, -C(O)N(R41)2, -S(O)2R40, -SO2N(R41)2, -S(O)R42, -SO3R40, Ar2, V2-Ar2, -V2-OR40, -V2-O(haloalkyl), -V2-SR40, -V2-NO2, -V2-CN, -V2-N(R41)2,
-V2-NR41C(O)R40, -V2-NR41CO2R42, -V2-N(R41)C(O)N(R41)2, -V2-C(O)R40, -V2-C(S)R40, -V2-CO2R40, -V2-OC(O)R40, -V2-C(O)N(R41),-, -V2-S(O)2R40, -V2-SO2N(R41),, -V2-S(O)R42, -V2-SO3R40, -0-V2-Ar2 and -S-V2-Ar2; each V2 is independently a C1-C4 alkylene group;
Ar2 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxy carbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R40 is independently i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C6 alkyl, amino, C 1 -C6 alkylamino, C 1 -
C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R41 is independently R40, -CO2R40, -SO2R40 or -C(O)R40; or -N(R41)2 taken together is an optionally substituted non-aromatic heterocyclic group; and each R42 is independently: i) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl-
C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or ii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
5. The compound of Claim 4, wherein R5 and R6 are each independently -H; -OH; a halogen; or a lower alkoxy or lower alkyl group.
6. The compound of Claim 5, wherein Y is -H.
7. The compound of Claim 6, wherein: R4 is an aliphatic or aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar3, Ar3-Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -NCS, -N(R51)2, -NR51C(O)R50, -NR51C(O)OR52, -N(R51)C(O)N(R51)2, -C(O)R50, -C(S)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -S(O)2R50, -SO2N(R51)2, -S(O)R52, -SO3R50,
-NR5ISO2N(R51)2, -NR51SO2R52 , -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-NR51CO2R52, -V4-N(R51)C(O)N(R51)2, -V4-C(O)R50, , -V4-C(S)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R51)2-, -V4-S(O)2R50, -V4-SO2N(R51)2, -V4-S(O)R52, -V4-SO3R50, -V4-NR51SO2N(R51);,, -V4-NR51SO2R52, -0-V4-Ar3, -0-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R51)- V4- Ar3, -N(R51)-V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51),, -C(O)-V4-Ar3, -C(S)-V4-N(R51)2, -C(S)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -0-C(O)-V5-N(R5 {)2,
-0-C(O)-V4-Ar3, -C(O)N(R51)- V5-N(R51)2, -C(O)N(R51)-V4-Ar3, -S(O)2-V4-N(R51),, -S(O)2-V4-Ar3, -SO2N(R51)-V5-N(R51)2, -SO2N(R51)- V4-Ar3, -S(O)-V4-N(R5 \, -S(O)-V4-Ar3, -S(O)2-O-V5-N(R51)2, -S(O)2-O-V4-Ar3, -NR51SO2-V4-N(R51),, -NR51SO2-V4-Ar3, -0-[CH2]p-0-, -S-[CH2Jp-S-, and -[CH2]r ; each V4 is independently a Cl-ClO alkylene group; each V5 is independently a C2-C10 alkylene group; each Ar3 is independently an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy and haloalkyl; and each R50 is independently i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or iii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; and each R51 is independently R50, -CO2R50, -SO2R50 or -C(O)R50; or
-N(R5 ")2 taken together is an optionally substituted non-aromatic heterocyclic group; and each R52 is independently: i) an aryl group optionally substituted with one or two substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or ii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; and each p1 is 1, 2, 3 or 4; and each q1 is 3, 4, 5 or 6.
The compound of Claim 7, represented by the following structural formula:
Figure imgf000302_0001
or a pharmaceutically acceptable salt thereof.
The compound of Claim 8, wherein:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V,-N(R31)2, -N(R31)-V0-Ar1, -N(R31)-V,-N(R31)2, -O-[CH2]p-O-, -S-[CH2]P-S-, and -[CH2],- ;
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl,
C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R31 is independently R30, or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
10. The compound of Claim 9, wherein -N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, Cl- C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
11. The compound of Claim 10, wherein R4 is an optionally substituted aryl group or an optionally substituted lower arylalkyl group.
12. The compound of Claim 11, wherein Q is -O- , -S-, -C(O)-, -C(S)-, -NR7(CO)- or -C(O)NR7-.
13. The compound of Claim 7, represented by the following structural formula:
Figure imgf000304_0001
or a pharmaceutically acceptable salt thereof.
14. The compound of Claim 13, wherein:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -0-V1 -N(R3 ^2, -S-V0-Ar1, -S-Vi-N(R31)2, -N(R3^-V0-Ar1, -N(R31)-V1 -N(R31)2, -O-[CH2]p-O-, -S-[CH2Jp-S-, and -[CH2],-;
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C 1 -C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl,
C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R31 is independently R30, or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
15. The compound of Claim 14, wherein -N(R R ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
16. The compound of Claim 15, wherein R4 is an optionally substituted aryl group or an optionally substituted lower alkyl group.
17. The compound of Claim 16, wherein R4 is an aryl or a lower arylalkyl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, Ar3, Ar3-Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R5!)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR5 ' C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50,
-V4-C(O)N(R51)2-, -0-V4-Ar3, -0-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R5I)-V4-Ar3, -N(R51)- V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51)2, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -O-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)- V5-N(R51)2, -C(O)N(R51)- V4-Ar3, -O-[CH2]P-O- and -[CH2],-.
18. The compound of Claim 17, wherein n is 1, 2, 3 or 4.
19. The compound of Claim 18, represented by by the following structural formula:
Figure imgf000306_0001
or a pharmaceutically acceptable salt thereof.
20. The compound of Claim 19, wherein R4 is selected from the group consisting of:
Figure imgf000306_0002
Figure imgf000307_0001
wherein: each of rings A-Z5 is optionally and independently substituted; and each x is independently 0 or 1.
21. The compound of Claim 20, represented by the following structural formula:
Figure imgf000307_0002
or a pharmaceutically acceptable salt thereof, wherein phenyl ring A is optionally substituted.
22. The compound of Claim 21 , wherein -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
23. The compound of Claim 22, wherein: the phenyl group represented by R1 is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-; phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino,
Cl-ClO dialkylamino, -OR50, -Ar3, -V4-Ar3, -V-OR50, -0(Cl-ClO haloalkyl), -V4-O(Cl-ClO haloalkyl), -0-V4-Ar3, -O-[CH2]P-O- and -[CH2]q.-;
Ar3 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -
C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R50 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl,
C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl.
24. The compound of Claim 23, wherein:
-N(R2R3) is pyrrolidinyl; and phenyl ring A is optionally substituted with one or more halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl- ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl- 10 alkoxy, -O-[CH2]P-O- or -[CH2],,-.
25. The compound of Claim 24, wherein phenyl ring A is optionally substituted with -OH, -OCH3 or -OC2H5.
26. The compound of Claim 7, represented by the following structural formula:
Figure imgf000309_0001
or a pharmaceutically acceptable salt thereof.
27. The compound of Claim 26, wherein:
R1 is a phenyl group optionally substituted with one or more halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -V-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V1 -N(R31)2, -N(R31)- V0- Ar1, -N(R31)-V1-N(R31)2, -O-[CH2]P-O-, -S-[CH2]P-S-, or -[CH2]q-;
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl,
C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R31 is independently R30, or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
28. The compound of Claim 27, wherein -N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and
C1-C5 dialkylamino.
29. The compound of Claim 28, wherein R4 is an optionally substituted aryl group or an optionally substituted lower alkyl group.
30. The compound of Claim 29, wherein R4 is an aryl or lower arylalkyl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, Cl- ClO alkyl, Cl-ClO haloalkyl, Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R5 ^2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R5 V, -0-V4-Ar3, -O-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R51)- V4-Ar3, -N(R51)-V5-N(R5I)2, -NR51 C(O)-V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51),, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -0-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)-V5-N(R51)2, -C(O)N(R51)- V4-Ar3, -O-[CH2]P-O- and -[CH2]q.-.
31. The compound of Claim 30, wherein n is 3, 4 or 5.
32. The compound of Claim 31 , represented by the following structural formula:
Figure imgf000311_0001
or a pharmaceutically acceptable salt thereof.
33. The compound of Claim 32, wherein R4 is selected from the group consisting of:
Figure imgf000312_0001
wherein: each of rings A-Z5 is optionally and independently substituted.
34. The compound of Claim 33, represented by the following structural formula:
Figure imgf000313_0001
or a pharmaceutically acceptable salt thereof, wherein phenyl ring A is optionally substituted.
35 . The compound of Claim 34, wherein -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
36. The compound of Claim 35, wherein: the phenyl group represented by R1 is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-; phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, -OR50, -Ar3, -V4-Ar3, -V-OR50, -0(Cl-ClO haloalkyl), -V4-O(Cl-ClO haloalkyl), -0-V4-Ar3, -O-[CH2]P-O- and -[CH2]C-;
Ar3 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy and C1-C6 haloalkyl; and each R50 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy and C1-C6 haloalkyl; or iii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxyl, C1-C6 alkoxy, nitro, cyano, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkoxy.
37. The compound of Claim 36, wherein:
-N(R2R3) is pyrrolidinyl; and phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino,
Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-10 alkoxy, -0-[CH2Jp-O- and -[CH2],-.
38. The compound of Claim 37, wherein phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3 and -OC2H5.
39. The compound of Claim 7, represented by the following structural formula:
Figure imgf000315_0001
or a pharmaceutically acceptable salt thereof, wherein R4 is an optionally substituted aryl group.
40. The compound of Claim 39, wherein:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V-OR30, -V-N(R31)2, -V-Ar1, -O-V-Ar1, -O-V,-N(R31)2, -S-V-Ar1, -S-V,-N(R31)2, -N(R3^-V-Ar1, -N(R3I)-V,-N(R31)2, -O-[CH2]P-O-, - S-[CH2]P-S- and -[CH2]q-;
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R3 ' is independently R30, or -N(R3 ' )2 is an optionally substituted non-aromatic heterocyclic group.
41. The compound of Claim 40, wherein -N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group, which is optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, C1-C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
42. The compound of Claim 41, wherein R4 is an aryl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R51)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50,
-V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R5 V, -0-V4-Ar3, -O-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R51)- V4- Ar3, -N(R51)-V5-N(R51)2, -NR51C(O)- V4-N(R5I)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R5I)2, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -0-C(O)-V5-N(R51^, -0-C(O)-V4-Ar3,
-C(O)N(R51)- V5-N(R51)2, -C(O)N(R51)- V4- Ar3, -0-[CH2]r0- and -[CH2]r.
43. The compound of Claim 42, represented by the following structural formula:
Figure imgf000317_0001
or a pharmaceutically acceptable salt thereof.
44. The compound of Claim 43, wherein R4 is selected from the group consisting of:
Figure imgf000317_0002
wherein: each of rings A-Z5 is optionally and independently substituted.
45. The compound of Claim 44, wherein -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
46. The compound of Claim 45, wherein R4 is a biaryl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy.
47. The compound of Claim 46, wherein the optionally substituted biaryl group is an optionally substituted biphenyl group.
48. The compound of Claim 47, wherein:
-N(R2R3) is pyrrolidinyl; and
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-.
49. The compound of Claim 48, wherein n is 1 , 2, 3 or 4.
50. The compound of Claim 44, wherein -(CHa)n-R4 is
Figure imgf000318_0001
, and wherein phenyl ring A is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, amino, nitro, Ar3, C1-C6 alkyl, C1-C6 haloalkyl, C1-C6 alkoxy, hydroxy and C1-C6 haloalkoxy.
51. The compound of Claim 50, wherein -N(R2R3) is pyrrolidinyl; and
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-.
52. The compound of Claim 7, represented by the following structural formula (XI) or (XII):
Figure imgf000319_0001
or a pharmaceutically acceptable salt thereof, wherein R7 is -H or Cl- C6 alkyl.
53. The compound of Claim 52, wherein:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -U-V0-Ar', -0-V1-N(R3'^, -S-V0-Ar1, -S-Vi -N(R31)2, -N(R3^-V0-Ar1, -N(R3 I)-V,-N(R31)2, -O-[CH2]p-O-, -S-[CH2]p-S- and -[CH2]q-;
Ar1 is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl-
C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R31 is independently R30, or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
54. The compound of Claim 53, wherein -N(R R ) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C 1 -C5 alkyl, C 1 -C5 haloalkyl, hydroxyl, C 1 -
C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
55. The compound of Claim 54, wherein R7 is -H, and R4 is an optionally substituted aryl or arylalkyl group.
56. The compound of Claim 55, wherein R4 is an aryl or lower arylalkyl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, Cl- ClO alkyl, Cl-ClO haloalkyl, Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R5 I)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R51)2-, -0-V4-Ar3, -O-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51),, -N(R51)- V4-Ar3, -N(R51)-V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51),, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -O-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)- V5-N(R51)2, -C(O)N(R51)-V4-Ar3, -O-[CH2]P-O- and -[CH2]q.-.
57. The compound of Claim 54, represented by the following structural formula:
Figure imgf000321_0001
or a pharmaceutically acceptable salt thereof, wherein R8 is -H, or an aryl or lower alkyl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R51)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R5 V, -0-V4-Ar3, -O-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51);,, -N(R51)-V4-Ar3, -N(R51)-V5-N(R51)2, -NR51C(O)-V4-N(R51);,, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51)2, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -O-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)-V5-N(R51)2, -C(O)N(R51)- V4- Ar3, -0-[CH2]p-0- and -[CH2]q-; and k is 0, 1, 2, 3, 4, 5 or 6.
58. The compound of Claim 57, wherein R8 is selected from the group consisting of:
Figure imgf000322_0001
wherein: each of rings A-Z5 is optionally substituted.
59. The compound of Claim 58, wherein -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
60. The compound of Claim 59, wherein each of rings A-Z5 is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-10 alkoxy, -O-[CH2]P-O- or -[CH2],-.
61. The compound of Claim 60, wherein:
-N(R2R3) is pyrrolidinyl; and the phenyl group represented by R1 is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-.
62. The compound of Claim 7, represented by the following structural formula:
Figure imgf000323_0001
or a pharmaceutically acceptable salt thereof, wherein R4 is an optionally substituted aryl group.
63. The compound of Claim 62, wherein:
R1 is a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, C1-C6 alkyl, C1-C6 haloalkyl, -OR30, -SR30, -N(R31)2, Ar1, -V0-OR30, -VO-N(R31)2, -V0-Ar1, -0-V0-Ar1, -O-V,-N(R31)2, -S-V0-Ar1, -S-V1-N(R31);,, -N(R31KV0-Ar1, -N(R31)-V,-N(R31)2, -O-[CH2]P-O-, -S-[CH2]P-S- and -[CH2]q-;
Ar is a phenyl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-
C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R30 is independently i) hydrogen; ii) a phenyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C 1 -C6 haloalkoxy, C 1 -C6 alkoxycarbonyl,
C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an C 1 -C 10 alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R31 is independently R , or -N(R31)2 is an optionally substituted non-aromatic heterocyclic group.
64. The compound of Claim 63, wherein -N(R2R3) is a pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C5 alkyl, C1-C5 haloalkyl, hydroxyl, Cl- C5 alkoxy, nitro, cyano, C1-C5 alkoxycarbonyl, C1-C5 alkylcarbonyl or C1-C5 haloalkoxy, amino, C1-C5 alkylamino and C1-C5 dialkylamino.
65. The compound of Claim 64, wherein R4 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, Ar3, -OR50, -O(haloalkyl), -SR50, -NO2, -CN, -N(R51)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R51)2-, -0-V4-Ar3, -0-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51)2, -N(R51)- V4-Ar3, -N(R51)-V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51)2, -C(O)-V4-Ar3, -C(O)O-V5-N(R51)2, -C(O)O-V4-Ar3, -O-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)- V5-N(R51)2, -C(O)N(R51)- V4-Ar3, -O-[CH2]p-O- and -[CH2]q-.
66. The compound of Claim 65, wherein R4 is selected from the group consisting of:
Figure imgf000325_0001
Figure imgf000326_0001
wherein: each of rings A-Z5 is optionally substituted with.
67. The compound of Claim 66, wherein -N(R2R3) is an unsubstituted pyrrolidinyl, azetidinyl, piperidinyl, piperazinyl or morpholinyl group.
68. The compound of Claim 67, wherein: the phenyl group represented by R1 is optionally substituted with one or more substituents selected from the group consisting of -OH, -OCH3, -OC2H5 and -O-[CH2]P-O-; and each of rings A-U is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, -OR50, -Ar3, -V4-Ar3, -V-OR50, -0(Cl-ClO haloalkyl), -V4-O(Cl-ClO haloalkyl), -0-V4-Ar3, -O-[CH2]P-O- and -[CH2]r.
69. The compound of Claim 68, wherein:
-N(R2R3) is pyrrolidinyl; and each of rings A-U is optionally substituted with one or more substituents selected from the group consisting of halogen, cyano, nitro, Cl-ClO alkyl, Cl-ClO haloalkyl, amino, Cl-ClO alkylamino, Cl-ClO dialkylamino, aryl, aryloxy, hydroxy, Cl-IO alkoxy, -O-[CH2]p-O- and -[CH2],-.
70. The compound of Claim 7, represented by the following structural formula:
Figure imgf000327_0001
or a pharmaceutically acceptable salt thereof, wherein: Q is -O- or -C(O)-; and r and s are each independently 1, 2, 3 or 4.
71. The compound of Claim 70, wherein R4 is an optionally substituted aryl group.
72. The compound of Claim 71, wherein R4 is selected from the group consisting of:
Figure imgf000327_0002
Figure imgf000328_0001
wherein: each of rings A-Z5 is optionally substituted with one or more substituents selected from the group consisting of halogen, Cl-ClO alkyl, Cl-ClO haloalkyl, Ar3, -OR50, -0(Cl-ClO haloalkyl), -SR50, -NO2, -CN, -N(R51)2, -NR51C(O)R50, -C(O)R50, -C(O)OR50, -OC(O)R50, -C(O)N(R51)2, -V4-Ar3, -V-OR50, -V4-O(Cl-ClO haloalkyl), -V4-SR50, -V4-NO2, -V4-CN, -V4-N(R51)2, -V4-NR51C(O)R50, -V4-C(O)R50, -V4-CO2R50, -V4-OC(O)R50, -V4-C(O)N(R51)2-, -0-V4-Ar3, -O-V5-N(R51)2, -S-V4-Ar3, -S-V5-N(R51);., -N(R51)-V4-Ar3, -N(R51)- V5-N(R51)2, -NR51C(O)- V4-N(R51)2, -NR51C(O)-V4-Ar3, -C(O)-V4-N(R51)2, -C(O)-V4-Ar3, -C(O)O-V5-N(R51);., -C(O)O-V4-Ar3, -O-C(O)-V5-N(R51)2, -0-C(O)-V4-Ar3, -C(O)N(R51)- V5-N(R51);,, -C(O)N(R51)- V4- Ar3, -0-[CH2]P-O- and -[CH2]q-; each V4 is independently a C1-C4 alkylene group; each V5 is independently a C2-C4 alkylene group;
Ar3 is an aryl group each optionally substituted with one or more substituents selected from the group consisting of halogen, Cl- C6 alkyl, amino, C1-C6 alkylamino, C1-C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R50 is independently i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, C1-C6 alkyl, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; or iii) an Cl-ClO alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, C1-C6 alkylamino, Cl- C6 dialkylamino, C1-C6 alkoxy, nitro, cyano, hydroxy, C1-C6 haloalkoxy, C1-C6 alkoxycarbonyl, C1-C6 alkylcarbonyl and C1-C6 haloalkyl; and each R51 is independently R50, -CO2R50, -SO2R50 or -C(O)R50; or
-N(R51)2 taken together is an optionally substituted non-aromatic heterocyclic group.
73. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound represented by the following structural formula:
Figure imgf000329_0001
or a pharmaceutically acceptable salt thereof, wherein: R1 is a substituted or unsubstituted aryl group; Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R and R are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5R6VQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-,
-OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
74. A method of treating a subject having type 2 diabetes, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000331_0001
or a pharmaceutically acceptable salt thereof, wherein: R1 is a substituted or unsubstituted aryl group; Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R and R3 are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or
X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
A method of treating a subject having renal hypertrophy or hyperplasia associated with diabetic nephropathy, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000332_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R2 and R3 are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -O-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or
X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
76. A method of decreasing plasma TNF-α in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000333_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R2 and R3 are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6),,-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or
X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and
R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group. A method of lowering blood glucose levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000335_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R and R are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R and R taken together with the nitrogen atom of N(R R ) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5R6)n-Q-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or
X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
78. A method of decreasing glycated hemoglobin levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000336_0001
or a pharmaceutically acceptable salt thereof, wherein: R1 is a substituted or unsubstituted aryl group; Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R2 and R3 are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R and R taken together with the nitrogen atom of N(R R ) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-,
-OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -O-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
79. A method of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000338_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R and R are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R2 and R3 taken together with the nitrogen atom OfN(R2R3) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R )n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or
X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
A method of treating a subject with Tay-Sachs, Gaucher's or Fabry's disease, comprising administering to the subject a therapeutically effective amount of a compound represented by the following structural formula:
Figure imgf000339_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is a substituted or unsubstituted aryl group;
Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group;
R2 and R3 are each independently -H, a substituted or unsubstituted aliphatic gropu, or a substituted or unsubstituted aryl group, or R and R taken together with the nitrogen atom of N(R R ) form a substituted or unsubstituted non-aromatic heterocyclic ring; and
X is -(CR5RVQ-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-, -C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or
X is -O-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic, or substituted or unsubstituted aryl group; or
X is -(CR5R6)n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, or a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or
X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; n is 1, 2, 3, 4, 5 or 6; and each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group.
81. A compound represented by the following structural formula:
Figure imgf000340_0001
or a pharmaceutically acceptable salt thereof, wherein:
R1 is an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, haloalkyl, Ar1, -OR30, -O(haloalkyl), -SR30, -NO2, -CN, -NCS, -N(R31)2, -NR31C(O)R30, -NR31C(O)OR32, -N(R31)C(O)N(R31)2, -C(O)R30, -C(S)R30, -C(O)OR30, -OC(O)R30, -C(O)N(R31)2, -S(O)2R30, -SO2N(R31):-, -S(O)R32, -SO3R30, -NR31SO2N(R31)2, -NR3 ' SO2R32 , -V0-Ar1 , -V0-OR30, -Vo-O(haloalkyl), -V0-SR30,
-V0-NO2, -V0-CN, -VO-N(R31)2, -V0-NR31C(O)R30, -V0-NR31CO2R32, -VO-N(R31)C(O)N(R31)2, -V0-C(O)R30, -V0-C(S)R30, -V0-CO2R30, -V0-OC(O)R30, -V0-C(O)N(R3V, -V0-S(O)2R30, -V0-SO2N(R31)2, -V0-S(O)R32, -V0-SO3R30, -V0-NR31 SO2N(R31)2, -V0-NR31SO2R32, -0-V0-Ar1, -O-V1-N(R31)2, -S-V0-Ar1, -S-V1 -N(R31)2,
-N(R3^-V0-Ar1, -N(R31)-V1-N(R31)2, -NR31 C(O)-V0-N(R31)2, -NR31C(O)-V0-Ar1, -C(O)-V0-N(R3 1)2, -C(O)-V0-Ar1, -C(S)-V0-N(R31)2, -C(S)-V0-Ar1, -C(O)O-V1 -N(R31)2, -C(O)O-V0-Ar1, -O-C(O)-V,-N(R31)2, -0-C(O)-V0-Ar1, -C(O)N(R31)-V1-N(R31)2, -C(O)N(R31)- V0-Ar1, -S(O)2-V0-N(R31)2,
-S(O)2-V0-Ar1, -SO2N(R31)-Vi-N(R31)2, -SO2N(R31)-V0-Ar1, -S(O)-VO-N(R31)2, -S(O)-V0-Ar1, -S(O)2-O-V1 -N(R31)2, -S(O)2-O-V0-Ar1, -NR31SO2-V0-N(R3 ^2, -NR31SO2-V0-Ar1, -0-[CH2]p-0-, -S-[CH2]p-S- and -[CH2]q- ; R and R are each independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R and R taken together with the nitrogen atom of N(R R ) form a substituted or unsubstituted non-aromatic heterocyclic ring; and X is -(CR5R6)n-Q-; Q is -O-, -S-, -C(O)-, -C(S)-, -C(O)O-,
-C(S)O-, -C(S)S-, -C(O)NR7-, -NR7-, -NR7C(O)-, -NR7C(O)NR7-, -OC(O)-, -SO3-, -SO-, -S(O)2-, -SO2NR7-, or -NR7SO2-; and R4 is -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group; or X is -0-, -S- or -NR7-; and R4 is a substituted or unsubstituted aliphatic group, or substituted or unsubstituted aryl group; or X is -(CR5R )n-; and R4 is a substituted or unsubstituted cyclic alkyl group, or a substituted or unsubstituted cyclic alkenyl group, a substituted or unsubstituted aryl group, -CN, -NCS, -NO2 or a halogen; or X is a covalent bond; and R4 is a substituted or unsubstituted aryl group; and
R5 and R6 are each independently -H, -OH, -SH, a halogen, a substituted or unsubstituted lower alkoxy group, a substituted or unsubstituted lower alkylthio group, or a substituted or unsubstituted lower aliphatic group; each R7 is independently -H, a substituted or unsubstituted aliphatic group, or a substituted or unsubstituted aryl group, or R7 and R4 taken together with the nitrogen atom OfNR7R4 form a substituted or unsubstituted non-aromatic heterocyclic group; Y is -H, a hydrolyzable group, or a substituted or unsubstituted alkyl group; and each V0 is independently a Cl-ClO alkylene group; each Vi is independently a C2-C10 alkylene group; Ar1 is an aryl group each optionally and independently substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; and each R30 is independently i) hydrogen; ii) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkoxycarbonyl, alkylcarbonyl and haloalkyl; or iii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl, alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl, wherein each of the phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl for the substituents of the alkyl group respresented by R30 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, C1-C5 alkyl, C1-C5 haloalkyl, C 1 -C5 alkoxy, C 1 -C5 haloalkoxy, C 1 -C5 alkylamino, C1-C5 dialkylamino, (C1-C5 alkoxy)carbonyl and (Cl -C 5 alkyl)carbonyl, and wherein each of the alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl for the substituents of the alkyl group respresented by R30 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, phenyl, C1-C5 alkoxy, C1-C5 haloalkoxy, phenylamino, C1-C5 alkylamino, C1-C5 dialkylamino, diphenylamino, (C 1 -C5 alkoxy)carbonyl, (C 1 -C5 alkyl)carbonyl, benzoyl and phenoxycarbonyl; and each R31 is independently R30, -CO2R30, -SO2R30 or -C(O)R30; or -N(R31)2 taken together is an optionally substituted non-aromatic heterocyclic group; and each R32 is independently: i) an aryl group optionally substituted with one or more substituents selected from the group consisting of halogen, alkyl, amino, alkylamino, dialkylamino, alkoxy, nitro, cyano, hydroxy, haloalkoxy, alkylcarbonyl and haloalkoxy and haloalkyl; or ii) an alkyl group optionally substituted with one or more substituents selected from the group consisting of halogen, amino, nitro, cyano, hydroxy, phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl, alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl, wherein each phenyl group of the phenyl, phenylamino, diphenylamino, aryloxy, benzoyl, phenoxycarbonyl for the substituents of the alkyl group
10 respresented by R is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, C 1 -C5 alkyl, C 1 -C5 haloalkyl, C 1 -C5 alkoxy, C 1 -
C5 haloalkoxy, C1-C5 alkylamino, C1-C5 dialkylamino, (C1-C5 alkoxy)carbonyl and (C1-C5 alkyl)carbonyl, and wherein each alkyl group of the alkylamino, dialkylamino, alkoxy, alkoxycarbonyl and alkylcarbonyl for the substituents of the alkyl group respresented by R32 is independently and optionally substituted with one or more substituents selected from the group consisting of halogen, hydroxy, cyano, nitro, amino, phenyl, C1-C5 alkoxy, Cl- C5 haloalkoxy, phenylamino, C1-C5 alkylamino, C1-C5 dialkylamino, diphenylamino, (C1-C5 alkoxy)carbonyl,
(C1-C5 alkyl)carbonyl, benzoyl and phenoxycarbonyl; and n is 1, 2, 3, 4, 5 or 6; each p is independently 1, 2, 3 or 4; and each q is independently 3, 4, 5 or 6.
82. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
83. A method of treating a subject having type 2 diabetes, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
84. A method of treating a subject having renal hypertrophy or hyperplasia associated with diabetic nephropathy, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
85. A method of decreasing plasma TNF-α in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
86. A method of lowering blood glucose levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
87. A method of decreasing glycated hemoglobin levels in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
88. A method of inhibiting glucosylceramide synthase or lowering glycosphingolipid concentrations in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
89. A method of treating a subject with Tay-Sachs, Gaucher's or Fabry's disease, comprising administering to the subject a therapeutically effective amount of a compound of Claim 81 or a pharmaceutically acceptable salt thereof.
PCT/US2008/006906 2007-05-31 2008-05-30 2-acylaminopropoanol-type glucosylceramide synthase inhibitors WO2008150486A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
EP08768008.8A EP2167485B1 (en) 2007-05-31 2008-05-30 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US12/601,871 US8304447B2 (en) 2007-05-31 2008-05-30 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
EP13154955.2A EP2594563B1 (en) 2007-05-31 2008-05-30 2-acylaminopropanol-type glucosylceramide synthase inhibitors
EP13154970.1A EP2594565B1 (en) 2007-05-31 2008-05-30 2-acylaminopropanol-type glucosylceramide synthase inhibitors
HK10105161.0A HK1138282A1 (en) 2007-05-31 2010-05-26 2-acylaminopropoanol-type glucosylceramide synthase inhibitors 2-
US13/595,349 US8940776B2 (en) 2007-05-31 2012-08-27 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US14/571,922 US9745294B2 (en) 2007-05-31 2014-12-16 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US15/649,128 US20180093981A1 (en) 2007-05-31 2017-07-13 2-Acylaminopropoanol-Type Glucosylceramide Synthase Inhibitors

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US93237007P 2007-05-31 2007-05-31
US60/932,370 2007-05-31
US99784607P 2007-10-05 2007-10-05
US60/997,846 2007-10-05

Related Child Applications (2)

Application Number Title Priority Date Filing Date
US12/601,871 A-371-Of-International US8304447B2 (en) 2007-05-31 2008-05-30 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US13/595,349 Continuation US8940776B2 (en) 2007-05-31 2012-08-27 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Publications (2)

Publication Number Publication Date
WO2008150486A2 true WO2008150486A2 (en) 2008-12-11
WO2008150486A3 WO2008150486A3 (en) 2009-02-05

Family

ID=39730765

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/006906 WO2008150486A2 (en) 2007-05-31 2008-05-30 2-acylaminopropoanol-type glucosylceramide synthase inhibitors

Country Status (5)

Country Link
US (4) US8304447B2 (en)
EP (5) EP2594563B1 (en)
AR (1) AR066817A1 (en)
HK (3) HK1138282A1 (en)
WO (1) WO2008150486A2 (en)

Cited By (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519840A (en) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション How to treat diabetes
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
EP2349255A1 (en) * 2008-10-03 2011-08-03 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
EP2543660A1 (en) * 2010-03-04 2013-01-09 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for diabetes or obesity
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
WO2013059119A1 (en) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
JP2014523423A (en) * 2011-06-24 2014-09-11 上海医薬工業研究院 Amide compounds, their preparation and use
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2015042397A1 (en) * 2013-09-20 2015-03-26 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
WO2015065937A1 (en) * 2013-10-29 2015-05-07 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
CN105753846A (en) * 2009-11-27 2016-07-13 基酶有限公司 Amorphous And Crystalline Form Of Genz 112638 Hemitartrat As Inhibitor Of Glucosylceramide Synthase
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP3036220A4 (en) * 2013-08-21 2017-04-12 Alios Biopharma, Inc. Antiviral compounds
WO2019126776A1 (en) 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
WO2021081141A1 (en) 2019-10-23 2021-04-29 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
US11014935B2 (en) 2012-08-23 2021-05-25 Janssen Biopharma, Inc. Compounds for the treatment of paramyxovirus viral infections
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same
EP4389744A1 (en) 2019-11-15 2024-06-26 Yuhan Corporation Derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016001885A2 (en) * 2014-07-03 2016-01-07 Dr. Reddy’S Laboratories Limited Amorphous form of eliglustat hemitartarate
MX370270B (en) * 2015-03-11 2019-12-09 Biomarin Pharm Inc Glucosylceramide synthase inhibitors for the treatment of diseases.
EA201891170A1 (en) 2015-11-18 2018-11-30 Джензим Корпорейшн BIOMARKER OF POLYCYSTIC KIDNEY DISEASE AND OPTIONS FOR ITS APPLICATION
WO2017165766A2 (en) 2016-03-25 2017-09-28 Genzyme Corporation Biomarkers of proteopathies and uses thereof

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144290A2 (en) * 1983-12-01 1985-06-12 Ciba-Geigy Ag Substituted ethylenediamine derivatives
US5907039A (en) * 1995-12-08 1999-05-25 Seikagaku Kogyo Kabushiki Kaisha Amino alcohol derivative and method for preparing the same
US6051598A (en) * 1995-09-20 2000-04-18 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20010003741A1 (en) * 1999-12-06 2001-06-14 Hiroyuki Masuda Aminoalcohol derivative and medicament comprising the same
WO2002050019A2 (en) * 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Co. Diamines as modulators of chemokine receptor activity
WO2006053043A2 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
WO2007134086A2 (en) * 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis

Family Cites Families (66)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1555654A (en) 1977-06-25 1979-11-14 Exxon Research Engineering Co Agricultural burner apparatus
US4065562A (en) 1975-12-29 1977-12-27 Nippon Shinyaku Co., Ltd. Method and composition for reducing blood glucose levels
NO154918C (en) 1977-08-27 1987-01-14 Bayer Ag ANALOGUE PROCEDURE FOR THE PREPARATION OF THERAPEUTIC ACTIVE DERIVATIVES OF 3,4,5-TRIHYDROXYPIPERIDINE.
GB2020278B (en) 1978-05-03 1983-02-23 Nippon Shinyaku Co Ltd Moranoline dervitives
JPS568318A (en) 1979-06-28 1981-01-28 Janssen Pharmaceutica Nv Non oral long acting composition of haloperidol and bromperidol derivative
GB8311286D0 (en) 1983-04-26 1983-06-02 Searle & Co Carboxyalkyl peptide derivatives
US5041441A (en) 1988-04-04 1991-08-20 The Regents Of The University Of Michigan Method of chemotherapy using 1-phenyl-2-decanoylamino-3-morpholino-1-propanol
US5302609A (en) 1992-12-16 1994-04-12 The Regents Of The University Of Michigan Treatment of diabetic nephropathy
US5399567A (en) 1993-05-13 1995-03-21 Monsanto Company Method of treating cholera
HUT73527A (en) 1993-08-13 1996-08-28 Seikagaku Kogyo Co Ltd Remedy for nervous diseases
US5631394A (en) 1994-02-02 1997-05-20 The Liposome Company, Inc. Pharmaceutically active ceramide-related compounds
CA2192555C (en) 1994-06-10 2005-01-11 Jinichi Inokuchi 2-acylaminopropanol compound and medicinal composition
US6255336B1 (en) 1995-09-20 2001-07-03 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US6890949B1 (en) 1999-07-09 2005-05-10 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
WO2001004108A1 (en) 1999-07-09 2001-01-18 Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20030073680A1 (en) 1995-09-20 2003-04-17 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
JP3993908B2 (en) 1995-12-08 2007-10-17 生化学工業株式会社 Amino alcohol derivative and method for producing the derivative
JP4140984B2 (en) 1995-12-20 2008-08-27 生化学工業株式会社 Drug with differentiation-inducing action
US5972928A (en) 1997-05-21 1999-10-26 Johns Hopkins University Methods for treatment of conditions associated with lactosylceramide
JP4036500B2 (en) 1997-05-23 2008-01-23 生化学工業株式会社 Amino alcohol derivatives and pharmaceuticals containing the same
JP4176170B2 (en) 1997-06-06 2008-11-05 生化学工業株式会社 Medicine containing amino alcohol derivative and therapeutic agent for abnormal proliferative disease
US6465488B1 (en) 1997-12-11 2002-10-15 Chancellor, Masters & Scholars Of The University Of Oxford Inhibition of glycolipid biosynthesis
AU756008B2 (en) 1998-07-27 2003-01-02 Johns Hopkins University, The Methods for treating conditions modulated by lactosylceramide
US6610703B1 (en) 1998-12-10 2003-08-26 G.D. Searle & Co. Method for treatment of glycolipid storage diseases
GB0100889D0 (en) 2001-01-12 2001-02-21 Oxford Glycosciences Uk Ltd Compounds
JP5009459B2 (en) 1999-12-06 2012-08-22 生化学工業株式会社 Amino alcohol derivatives and pharmaceuticals containing the same
US6235737B1 (en) 2000-01-25 2001-05-22 Peter Styczynski Reduction of hair growth
US20040009961A1 (en) 2000-04-19 2004-01-15 Borody Thomas Julius Composition and therapies for hyperlipidaemia-associated disorders
MXPA03005855A (en) 2000-12-29 2003-09-10 Wyeth Corp Method for the regioselective preparation of substituted benzo[g]quinoline-3-carbonitriles and benzo[g]quinazolines.
US20040260099A1 (en) 2001-01-10 2004-12-23 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US7148251B2 (en) 2001-01-10 2006-12-12 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US20020198240A1 (en) 2001-01-10 2002-12-26 Shayman James A. Amino ceramide - like compounds and therapeutic methods of use
JP2004531478A (en) 2001-01-10 2004-10-14 ザ リージェンツ オブ ザ ユニバーシティ オブ ミシガン Aminoceramide-like compounds and methods of use for therapeutic purposes
PT2266968E (en) 2001-07-16 2013-02-25 Genzyme Corp Synthesis of udp-glucose: n-acylsphingosine glucosyltransferase inhibitors
US6835831B2 (en) 2001-11-26 2004-12-28 Genzyme Corporation Diastereoselective synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors
GB0229931D0 (en) 2002-12-21 2003-01-29 Astrazeneca Ab Therapeutic agents
AU2002367266A1 (en) 2001-12-28 2003-07-24 Sumitomo Pharmaceuticals Company, Limited Disease markers for renal diseaes and utilization thereof
EP1336411A1 (en) 2002-02-14 2003-08-20 Academisch Medisch Centrum bij de Universiteit van Amsterdam Compositions and methods for improving enzyme replacement therapy of lysosomal storage diseases
JP2003238410A (en) 2002-02-21 2003-08-27 Seibutsu Yuki Kagaku Kenkyusho:Kk Insulin resistance elimination agent
US20060217560A1 (en) 2002-04-29 2006-09-28 Shayman James A Amino ceramide-like compounds and therapeutic methods of use
US6916802B2 (en) 2002-04-29 2005-07-12 Genzyme Corporation Amino ceramide-like compounds and therapeutic methods of use
NZ538217A (en) 2002-07-17 2007-04-27 Biogen Idec Inc Beta interferon when used to treat proteinuria, glomerular cell proliferation and inflammation
CA2492404C (en) 2002-07-17 2012-02-07 Oxford Glycosciences (Uk) Ltd Piperidinetriol derivatives as inhibitors of glycosylceramide synthase
AU2003225670A1 (en) 2003-02-28 2004-09-28 Intermune, Inc. Interferon drug therapy for the treatment of viral diseases and liver fibrosis
GB0313678D0 (en) 2003-06-13 2003-07-16 Oxford Glycosciences Uk Ltd Novel compounds
DE602004030604D1 (en) 2003-10-29 2011-01-27 Genzyme Corp N- (5-ADAMANTANE-1-YL-METHOXY-PENTYL) DESOXYNOJIRIMYCIN OR A PHARMACEUTICAL SALT THEREOF FOR USE IN THE TREATMENT OF INSULIN RESISTANCE
EP1528056A1 (en) 2003-10-29 2005-05-04 Academisch Ziekenhuis bij de Universiteit van Amsterdam Deoxynojirimycin analogues and their uses as glucosylceramidase inhibitors
CA2548313A1 (en) 2003-12-23 2005-07-14 Musc Foundation For Research Development Methods and compositions for the prevention and treatment of inflammatory diseases or conditions
GB0400812D0 (en) 2004-01-14 2004-02-18 Celltech R&D Ltd Novel compounds
EP1576894A1 (en) 2004-03-16 2005-09-21 Nederlandse Organisatie voor toegepast-natuurwetenschappelijk Onderzoek TNO The use of sphingolipids in the treatment and prevention of type 2 diabetes mellitus, insulin resistance and Metabolic Syndrome
US20070207983A1 (en) 2004-03-16 2007-09-06 Nieuwenhuizen Willem F Use of Sphingolipids in the Treatment and Prevention of Type 2 Diabetes Mellitus, Insulin Resistance and Metabolic Syndrome
AU2005240714B2 (en) 2004-05-07 2011-07-07 Merck Patent Gmbh GM3 synthase as a therapeutic target in microvascular complications of diabetes
US20090111812A1 (en) 2004-06-14 2009-04-30 Musc Foundation For Research Development Methods for treating inflammatory disorders
AU2005277186A1 (en) 2004-08-20 2006-03-02 The Johns Hopkins University Methods for treatment of angiogenesis
CA2595519C (en) 2005-01-26 2013-10-29 Allergan, Inc. Methods of using as analgesics 1-benzyl-1-hydroxy-2,3-diamino-propyl amines, 3-benzyl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2007022518A2 (en) 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. New uses of glucoregulatory proteins
WO2008011478A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. Methods for treating chronic pain using 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds
WO2008011487A2 (en) 2006-07-19 2008-01-24 Allergan, Inc. L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
GB0614947D0 (en) 2006-07-27 2006-09-06 Isis Innovation Epitope reduction therapy
TWI389895B (en) * 2006-08-21 2013-03-21 Infinity Discovery Inc Compounds and methods for inhibiting the interaction of bcl proteins with binding partners
MX2009008493A (en) 2007-02-09 2009-08-20 Irm Llc Compounds and compositions as channel activating protease inhibitors.
WO2008150486A2 (en) 2007-05-31 2008-12-11 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
KR101640263B1 (en) 2007-10-05 2016-07-15 젠자임 코포레이션 Method of treating polycystic kidney diseases with ceramide derivatives
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
WO2010014554A1 (en) 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
JP2012504608A (en) 2008-10-03 2012-02-23 ジェンザイム コーポレーション 2-Acylaminopropanol-type glucosylceramide synthase inhibitor

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0144290A2 (en) * 1983-12-01 1985-06-12 Ciba-Geigy Ag Substituted ethylenediamine derivatives
US6051598A (en) * 1995-09-20 2000-04-18 The Regents Of The University Of Michigan Amino ceramide-like compounds and therapeutic methods of use
US5907039A (en) * 1995-12-08 1999-05-25 Seikagaku Kogyo Kabushiki Kaisha Amino alcohol derivative and method for preparing the same
US20010003741A1 (en) * 1999-12-06 2001-06-14 Hiroyuki Masuda Aminoalcohol derivative and medicament comprising the same
WO2002050019A2 (en) * 2000-12-20 2002-06-27 Bristol-Myers Squibb Pharma Co. Diamines as modulators of chemokine receptor activity
WO2006053043A2 (en) * 2004-11-10 2006-05-18 Genzyme Corporation Methods of treating diabetes mellitus
WO2007134086A2 (en) * 2006-05-09 2007-11-22 Genzyme Corporation Methods of treating fatty liver disease comprising inhibiting glucosphingolipid synthesis

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; ALBERTI, CARLO GIUSEPPE: "Chloramphenicol. XII and XIII. Chloramphenicol analogs. p-Nitrophenyldiaminopropanols" XP002495477 retrieved from STN Database accession no. 1957:17088 & GAZZETTA CHIMICA ITALIANA , 86, 240-9 CODEN: GCITA9; ISSN: 0016-5603, 1956, *
DATABASE CA [Online] CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; INOKUCHI, KIMIKAZU ET AL: "Aminoalcohol derivatives for treatment of abnormal proliferative diseases" XP002495476 retrieved from STN Database accession no. 1998:816280 -& JP 10 338636 A (SEIKAGAKU KOGYO CO., LTD., JAPAN) 22 December 1998 (1998-12-22) *
JIMBO ET AL: "Development of a new inhibitor of glucosylceramide synthase" JOURNAL OF BIOCHEMISTRY, vol. 127, no. 3, 2000, pages 485-491, XP002372070 ISSN: 0021-924X *

Cited By (73)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008519840A (en) * 2004-11-10 2008-06-12 ジェンザイム・コーポレイション How to treat diabetes
US9532976B2 (en) 2004-11-10 2017-01-03 Genzyme Corporation Method of lowering blood glucose
US8003617B2 (en) 2004-11-10 2011-08-23 Genzyme Corporation Methods of treating diabetes mellitus
US8716327B2 (en) 2006-05-09 2014-05-06 Genzyme Corporation Methods of treating fatty liver disease
US9556155B2 (en) 2006-05-09 2017-01-31 Genzyme Corporation Methods of treating fatty liver disease
US8304447B2 (en) 2007-05-31 2012-11-06 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8940776B2 (en) 2007-05-31 2015-01-27 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9745294B2 (en) 2007-05-31 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8912177B2 (en) 2007-10-05 2014-12-16 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
US10220039B2 (en) 2007-10-05 2019-03-05 Genzyme Corporation Method of treating polycystic kidney diseases with ceramide derivatives
WO2009117150A2 (en) * 2008-03-20 2009-09-24 Genzyme Corporation Method of treating lupus with ceramide derivatives
WO2009117150A3 (en) * 2008-03-20 2010-01-14 Genzyme Corporation Method of treating lupus with ceramide derivatives
US8729075B2 (en) 2008-07-28 2014-05-20 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US8389517B2 (en) 2008-07-28 2013-03-05 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
US9481671B2 (en) 2008-07-28 2016-11-01 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
WO2010014554A1 (en) * 2008-07-28 2010-02-04 Genzyme Corporation Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular disease
EP2349255A1 (en) * 2008-10-03 2011-08-03 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9272996B2 (en) 2008-10-03 2016-03-01 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US8309593B2 (en) 2008-10-03 2012-11-13 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
EP2349255B1 (en) * 2008-10-03 2016-03-30 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
US9744153B2 (en) 2008-10-03 2017-08-29 Genzyme Corporation 2-acylaminopropoanol-type glucosylceramide synthase inhibitors
JP2015129186A (en) * 2008-10-03 2015-07-16 ジェンザイム コーポレーション 2-acylaminopropanol-type glucosylceramide synthase inhibitors
WO2010091104A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Glucosylceramide synthase inhibitors
WO2010091164A1 (en) * 2009-02-06 2010-08-12 Exelixis, Inc. Inhibitors of glucosylceramide synthase
EP3896069A1 (en) * 2009-11-27 2021-10-20 Genzyme Corporation Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
EP3599237A1 (en) * 2009-11-27 2020-01-29 Genzyme Corporation Pharmaceutical composition of the glucosylceramide synthase inhibitor eliglustat for the treatment gaucher's disease comprising adjusting the individual therapeutical dose to the p450 metabolism of the patient
EP3133070B1 (en) 2009-11-27 2019-08-14 Genzyme Corporation Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient
US11458119B2 (en) 2009-11-27 2022-10-04 Genzyme Corporation Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
EP3133070A1 (en) * 2009-11-27 2017-02-22 Genzyme Corporation Eliglustat (genz 112638) as inhibitor of glucosylceramide synthase for use in a method of treating fabry's or gaucher's disease, the method comprising adjusting the individual therapeutical dose to the p-450 metabolism of the patient
CN105753846A (en) * 2009-11-27 2016-07-13 基酶有限公司 Amorphous And Crystalline Form Of Genz 112638 Hemitartrat As Inhibitor Of Glucosylceramide Synthase
CN105777707A (en) * 2009-11-27 2016-07-20 基酶有限公司 An amorphous and a crystalline form of Genz 112638 hemitartrat as inhibitor of glucosylceramide synthase
US10888547B2 (en) 2009-11-27 2021-01-12 Genzyme Corporation Amorphous and a crystalline form of genz 112638 hemitartrate as inhibitor of glucosylceramide synthase
US9150505B2 (en) 2010-03-04 2015-10-06 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for diabetes or obesity
EP2543660A4 (en) * 2010-03-04 2014-04-30 Ajinomoto Kk Prophylactic or therapeutic agent for diabetes or obesity
EP2543660A1 (en) * 2010-03-04 2013-01-09 Ajinomoto Co., Inc. Prophylactic or therapeutic agent for diabetes or obesity
JP5761173B2 (en) * 2010-03-04 2015-08-12 味の素株式会社 Preventive or therapeutic agent for diabetes or obesity
JP2014523423A (en) * 2011-06-24 2014-09-11 上海医薬工業研究院 Amide compounds, their preparation and use
US10428013B2 (en) 2011-06-24 2019-10-01 Shanghai Institute Of Phamaceutical Industry Amide compound, preparation method and uses thereof
EP2567959A1 (en) 2011-09-12 2013-03-13 Sanofi 6-(4-Hydroxy-phenyl)-3-styryl-1H-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
US8961959B2 (en) 2011-10-17 2015-02-24 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2013059119A1 (en) * 2011-10-17 2013-04-25 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
US11014935B2 (en) 2012-08-23 2021-05-25 Janssen Biopharma, Inc. Compounds for the treatment of paramyxovirus viral infections
US11021444B2 (en) 2013-08-21 2021-06-01 Janssen Biopharma, Inc. Antiviral compounds
EP3036220A4 (en) * 2013-08-21 2017-04-12 Alios Biopharma, Inc. Antiviral compounds
JP2016534023A (en) * 2013-09-20 2016-11-04 ビオマリン プハルマセウトイカル インコーポレイテッド Glucosylceramide synthase inhibitors for disease treatment
US10927092B2 (en) 2013-09-20 2021-02-23 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
US10227323B2 (en) 2013-09-20 2019-03-12 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
CN110372636B (en) * 2013-09-20 2023-03-28 生物马林药物股份有限公司 Glucose ceramide synthase inhibitors for the treatment of diseases
WO2015042397A1 (en) * 2013-09-20 2015-03-26 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
EP3912977A1 (en) * 2013-09-20 2021-11-24 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
AU2014321397C1 (en) * 2013-09-20 2019-08-01 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
CN105745206B (en) * 2013-09-20 2019-08-13 生物马林药物股份有限公司 For treating the Glucosylceramide synthase inhibitor of disease
AU2014321397B2 (en) * 2013-09-20 2019-02-07 Biomarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
EP3046920B1 (en) * 2013-09-20 2021-08-04 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
JP2019182869A (en) * 2013-09-20 2019-10-24 ビオマリン プハルマセウトイカル インコーポレイテッド Glucosylceramide synthase inhibitors for treatment of diseases
CN110372636A (en) * 2013-09-20 2019-10-25 生物马林药物股份有限公司 For treating the Glucosylceramide synthase inhibitor of disease
CN105745206A (en) * 2013-09-20 2016-07-06 生物马林药物股份有限公司 Filtration device, filtration method, acetate fiber manufacturing method
EP3046920A1 (en) * 2013-09-20 2016-07-27 BioMarin Pharmaceutical Inc. Glucosylceramide synthase inhibitors for the treatment of diseases
CN105849102A (en) * 2013-10-29 2016-08-10 生物马林药物股份有限公司 N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
US11358932B2 (en) 2013-10-29 2022-06-14 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
CN105849102B (en) * 2013-10-29 2020-10-16 生物马林药物股份有限公司 N- (1-hydroxy-3 (pyrrolidinyl) propan-2-yl) pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
US10239832B2 (en) 2013-10-29 2019-03-26 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
JP2016535051A (en) * 2013-10-29 2016-11-10 ビオマリン プハルマセウトイカル インコーポレイテッド N- (1-hydroxy-3- (pyrrolidinyl) propan-2-yl) pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
WO2015065937A1 (en) * 2013-10-29 2015-05-07 Biomarin Pharmaceutical Inc. N-(1-hydroxy-3-(pyrrolidinyl)propan-2-yl)pyrrolidine-3-carboxamide derivatives as glucosylceramide synthase inhibitors
TWI655185B (en) * 2013-10-29 2019-04-01 拜奧馬林製藥公司 Glucosamineamine synthase inhibitor for treating diseases
US10202340B2 (en) 2015-02-02 2019-02-12 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2016126572A2 (en) 2015-02-02 2016-08-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2019126776A1 (en) 2017-12-21 2019-06-27 Lysosomal Therapeutics Inc. Crystalline substituted cyclohexyl pyrazolo[1,5-a]pyrimidinyl carboxamide compound and therapeutic uses thereof
WO2020193746A1 (en) 2019-03-28 2020-10-01 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the survival of patients suffering from melanoma
US11220479B2 (en) 2019-10-23 2022-01-11 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
WO2021081141A1 (en) 2019-10-23 2021-04-29 The Regents Of The University Of Michigan Glucosylceramide synthase inhibitors and therapeutic methods using the same
EP4389744A1 (en) 2019-11-15 2024-06-26 Yuhan Corporation Derivatives having 2,3-dihydro-1h-indene or 2,3-dihydrobenzofuran moiety or pharmaceutically acceptable salt thereof and pharmaceutical compositions comprising the same
WO2021221953A1 (en) 2020-04-28 2021-11-04 The Regents Of The University Of Michigan Pyridine inhibitors of glucosylceramide synthase and therapeutic methods using the same

Also Published As

Publication number Publication date
EP2594562A3 (en) 2013-08-14
EP2594564A3 (en) 2013-08-21
EP2594562B1 (en) 2016-07-20
EP2594565A3 (en) 2013-08-07
US20180093981A1 (en) 2018-04-05
HK1138282A1 (en) 2010-08-20
EP2594563B1 (en) 2018-07-18
EP2594564A2 (en) 2013-05-22
AR066817A1 (en) 2009-09-16
EP2594562A2 (en) 2013-05-22
US8304447B2 (en) 2012-11-06
EP2594564B1 (en) 2016-09-28
EP2594563A2 (en) 2013-05-22
EP2594565A2 (en) 2013-05-22
US9745294B2 (en) 2017-08-29
HK1185076A1 (en) 2014-02-07
WO2008150486A3 (en) 2009-02-05
US20100256216A1 (en) 2010-10-07
EP2594565B1 (en) 2018-10-24
EP2594563A3 (en) 2013-08-07
US8940776B2 (en) 2015-01-27
US20150225393A1 (en) 2015-08-13
US20120322787A1 (en) 2012-12-20
EP2167485A2 (en) 2010-03-31
EP2167485B1 (en) 2015-09-30
HK1185341A1 (en) 2014-02-14

Similar Documents

Publication Publication Date Title
EP2594564B1 (en) 2-acylaminopropanol-type glucosylceramide synthase inhibitors
JP6297194B2 (en) 2-Acylaminopropanol-type glucosylceramide synthase inhibitor
JP6038213B2 (en) Glucosylceramide synthase inhibition for the treatment of collapsing glomerulopathy and other glomerular diseases

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08768008

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2008768008

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 12601871

Country of ref document: US